O
f
f
i
c
i
a
l
T
i
t
l
e
:
A
P
h
a
s
e
1
,
S
i
n
g
l
e
D
o
s
e
S
t
u
d
y
o
f
t
h
e
S
a
f
e
t
y
a
n
d
V
i
r
o
l
o
g
i
c
E
f
f
e
c
t
o
f
a
n
H
I
V
-
1
S
p
e
c
i
f
i
c
Broa
d
l
y
N
e
u
t
r
a
l
i
z
i
n
g
H
u
m
a
n
M
o
n
o
c
l
o
n
a
l
A
n
t
i
b
o
d
y
,
V
R
C
-
HIVMAB080
-
00
-
AB
(
V
R
C
0
1
L
S
)
o
r
VRC
-
HIVMAB075
-
00
-
A
B
(
V
R
C
0
7
-
5
2
3
L
S
)
,
A
d
m
i
n
i
s
t
e
r
e
d
I
n
t
r
a
v
e
n
o
u
s
l
y
t
o
H
I
V
-
I
n
f
e
c
t
e
d
A
d
u
l
t
s
C
l
i
n
i
c
a
l
T
r
i
a
l
s
.
g
o
v
I
d
e
n
t
i
f
i
e
r
:
[STUDY_ID_REMOVED]
D
o
c
u
m
e
n
t
T
y
p
e
:
•
 
R
e
d
a
c
t
e
d
F
i
n
a
l
V
e
r
s
i
o
n
o
f
t
h
e
S
t
u
d
y
P
r
o
t
o
c
o
l
(
S
t
a
t
i
s
t
i
c
a
l
A
n
a
l
y
s
i
s
C
o
n
s
i
d
e
r
a
t
i
o
n
s
l
o
c
a
t
e
d
i
n
S
e
c
t
i
o
n
6
o
f
t
h
e
P
r
o
t
o
c
o
l
)
•
 
Redacted
F
i
n
a
l
V
e
r
s
i
o
n
o
f
IRB
-
a
p
p
r
o
v
e
d
I
n
f
o
r
m
e
d
C
o
n
s
e
n
t
Document/Da
te
:
•
 
P
r
o
t
o
c
o
l
V
e
r
s
i
o
n
4
.
0
:
Ma
y
2
9
,
2
0
1
8
•
 
V
e
r
s
i
o
n
4
.
0
I
R
B
-
a
p
p
r
o
v
e
d
I
n
f
o
r
m
e
d
C
o
n
s
e
n
t
 
Version 
4
.0
 
May
 
29
, 2018
 
 
VACCINE RESEARCH CEN
TER
 
AIDS CLINICAL TRIALS
 
GROUP
 
 
Protocol VRC 
607
/ACTG A5378
 
(
NIH 1
6
-
I
-
0147
)
 
(DAIDS
-
ES ID 
30089
)
 
 
A
 
P
HASE 
1,
 
S
INGLE 
D
OSE 
S
TUDY OF THE 
S
AFETY AND 
V
IROLOGIC 
E
FFECT OF 
A
N 
HIV
-
1
 
S
PECIFIC 
B
ROADLY 
N
EUTRALIZING
 
H
UMAN 
M
ONOCLONAL 
A
NTIBOD
Y
,
 
VRC
-
HIVMAB080
-
00
-
AB
 
(VRC01LS)
 
OR
 
VRC
-
HIV
MAB
075
-
00
-
AB
 
(VRC07
-
523LS)
,
 
A
DMINISTERED 
I
NTRAVENOUSLY TO 
HIV
-
I
NFECTED
 
A
DULTS
 
 
Stud
y 
Product
 
Provided by
:
 
Vaccine Research Center/NIAID/NIH, Bethesda, MD
 
 
Clinical Trial Sponsored by:
 
National Institute of Allergy and Infectious Diseases (NIAID)
 
Vaccine Research Center (VRC)
 
Bethesda, Maryland
 
AIDS Clinical
 
Trials Group (ACTG)
 
Network
 
 
IND Sponsored by:
 
National Institute of Allergy and Infectious Diseases
 
Division of AIDS (DAIDS)
 
Bethesda, Maryland
 
 
IND
 
130,804 
-
 
held by DAIDS
 
 
 
 
 
IRB Initial Review Date: 
June 6, 2016
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0
 
DATE:  MAY 29, 2018
 
 
Page 
2
 
of 70
 
 
A
 
P
HASE 
1,
 
S
INGLE 
D
OSE 
S
TUDY OF THE 
S
AFETY AND 
V
IROLOGIC 
E
FFECT OF 
A
N 
HIV
-
1
 
S
PECIFIC 
B
ROADLY 
N
EUTRALIZING
 
H
UMAN 
M
ONOCLONAL 
A
NTIBODY
,
 
VRC
-
HIVMAB080
-
00
-
AB
 
(VRC01LS)
 
OR 
VRC
-
HIV
MAB
075
-
00
-
AB
 
(VRC07
-
523LS),
 
A
DMINISTERED 
I
NTRAVENOUSLY TO 
HIV
-
I
NFECTED 
A
DULTS
 
 
 
SIGNATURE PAGE
 
 
 
I will conduct the study in accordance with the provisions of this protocol and all applicable 
protocol
-
related documents. I agree to conduct this study
 
in compliance with United States 
(US) Health and Human Service regulations (45 CFR 46); applicable U.S. Food and Drug 
Administration regulations; standards of the International Conference on Harmonization 
Guideline for Good Clinical Practice (E6); Institu
tional Review Board/Ethics Committee 
determinations; all applicable in
-
country, state, and local laws and regulations; and other 
applicable requirements (e.g., US National Institutes of Health, Division of AIDS) and 
institutional policies.
 
 
 
 
 
 
Principal 
Investigator: _______________________________________________
 
Print/Type
 
 
 
 
 
 
Signed: ___________________________________ Date: _____________
 
Name/Title
 
 
 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0
 
DATE:  MAY 29, 2018
 
 
Page 
3
 
of 70
 
TABLE OF CONTENTS
 
 
Page
 
SIGNATURE PAGE
 
................................
................................
................................
.................
2
 
ABBREVIATIONS
 
................................
................................
................................
...................
6
 
PRÉCIS
 
................................
................................
................................
................................
......
9
 
 
INTRODUCTION
................................
................................
................................
.....
 
11
 
 
Rationale for the Study
 
................................
................................
................................
12
 
 
VRC01LS and VRC07
-
523LS Specific Research Laboratory Assessments
 
...............
12
 
 
Previous human experience
 
................................
................................
.........................
13
 
1.3.1
 
VRC01 Safety Data
 
................................
................................
..........................
13
 
1.3.2
 
VRC01LS Safety Data
 
................................
................................
......................
14
 
1.3.3
 
VRC07
-
523LS Safety Data
 
................................
................................
...............
15
 
1.3.4
 
Antiviral Effect of VRC01
 
................................
................................
................
16
 
 
Pharmacokinetic Parameters
 
................................
................................
........................
17
 
 
STUDY PRODUCTS
 
................................
................................
................................
 
17
 
 
VRC
-
HIVMAB080
-
00
-
AB
................................
................................
..........................
17
 
 
VRC
-
HIVMAB075
-
00
-
AB
................................
................................
..........................
18
 
 
Preclinical Safety Studies
 
................................
................................
............................
18
 
 
Nonhuman Primate (NHP) Studies
 
................................
................................
..............
19
 
 
STUDY OBJECTIVES
 
................................
................................
.............................
 
21
 
 
Primary Objectives
................................
................................
................................
.......
21
 
 
Se
condary Objectives
................................
................................
................................
...
21
 
 
Exploratory Objectives
 
................................
................................
................................
21
 
 
STUDY DESIGN
 
................................
................................
................................
.......
 
21
 
 
Study 
Population
 
................................
................................
................................
..........
22
 
4.1.1
 
Inclusion Criteria
 
................................
................................
.............................
22
 
4.1.2
 
Exclusion Criteria
 
................................
................................
............................
23
 
 
Clinical Procedures and Laboratory Assays
 
................................
................................
24
 
4.2.1
 
Screening
................................
................................
................................
..........
24
 
4.2.2
 
Enrollment, Study Days and Visit Numbers
 
................................
.....................
25
 
4.2.3
 
Administration of Study Product
 
................................
................................
......
25
 
4.2.4
 
Solicited Adverse Events and Clinical Follow
-
up
 
................................
...........
26
 
4.2.5
 
Pharmacokinetics Procedures
 
................................
................................
.........
26
 
4.2.6
 
Schedule of Evaluations
 
................................
................................
...................
27
 
4.2.7
 
Monitoring HIV Infection Status
 
................................
................................
......
27
 
4.2.8
 
Concomitant Medications
 
................................
................................
................
27
 
 
Discontinuation of Study Participation Following Product Administration
 
................
27
 
 
Protocol Criteria for Pausing the Study and Resuming the Study
 
...............................
28
 
 
Plan for Review of Pauses and Resuming Rules
 
................................
.........................
28
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0
 
DATE:  MAY 29, 2018
 
 
Page 
4
 
of 70
 
 
SAFETY AND ADVERSE E
VENT REPORTING
 
................................
...............
 
29
 
 
Adverse Events
 
................................
................................
................................
............
29
 
 
Seriou
s Adverse Events (SAE)
 
................................
................................
....................
29
 
 
Adverse Event Reporting to the IND Sponsor
 
................................
.............................
29
 
5.3.1
 
Expedited Adverse Event (EAE) Reporting Criteria
 
................................
........
29
 
5.3.2
 
Attribution Categories
 
................................
................................
.....................
31
 
 
Reporting to the Institutional Review Board
 
................................
...............................
31
 
5.4.1
 
Unanticipated Problem (UP) Definition
 
................................
..........................
31
 
5.4.2
 
Protocol Deviation Definition
................................
................................
..........
32
 
5.4.3
 
Non
-
Compliance Definition
 
................................
................................
.............
32
 
5.4.4
 
Expedited Reporting to the IRB
 
................................
................................
.......
32
 
5.4.5
 
Annual Reporting to the IRB
 
................................
................................
............
33
 
 
STATISTICAL CONSIDER
ATIONS
 
................................
................................
....
 
33
 
 
Overview
 
................................
................................
................................
......................
33
 
 
Objectives
 
................................
................................
................................
....................
33
 
 
Size and Accrual
 
................................
................................
................................
..........
34
 
6.3.1
 
Sample Size Considerations
 
................................
................................
.............
34
 
 
Statistical Analysis
 
................................
................................
................................
.......
35
 
6.4.1
 
Analysis Variables
 
................................
................................
...........................
35
 
6.4.2
 
Baseline Demographics
 
................................
................................
...................
35
 
6.4.3
 
Safety Analysis
 
................................
................................
................................
.
35
 
6.4.4
 
Tolerability Evaluation
 
................................
................................
....................
36
 
6.4.5
 
Analysis of effect on CD4
+
 
and HIV Viral load
 
................................
...............
36
 
6.4.6
 
Pharmacokinetics Analysis
 
................................
................................
..............
36
 
6.4.7
 
Interim Analyses
................................
................................
...............................
37
 
 
PHARMACY PROCEDURES
 
................................
................................
................
 
37
 
 
Study Products and Administration Regimen
 
................................
..............................
37
 
 
Vialed Study Product Storage
 
................................
................................
......................
38
 
7.2.1
 
Temperature Excursions
 
................................
................................
..................
38
 
 
Preparation of Study Products for Administration
................................
.......................
38
 
7.3.1
 
VRC
-
HIVMAB080
-
00
-
AB or VRC
-
HIVMAB075
-
00
-
AB: Preparation for IV 
Administration
................................
................................
................................
..
39
 
 
Labeling of Study Products
 
................................
................................
..........................
40
 
 
Study Product 
Distribution/Accountability
................................
................................
..
40
 
 
Study Product Disposition
 
................................
................................
...........................
41
 
 
HUMAN SUBJECT PROTEC
TIONS AND ETHICAL OB
LIGATIONS
 
.........
 
41
 
 
Informed Consent
................................
................................
................................
.........
41
 
 
Risk
s and Benefits
................................
................................
................................
........
41
 
8.2.1
 
Risks
 
................................
................................
................................
.................
41
 
8.2.2
 
Benefits
 
................................
................................
................................
.............
43
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0
 
DATE:  MAY 29, 2018
 
 
Page 
5
 
of 70
 
 
Institutio
nal Review Board
 
................................
................................
..........................
43
 
 
Protocol Registration
 
................................
................................
................................
...
43
 
 
Participant Confidentiality
 
................................
................................
...........................
44
 
8.5.1
 
Loss or Destruction of Samples, Specimens or Data
 
................................
.......
44
 
 
Plan for Use and Storage of Biological Samples
 
................................
.........................
44
 
8.6.1
 
Use of Samples, Specimens and Data
 
................................
..............................
44
 
8.6.2
 
Storage and Tracking of Blood Samples and Other Specimens
 
......................
44
 
 
Participant Identification and Enrollment of Study Participants
 
................................
.
45
 
8.7.1
 
Participation of Children
 
................................
................................
.................
45
 
8.7.2
 
Participation of Site Employees
 
................................
................................
.......
45
 
 
Compensation
 
................................
................................
................................
..............
46
 
 
Safety Monitoring
 
................................
................................
................................
........
46
 
 
ADM
INISTRATIVE AND LEGA
L OBLIGATIONS
 
................................
..........
 
46
 
 
Protocol Amendments and Study Termination
 
................................
............................
46
 
 
Study Documentation and Storage
 
................................
................................
...............
46
 
 
Study Monitoring, Data Collection and Data Sharing
 
................................
.................
47
 
9.3.1
 
Study Monitoring
 
................................
................................
.............................
47
 
9.3.2
 
Data Collection
 
................................
................................
................................
47
 
9.3.3
 
Data Sharing
 
................................
................................
................................
....
48
 
 
Language
 
................................
................................
................................
......................
48
 
 
Policy Regarding Research
-
Related Injuries
 
................................
...............................
48
 
 
Multi
-
site Management
 
................................
................................
................................
48
 
 
REFERENCES
 
................................
................................
................................
..........
 
49
 
APPENDIX I
 
................................
................................
................................
.........................
 
51
 
APPENDIX II
 
................................
................................
................................
........................
 
63
 
APPENDIX III
 
................................
................................
................................
......................
 
65
 
APPENDIX IV
 
................................
................................
................................
......................
 
72
 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0
 
DATE:  MAY 29, 2018
 
 
Page 
6
 
of 73
 
 
ABBREVIATIONS
 
 
Abbreviation
 
Term
 
ACTG
 
AIDS Clinical Trials Group
 
ADA
 
anti
-
drug a
ntibody
 
ADL
 
activities of daily living
 
AE
 
adverse event
 
AIDS
 
Acquired Immunodeficiency Syndrome
 
ALP
 
alkaline phosphatase
 
ALT
 
alanine aminotransferase
 
AoU
 
Assessment of 
Understanding
 
AR
V
 
a
ntiretroviral
 
AST
 
aspartate aminotransferase
 
AUC
 
area under the curve
 
β
-
HCG
 
human chorionic 
gonadotropin
 
BMI
 
body mass index
 
CBC
 
complete blood count
 
CCR5
 
CC family of chemokines, receptor type 5
 
CL
 
clearance
 
CHO
 
Chinese Hamster
 
Ovary
 
Cmax
 
maximum concentration
 
CRPMC
 
Clinical Research Products Management Center
 
CRS
 
cytokine release syndrome 
 
cGMP
 
current Good Manufacturing Practice
 
DAERS
 
DAIDS Adverse 
Experience 
Reporting System
 
DAIDS
 
Division of AIDS
 
DAIDS MO 
 
DAIDS 
Medical Officer
 
DAIDS PRO
 
DAIDS Protocol Registration Office 
 
DHHS
 
Department 
of 
Health & Human Services
 
DNA
 
deoxyribonucleic acid
 
DSMB
 
Data and Safety Monitoring Board
 
EAE
 
expedited adverse event
 
EC
 
ethics committee
 
EC50
 
h
alf
-
maximal effective 
concentration
 
EDTA
 
Ethylenediaminetetraacetate
 
ELISA
 
enzyme
-
linked immunosorbent assay
 
Env
 
e
nvelope
 
EOI
 
end of infusion
 
F
 
bioavailability
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0
 
DATE:  MAY 29, 2018
 
 
Page 
7
 
of 73
 
Abbreviation
 
Term
 
FDA
 
Food and Drug Administration
 
GCP
 
Good Clinical Practice
 
GLP
 
Good Laboratory Practice
 
GLT
 
(green) lithium 
heparin tube
 
HIV
 
human immunodeficiency virus
 
HLA
 
human leukocyte antigen
 
HRPP
 
Human Research Protections Program
 
IB
 
Investigator’s Brochure
 
ICF
 
Informed Consent Form
 
IgG1
 
Immunoglobulin G1
 
IND
 
investigational new drug application
 
IRB
 
Institutional
 
Review Board
 
ISM
 
Independent Safety Monitor
 
IV
 
intravenous
 
kg
 
kilogram
 
L
 
liter
 
LIMS
 
Laboratory Information Management System
 

z
 
terminal slope of concentration vs time profile
 
MAb
 
monoclonal antibody
 
mcg
 
microgram
 
mcL
 
microliter
 
mg
 
milligram
 
mL
 
milliliter
 
mM, mmol
 
millimole
 
MO
 
Medical Officer 
 
MSD
 
Meso Scale Discovery
 
NIAID
 
National Institute of Allergy and Infectious Diseases
 
NIH
 
National Institutes of Health
 
NIH CC
 
National Institutes of Health Clinical Center
 
NHP
 
n
on
-
human primate
 
NVITAL
 
NIAID Vaccine Immune T
-
Cell and Antibody Laboratory 
 
OHRP
 
Office for Human Research Protections
 
PBMC
 
peripheral blood mononuclear cells
 
PBS
 
phosphate buffered saline
 
PCR
 
polymerase chain reaction
 
PI
 
Principal Investigator
 
PK
 
pharmacokinetic
 
PSRT
 
Protocol Safety Review Team
 
Q
 
i
nter
-
compartmental clearance
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0
 
DATE:  MAY 29, 2018
 
 
Page 
8
 
of 73
 
Abbreviation
 
Term
 
QA
 
quality assurance
 
RE
 
regulatory entity
 
RSC
 
Regulatory Support Center
 
SAE
 
serious adverse event
 
SC
 
subcutaneous
 
SHIV
 
simian
-
human immunodeficiency virus
 
SSRI
 
selective serotonin 
reuptake inhibitor
 
SST
 
serum separator tube
 
TCR
 
tissue cross reactivity
 
T
½
 
half
-
life
 
Tmax
 
time of maximal concentration (Cmax)
 
UNAIDS
 
Joint United Nations Programme on HIV/AIDS
 
UP
 
unanticipated problem
 
USP
 
United States Pharmacopeia
 
VCMP 
 
Vaccine 
Clinical Materials Program
 
Vd
 
volume of distribution
 
VRC
 
Vaccine Research Center
 
WBC
 
white blood cell
 
WT
 
Wild Type
 
 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
9
 
of 73
 
PRÉCIS
 
 
VRC 607
/A5378
:
 
A Phase 1, Single Dose Study of the Safety and Virologic Effect of 
an 
HIV
-
1 Specific 
Broadly Neutralizing 
Human Monoclonal Antibod
y
, 
VRC
-
HIVMAB080
-
00
-
AB 
(VRC01LS)
 
or
 
VRC
-
HIVMAB07
5
-
00
-
AB (VRC07
-
523LS)
, Administered 
Intravenously to HIV
-
Infected Adults.
 
Study Design:  
 
O
pen
-
label, single dose study
 
to examine safety, tolerability, pharmacokinetics and 
virologic impact of VRC01LS or VRC07
-
523LS in HIV
-
infected viremic adults
.
 
Study Hypotheses:
 
This is the first study of VRC01LS or VRC07
-
523LS in HIV
-
infected viremic adults. 
The primary hypothesis is that
 
both
 
VRC01LS 
and 
VRC07
-
523LS 
will be 
safe for 
intravenous administration to HIV
-
1
-
infec
ted adults.
 
The secondary hypothesis is that 
VRC01LS 
and VRC07
-
523LS 
will be detectable in human sera with a definable half
-
life. 
Part A (VRC01LS) of the study has completed
 
enrollment
.
 
Product
 
Description
: 
 
VRC
-
HIVMAB080
-
00
-
AB (VRC01LS) 
and 
VRC
-
HIVMAB075
-
00
-
AB are
 
human 
MAb
s
 
targeted to the CD4
+
 
binding site of HIV
-
1.
 
Both MAbs are 
modification
s
 
of 
the VRC01 MAb (which has been shown to be safe
 
and to have antiviral activity
 
in 
human studies) with the addition of the “LS”, 
a 
2
-
amino acid muta
tion designed to 
improve the half
-
life of the antibody.
 
There are no changes to the Fab binding sites.
 
These MAbs were
 
developed and manufactured by VRC/NIAID/NIH under cGMP at 
the VRC Vaccine Pilot Plant operated under contract by the Vaccine Clinical 
Mat
erials Program (VCMP), Leidos Biomedical Research, Inc., Frederick, MD. Vials 
are provided at 100 mg/mL. 
 
Participants
:
 
HIV
-
1
-
infected viremic adults; 18
-
70 years of age.
 
Study Plan:
 
This study 
will
 
assess VRC01LS
 
or VRC07
-
523LS
 
administered at 40 mg/kg IV in 
HIV
-
infected viremic 
participants
. 
Participants
 
will 
enroll
 
in
 
one of
 
two 
parts
:
 
Part A 
(VRC01LS) and Part B (VRC07
-
523LS)
. 
Enrollment into Part A
 
(VRC01LS)
 
is 
complete
.
 
Part B enrollment will 
include
 
7 
participants
 
(up to 1
0 
participants
 
may be 
enrolled in the event that there are 
participants
 
who do not complete the sampling 
schedule)
 
who will receive VRC07
-
523LS
.
 
Safety lab samples, HIV viral load, CD4
+
 
count, PK samples
,
 
and blood samples for human anti
-
VRC01LS antibody
 
(Part A)
 
and human anti
-
VRC07
-
523LS antibody
 
(Part B)
 
detection will be drawn at baseline 
and intervals throughout the study. 
Participants
 
will keep a daily diary of 
reactogenicity
 
symptoms for 3 days after 
study product 
adminis
tration
 
and will be 
queried 
at each study visit for adverse events.
 
Participants
 
in Part B
 
will 
be 
strongly 
encouraged
 
to 
initiate 3
-
drug ART (prescribed by their primary HIV clinician; not 
study
-
provided) 
any time 
after
 
completing
 
day 
14 
study
 
evaluations
.
 
 
Results from Part A and 
Part B may be analyzed, published, and presented separately 
since they involve two different MAbs.
 
 
 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
10
 
of 73
 
 
 
VRC 607
/A5378
 
Study Schema
 
Part
s
 
Participants
 
Product
 
Administration Schedule
 
Day 0
 
Part A
 
(Enrollment complete)
 
7
 
VRC01LS
 
40 mg/kg IV
 
Part B
 
7
 
VRC07
-
523LS
 
40
 
mg/kg IV
 
Total*
 
1
4
 
 
*The expected enrollment is 1
4
 
participants
 
(i.e., a minimum of 7 
participants
 
in each 
part
)
. 
However, up
 
to 20 
participants
 
(i.e., 10 
participants
 
in each 
part
)
 
may be enrolled in the event that there are 
participants
 
who do not complete the sampling 
schedule, if additional PK evaluations are needed, or if additional 
participants
 
are needed for safety evaluations
.
 
 
Study Duration:  
 
Participants
 
will be followed for 
48
 
weeks after study product administration.
 
 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
11
 
of 73
 
 
INTRODUCTION
 
The global incidence of new human immunodeficiency virus (HIV) infection
s
 
peaked in 
the mid
-
1990s
. The incidence of new infections 
in 201
4
 
is reported by 
Joint United Nations Programme on 
HIV/AIDS
 
(
UNAIDS
)
 
as 2 
million new cases, down from 2.9
 
million in 200
5
, 
with a
n estimated
 
global 
total of 3
6.9
 
million people living with HIV.
 
The reduction of HIV incidence is due to 
mul
tiple factors that include 
prevention
 
and treatment
 
programs.
 
The decrease in incidence is an 
encouraging trend, but the sc
ope and cost of the epidemic 
remains of 
great 
global concern
. The 
wider availability of 
anti
retroviral
 
(AR
V
)
 
treatment
, 
mother to child transmission prevention 
programs, and
 
a diverse array of
 
other prevention programs have all contributed to turning the t
ide 
of the epidemic
 
[
1
]
.
 
Each effective form of prevention and treatment is a welcome public health 
measure.
 
 
The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health 
(NIH) is committed
 
to the development of safe, effective methods to prevent and treat HIV 
in
fection and AIDS worldwide. 
In this regard, the Vacci
ne Research Center (VRC), NIAID, 
Division of AIDS (DAIDS), NIAID,
 
and AIDS Clinical Trials Group (ACTG)
 
are collaborating to 
eval
uate the potential clinical uses of HIV
-
specific broadly neutralizing human monoclonal 
antibodies (MAb) 
[
2
, 
3
, 
4
]
. 
 
The VRC, NIAID, NIH developed 
VRC01LS
 
and VRC07
-
523LS
, highly potent and broadly 
neutralizing HIV
-
1 human MAb
s
 
targeted against the HIV
-
1 CD4
+
 
binding site
 
[
5
]
. 
The predecessor 
of VRC01LS and VRC07
-
523LS, V
RC01, is in clinical trials under IND 113611 for prevention 
indication and under IND 126001 and IND 126664 for therapeutic indication. VRC01 was 
originally discovered in a subject infected with HIV
-
1 for more than 15 years and whose immune 
system controlle
d the virus without anti
-
retroviral therapy 
[
6
]
. 
The VRC01 sequence was modifie
d 
by site
-
directed mutagenesis to increase its binding affinity for the neonatal Fc receptor (FcRn) and 
the resulting antibody was designated VRC01LS. The LS designation specifies methionine to 
leucine (L) and asparagine to serine (S) 
(M428L/N434S, referre
d to as LS) 
changes within the C
-
terminus of the heavy chain constant region far outside of the antigen
-
binding site 
[
7
]
. Other than 
the two amino acid difference, VRC01LS is identical to VRC01. VRC01LS has an extended ha
lf
-
life in both serum and mucosal tissue compared to VRC01, persists at higher concentrations in 
mucosal tissues, and has demonstrated improved protection against primate 
simian
-
human 
immunodeficiency virus (
SHIV
)
 
infection 
[
5
]
. 
VRC01LS is currently in clinical trials
 
in HIV 
uninfected adults
 
under IND 125494 for 
its HIV 
prevention indication. 
The VRC07 (wild
-
type) 
heavy chain was identified by 454 deep sequencing based on its similarity to the VRC01 MAb and 
paired with the V
RC01 (wild
-
type) lig
ht chain. 
The mutations that together define the 523 
designations are a glycine to histidine mutation at residue 54 of the heavy chain, a deletion of the 
first two amino acids, glutamate and isoleucine, from the light chain, and a 
valine to serine mutation 
at the third amino ac
id residue of the light chain.
 
The LS designation specifies methionine to leucine 
(L) and asparagine to serine (S) 
(M428L/N434S, referred to as LS) 
changes within the C
-
terminus 
of th
e heavy chain constant reg
ion. 
Like VRC
0
1LS, t
he LS mutation 
of VRC07
-
523LS 
was 
introduced by site
-
directed mutagenesis to increase the binding affinity for the neonatal Fc
-
receptor 
(FcRn), resulting in increased recirculation of functional IgG 
[
5
, 
7
]
, thus increasing plasma half
-
life. 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
12
 
of 73
 
In this study, VRC01LS 
or VRC07
-
523LS 
will be evaluated in HIV
-
1 infected 
participants
 
for 
a 
pote
ntial treatment indication. 
 
 
R
ATIONALE FOR THE
 
S
TUDY 
 
The 
VRC considers the potential clinical uses for broadly neutralizing MAb in three broad areas: 1) 
prevention of transmission from HIV
-
1 infected mothers to newborn and breastfeeding infants, 2) 
prevention of HIV infection by sexual transmission, and 3) thera
peutic application in HIV
-
1 
infected individuals. 
This last application will be the focus of this study for a potential 
application
 
of VRC01LS
 
or VRC07
-
523LS 
in the mana
gement of HIV
-
1 infected 
people
.
 
The increased half
-
life and persistence 
of VRC01LS and
 
VRC07
-
523LS 
at higher concentrations in mucosal tissues 
correlate with improved protection against SHIV infection 
in vivo 
in animal studies,
 
suggesting a 
potential clinical application for the prevention or treatment of HIV
-
1 infection in humans. 
In th
is 
study, 
we will 
monitor
 
the viral load and 
pharmacokinetics 
and pharmacodynamics 
of VRC01LS 
or 
VRC07
-
523LS 
among
 
HIV
-
1 infected viremic adults 
to determine whether a therapeutic effect is 
present following the administration of one dose. 
 
 
VRC01LS
 
AND 
VRC07
-
523LS
 
S
PECIFIC 
R
ESEARCH 
L
ABORATORY 
A
SSESSMENTS
 
Research assays designed to characterize the investigational product rather than assess the health of 
the 
participants
 
are described below.
 
Laboratory assessments in the Phase 1 studies of the VRC01L
S 
or the VRC07
-
523LS 
MAb include 
pharmacokinetics, assessment for the development of anti
-
VRC01LS 
or anti
-
VRC07
-
523LS 
antibody following exposure to the 
study 
product
s
, and functional capacity (neutralization) of the 
MAb
s
 
following infusion.
 
 
Study product
 
(VRC01LS or VRC07
-
523LS) 
concentration for the PK analysis in this Phase 1 
study will be measured by an ELISA 
on a Beckman Biomek based automation platform. The 
MAb
 
is coated onto Immulon
-
4hXB microtiter plates overnight at 4
°
C at a concentration of 3.5 m
g/mL. 
Plates are washed and blocked (10% FBS in PBS) for 2 hours at room temperature. Duplicate serial 
3
-
fold dilutions covering the range of 100
-
24300 of the test sample are incubated 2 hours at 37
°
C 
followed by Horseradish Peroxidase
-
labeled goat anti
-
hu
man antibody (1 hour, 37
°
C), and TMB 
substrate (15 minutes, room temperature). Color development is stopped by addition of sulfuric acid 
and plates are read within 30 minutes at 450 nm via the Molecular Devices Paradigm plate reader. 
The 4
-
parameter logist
ic curve regression of a standard curve of 
the MAbs
 
covering the range from 
0.031 to 1.0 mcg/mL is utilized in this assay to quantitate the sample concentrations based upon the 
average of sample dilutions within the range of the assay.
 
 
 
Assessment for development of anti
-
VRC01LS 
or anti
-
VRC07
-
523LS 
antibodies in 
participants
 
will be performed
 
using the
 
Meso Scale Discovery (MSD) platform based on 
electrochemiluminescence.
 
The developed anti
-
drug antibody (ADA) assay uses the biotin
-
labele
d 
VRC01LS 
or VRC07
-
523LS 
immobilized on a streptavidin
-
coated MSD plate as the capture 
molecule, and 
the SULFO
-
TAG labeled VRC01LS 
or VRC07
-
523LS 
as the reporter molecule
. 
This 
assay is independent of the anti
-
VRC01LS 
or VRC07
-
523LS 
antibody isotype
 
and pe
rmits the 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
13
 
of 73
 
detection of both high and low affinity antibodies. Additional testing may be conducted with 
VRC01
-
based assay if positive ADA is detected to VRC01LS
 
or VRC07
-
523LS
.
 
Depending upon the concentrations measured in collected specimens, further evalu
ation of the 
research samples to assess for functional capacity to neutralize HIV may be conducted by an 
in 
vitro
 
cell
-
based virus neutralization assay using the pseudotyped viruses 
[
8
, 
9
, 
10
]
.
 
As an exploratory evaluation, 
participants
 
may be evaluated for their IgG1 allotypes to determine 
the potential for theoretical allotype
-
specific effects on the VRC01LS pharmacokinetics
,
 
such as 
reduced half
-
lif
e or anti
-
drug antibody response 
[
11
, 
12
, 
13
]
. Coded stored samples 
may 
be used for 
evaluation of the genetic sequence of the immunoglobulin heavy chain constant region 
allotype
.
 
 
P
REVIOUS HUMAN EXPERI
ENCE
 
VRC01LS and VRC07
-
523LS are very similar to t
heir predecessor, VRC01. VRC01 was tested in 
two phase 1 clinical trials
,
 
VRC 601 (in HIV
-
1 infected adults) and VRC 602 (in healthy adults) 
(see Section 1.
3
.1) at the VRC. VRC01LS and VRC07
-
523LS are currently being evaluated in 
clinical trials in healthy
 
adults at the 
VRC
, NIH, Bethesda, MD. Initial safety data for VRC01LS 
(data from VRC 606) and VRC07
-
523LS (data from VRC 605) is summarized below
 
1.3.1
 
VRC01 
Safety D
ata
 
 
Evaluations of the highly neutralizing
 
antibody 
VR
C01
 
as an investigational drug
 
began 
in
 
humans 
in
 
September 2013. 
As of 
the beginning of 
January
 
2017
, more than 
840 
adult
s
 
have received 
1 
or 
more study product administrations of VRC01 in a dose range from 1 to 40 mg/kg 
through 
intravenous (
IV
) administration
 
and at 5 mg/kg 
through subcutaneo
us (
SC
) administration
. 
VRC01
 
has
 
been tested
 
in 
27 
HIV
-
infected 
adults in
 
the 
VRC 601
 
study
 
[
14
]
, in 
29 and 84 
healthy adults in
 
VRC 602 
[
15
]
 
and 
HVTN 104 studies
,
 
respectively
 
(IND 11361
1)
. 
Under IND 126001 in 2015, 
studies were initiated in HIV
-
1 infected adults to evaluate the safety and virological effect of 
VRC01 administration during acute HIV infection (RV398), during a brief analytical treatment 
interruption 
in chronically infected
 
individuals 
(A5340)
,
 
and the effect on the HIV reservoir 
(A5342)
. 
 
Cu
mulatively
 
across 
all studies to 
date (
January 10, 2017
),
 
there have been no 
serious adverse 
events (SAEs) related to VRC01 that required 
expedited safety report
ing 
to the 
US 
Food and 
Drug 
Administration (
FDA
)
 
or 
other regulatory authorities
, and no
 
study saf
ety pauses for adverse events
 
(AEs)
. 
A non
-
serious AE of 
urticaria
 
was submitted to regulatory authorities as a safety report 
because urticaria, at the grade 3 severity, was not rep
orted in the 
Investigator’s Brochure (
IB
)
 
(Version 6.0, dated October 5, 2016).
 
As of May 10, 2018, no 
SAE
s
 
related to VRC01 have been 
reported across all studies (communication from DAIDS).
 
SC administrations
 
of VRC01
 
in adults 
have been 
associated with m
ild local reactions during 
product
 
administration
 
includ
ing
 
some 
pruritus, redness
,
 
and swelling
.
 
Symptoms generally 
resolve 
within a few minutes to a few hours after 
completion of product 
administration. 
In adults, 
e
rythema
/induration reactions were 
reported rarely; t
he largest 
observed 
diameter for erythema or 
induration 
events during infusions ranged up to about 
9
 
cm.  
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
14
 
of 73
 
In VRC 602, 2 out of 5 
subjects 
who received a 5
 
mg/kg SC dose of VRC01 reported mild pain 
during product administration that resol
ved within 5
-
7 minutes. In VRC 606, 2 out of 2 
subjects 
who received a 5
 
mg/kg SC dose of VRC01 reported
 
moderate 
pain during product administration 
that resolved within 
0
-
2 minutes. 
O
ne
 
(1)
 
subject in VRC 601 
(5 mg/kg SC) 
reported mild nausea 
during VRC01
 
SC administration.
 
Most subjects 
experienced
 
mild systemic reactogenicity
 
or none at all
. 
The 
systemic symptoms
 
most commonly reported
 
were
 
malaise/fat
igue, myalgias, and headaches. 
Of the 3 subjects who 
reported severe systemic reactogenicity in 
the 
HVTN
 
104 study, 2 had concurrent viral infections, 
and 1 had malaise lasting 1 day. 
 
Additional 
information on solicited reactogenicity in other s
tudies can be found in the IB. 
Overall, 
the solicited local and systemic signs and symptoms following administration of VRC01 
have
 
generally 
been 
none to mild.  
 
A
dverse events attributed to 
VRC01 
study product administration on the basis of temporal 
relationship 
that have not resulted 
in study product discontinuation
 
include 
transient laboratory 
abnormalities (
aspartate aminotransferase [
AST
]
, 
alanine aminotransferase [
ALT
],
 
and creatinine 
elevation
; 
decreased neutrophil count
)
, diarrhea,
 
herpes zoster,
 
urticaria, dizziness,
 
and pruritu
s at 
the a
dministration site. 
Adverse events attributed to study product administration
 
(VRC01 or 
placebo)
 
on the basis of temporal relationship for which the schedule of study product 
administration was discontinued include one subject 
(placebo recipient)
 
with 
mild 
chest discomfort
 
and one subject with 
a mild 
generalized
, pruritic, papular
 
rash
.
 
The participant with rash had 
received a loading IV dose of VRC01 and 2 weeks later received anoth
er VRC01 dose by SC 
injection. 
Symptoms developed 3 days after th
e 2
nd
 
dose and had resolved by the next day.
 
Both 
AEs 
resolved without clinical sequela
.
 
An HVTN 104 subject who experienced syncope a few hours 
after the IV infusion of VRC01 was also discontinued from 
the product administration schedule
, 
although the event was assessed as unrelated. 
 
In the P1112 study in infants, VRC01 has been very well tolerated when administered SC in either 
of the two single dose cohorts (Group 1 and Group 2) and in th
e monthly dose group (Group 3). 
There have been 
no systemic reactions to VRC01; local reactions (induration and/or erythema) have 
been mild and self
-
limiting.
 
Overall, VRC01 
administration 
in the dose range from 1 to 40 mg/kg IV and at 5 mg/kg SC have 
been assessed as well
-
tolerated and safe for further
 
evaluation
 
[
1
4
, 
15
]
. 
Refer to the current IB for a 
more updated information about the safety of VRC01. 
 
1.3.2
 
VRC01LS Safety Data
 
Evaluation of VRC01LS began in the VRC 606 study in healthy adults in November 2015.  The 
safety and PK data for the first 37 
subjects
 
who received administrations of VRC01LS 
were 
published in 2018
 
[
16
]
. 
 
In summary, VRC01Ls administrations have been generally well tolerated when delivered IV or 
SC, and there were no SAEs or dose
-
limiting toxicity. Post
-
administration symptoms were mi
ld or 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
15
 
of 73
 
moderate for local and systemic reactogenicity. Mild malaise and myalgia were the most common 
solicited AEs reported by 10 and 6 
subjects
, respectively. The most frequent local reaction was 
pain/tenderness at the injection site, reported by 14 
subjec
ts
 
(2 for IV and 12 for SC administration) 
at a maximum severity being mild and moderate by 1 
subject
 
for SC product administration. 
Observations during product administration included brief reactions of local pain and/or stinging 
sensations at SC administ
ration sites (15 of 18 
subjects
, 83.3%)
 
that
 
resolved within 2
-
5 minutes 
after injection. These reactions were consistent with known risks of injections and did not meet 
criteria for reporting as AEs as defined by the Table for Grading Severity of Adverse 
Events 
(
Appendix IV
). No systemic symptoms were reported during product administration. 
 
Six 
(6) 
AEs were assessed as possibly related to VRC01LS administration and all were mild in 
severity. Two
 
(2)
 
reports of diarrhea, 
1 
in Group 1 (5 mg/kg, IV, 
subject
 
01606101) and 
1 
in Group 
5 (5 mg/kg x 3 times, SC, 
subject
 
01606501), occurred on the day of VRC01LS administration and 
resolved the same day. One 
(1) 
Group 2 
subject 
(5 mg/kg, SC, 
subject
 
01606201) experienced 
lightheadedn
ess on the day following administration, and symptoms resolved within 24 hours. One
 
(1)
 
AE in Group 5 (5 mg/kg x 3 times, SC, 
subject
 
01606506) pertained to an injection site reaction 
with hyperpigmentation that resolved 14 days post administration. Two 
(2
) 
AEs in Group 5 (5 
mg/kg x 3 times, SC, 
subject
 
01606508) were due to elevated 
ALT
 
levels (56 and 69 IU/L) on day 
14 post injection and both resolved within 15 days after onset. No 
subject
 
had a positive HIV 
enzyme immunoassay (EIA) response during the st
udy.
 
As of January 17, 2018, 7 viremic participants were enrolled in
 
Part A of
 
VRC 607
/A5378
 
and 
received one infusion of VRC01LS at 40
 
mg/kg IV as planned and are in follow
-
up. During 
VRC01LS administrations, no local or systemic reactogenicity was report
ed. All 7 participants 
reported maximal solicited local reactogenicity as “none” on a 3
-
day diary card. As to systemic 
solicited reactogenicity, one participant 
reported 
mild symptoms of headache, chills
,
 
and nausea that 
resolved within 7
-
11 days after pro
duct administration. No SAEs were reported; all unsolicited AEs 
were Grade 1 (mild) or Grade 2 (moderate) and assessed as unrelated to study product.
 
Refer to the 
IB
 
for more details on the VRC01LS safety data.
 
1.3.3
 
VRC07
-
523LS Safety Data
 
As of January 15, 201
8, the VRC 605 study is fully enrolled. Twenty
-
five (25) of 26 
subjects
 
received at least 1 dose of VRC07
-
523LS (12 SC and 25 IV administrations). One subject withdrew 
from the study prior to receiving the study product. There have been no SAEs and no stud
y safety 
pauses for AEs. Overall, 15 of 25 subjects who received the product (60%) have had at least 
1 
AE 
with the maximum severity being 
Grade 
1 for 7 
subjects
 
and 
Grade 
2 for 6 
subjects
, 
Grade 
3 for 1 
subject and 
Grade 
4 for 
1 
subject
. The 
Grade 
3 AE was
 
for an elevated creatinine 56 day
s
 
after the 
last product administration. This was most likely related to dehydration following exercise. The 
creatinine value was determined to be a 
Grade 
3 based on the DAIDS Grading Table parameter of 
an increase of 1.5 
to 2 times the baseline value, which was still well within the institutional normal 
range. The 
Grade 
4 AE was for elevated li
ver enzymes likely related to 
starting a concomitant 
medication, fluoxetine, known to cause hepatoxicity, and not related to VRC07
-
523LS. VRC07
-
523LS administrations were discontinued for this subject due to the concomitant illness. While the 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
16
 
of 73
 
subject was being followed for safety, liver enzymes tests fluctuated again after starting citalopram
,
 
which reinforced that the event was most likely caused by an underlying sensitivity to selective 
serotonin reuptake inhibitor (SSRI) medications. This 
Grade 
4 laboratory abnormality was not 
considered life
-
threatening as it was not clin
ically significant 
as there was
 
no hospitalization, 
jaundice, coagulopathy, bleeding, or ascites. Six (6) mild or moderate AEs were assessed as related 
to study product including mild dizziness, 4 occasions of infusion reactions (1 mild and 3 moderate, 
reported for 2 subject
s), and mild abdominal pain. All AEs assessed as related to the study product 
have resolved without residual effects. 
 
Two 
(2) 
subjects developed infusion reactions shortly after IV product administration. Symptoms 
were typical of infusion reactions observ
ed with other 
MAbs
 
[
17
]
. No atypical symptoms or delayed 
symptoms were seen. Specifically, one subject enrolled in the 40
 
mg/kg IV group experienced a 
moderate infusion reaction with chills, ri
gors, fever, myalgia, and headache beginning 15 minutes 
after completion of the infusion. The subject was treated with acetaminophen and ibuprofen. All 
symptoms resolved within 12 hours. Another subject in the 20
 
mg/kg IV group experienced 3 
separate infus
ion reactions (n=2 moderate, n=1 mild) after each product infusion. The subject 
experienced nausea, chills, rigors, malaise, tachycardia, headache, myalgia, and arthralgia. 
Symptoms began 15 minutes to 1 hour after completion of each product administration
 
and 
completely resolved within 12 hours. The subject was treated with acetaminophen and ibuprofen. 
 
Overall, product administrations have been generally well tolerated with no unexpected reactions. 
 
For solicited local reactions in the week after 
VRC07
-
523LS administrations, one of 17 subjects 
(5.9%) who received the product by IV administration reported mild bruising at
 
the 
administration 
site, and 5 of 8 subjects (62.5%) who received the product SC reported mild pain/tendernes
s at the 
injection s
ite
 
[
Investigator’s Brochure
,
 
Version 4.0
,
 
dated February 26, 2018
;
 
VRC07
-
523LS VRC
-
HIVMAB075
-
00
-
AB CONFIDENTIAL 45]
.
 
For solicited systemic adverse events reported 3 days after product administration, 4 of 17 subjects 
(25%) receiving VRC07
-
523LS IV report
ed mild or moderate systemic reactogenicity symptoms. 
The reported symptoms were malaise (n=2 mild, n=1 moderate), myalgia (n=2 mild, n=1 moderate), 
mild headache (n=2), and moderate chills (n=2). Five (5) of 8 subjects (62.5%) receiving VRC07
-
523LS SC rep
orted mild systemic reactogenicity symptoms: malaise (n=3), myalgia (n=2), 
headache (n=3), chills (n=1), nausea (n=1), and joint pain (n=2).
 
Refer to the IB for m
ore 
details
 
on the VRC07
-
523LS
 
safety data.
 
1.3.4
 
A
ntiviral E
ffect of VRC01
 
Analysis of the VRC 601 
viral load data obtained from 8 viremic adults show
ed 
that VRC01 has a 
statistically significant 
in vivo
 
virological effect on HIV viral load 
when administered as a single 40 
mg/kg IV dose
.
 
None of these adults were taking AR
V
 
when enrolled into the study 
and had not 
started AR
V
 
during the time period when the 
viral load data were collected.
 
Six
 
(6)
 
of the 
8 
adult 
subjects had ≥1 log
10
 
copies/mL decrease in viral load and 
2 
subjects had a viral load drop of 0.26 
and 0.18 log
10
 
copies/mL
,
 
respectively
 
[
15
]
.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
17
 
of 73
 
These data indicate
d
 
the following
 
for a single dose of VRC01 at 40 mg/kg IV:
 
•
 
A statistically significant change from baseline viral load post
-
infusion days 5 to 16; 
 
•
 
The median time to reach ≥0.5 log
10
 
decrease in viral load 
was 
5 days; and,
 
•
 
The median time to greatest decrease in viral load 
was 
7 days.
 
A 0.5 log
10
 
copies/mL or greater decrease in viral load is considered to be a positive response to 
AR
V
 
[
18
]
.
 
To have clinical benefit, such a cha
nge would need
 
to be sustained.
 
In VRC 601, 
subjects were administered only one dose of VRC01 at 40 mg/kg and, thus, a sustained effect on 
viral load was not expected
. 
 
 
 
P
HARMACOKINETIC 
P
ARAMETERS
 
Based on animal studies, VRC01LS
 
has
 
a 2.5
-
 
to 3
-
fold increase in half
-
life in macaques 
as 
compared to VRC01
 
[
5
]
.
 
The PK parameters
 
of VRC01LS
 
is currently under evaluation in VRC 
606 in healthy individuals. 
In our interim, preliminary evaluation of the pharmac
okinetics
 
in
 
VRC 
606, VRC01LS appears to persist longer and at a higher serum concentration than VRC01 following 
infusion at comparable doses. Formal statistical and PK analysis is ongoing
.
 
Based on the Gaudinski
, et al. study of VRC01LS, the clearance for
 
the 5
-
40 mg/kg dose range 
(n=16) was 36 ±
 
8 mL/d with an elimination half
-
life of 71 ±
 
18 days [
16
].
 
 
T
his
 
trial will study VRC01LS 
and VRC07
-
523LS 
pharmacokinetics in HIV
-
1
 
infected adults. 
 
 
STUDY 
PRODUCT
S
 
The 
study
 
products
, 
VRC
-
HIVMAB08
0
-
00
-
AB
 
(VRC01
LS
)
 
and VRC
-
HIVMAB075
-
00
-
AB 
(VRC07
-
523LS)
,
 
w
ere
 
produced under current Good Manufacturing Practice (cGMP)
 
by 
VRC/NIAID/NIH
 
at the VRC Vaccine Pilot Plant operated 
under contract 
by
 
the
 
Vaccine
 
Clinical 
Materials Program (VCMP),
 
Le
idos Biomedical Research, Inc. (formerly 
SAIC
-
Frederick, 
Inc.
)
, 
Frederick, 
MD
. Specific manufacturing information is included on the 
study 
product vial labels and 
Certificates of Analysis
, and can be found in
 
the
 
IB
s
. 
Quality Assurance (
QA
)
 
lot release testing by 
the manufacturer 
and ongoing stability programs 
verif
y
 
conformance to product specifications prior 
to use in clinical trials.
 
 
VRC
-
HIVMAB08
0
-
00
-
AB
 
VRC
-
HIVMAB08
0
-
00
-
AB (VRC01
LS
) 
is a 
broad
ly
 
neutralizing 
human 
MAb
 
targeted against the
 
HIV
-
1 CD4
+
 
binding site
. It was
 
developed by VRC/NIAID/NIH
. 
 
VRC01 was modified by site
-
directed mutagenesis to increase its binding affinity for the neonatal 
Fc receptor (FcRn)
. T
he resulting antibody 
is 
designated VRC01LS.
 
The LS designation specifies 
methionine to leucine (L) and asparagine to serine (S) 
(M428L/N434S, referred to as LS) 
changes 
within the C
-
terminus of the heavy chain constant region far outside of the antigen
-
combining site 
[
7
]
. 
The VRC01LS
 
is an IgG1,
 
and the glycosylation pattern is derived from its production in a 
Chinese Hamster Ovary (CHO) 
mammalian 
cell line.
 
  
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
18
 
of 73
 
The bulk lot of the drug substance was manufactured
 
under cGMP
 
using
 
a 
stably transfected 
CHO
 
cell line
, 
purified
, and t
he drug product vials were filled and labeled. 
Each 
product 
vial contains 
6
.25 mL volume at a concentration of 100 mg/mL VRC01
LS
 
in formulation buffer
 
containing 
25 
mM 
s
odium 
c
itrate, 50 mM 
s
odium 
c
hloride, and 150 mM L
-
a
rginine 
h
ydrochlorid
e at pH 5.8
.  
 
More details on 
the 
VRC
-
HIVMAB0
8
0
-
00
-
AB
 
composition and manufacturing can be found in
 
the
 
IB. 
 
 
VRC
-
HIVMAB075
-
00
-
AB
 
Like VRC01LS, VRC
-
HIVMAB075
-
00
-
AB (VRC07
-
523LS) is a broadly neutralizing human MAb 
targeted against the HIV
-
1 CD4
+
 
binding site
.
 
VRC07
-
523LS was developed by VRC/NIAID/NIH.  
Generation and testing of VRC07
-
523LS is briefly described
.
 
The VRC07 (wild
-
type) heavy chain 
was identified by 454 deep sequencing based on its similarity to the VRC01 MAb and paired with 
the VRC
01 (wild
-
type) light chain. The mutations that together define the 523 designations are a 
glycine to histidine mutation at residue 54 of the heavy chain, a deletion of the first 
2 
amino acids, 
glutamate and isoleucine, from the light chain, and a valine to
 
serine mutation at the third amino 
acid residue of the light chain. The LS designation specifies methionine to leucine (L) and 
asparagine to serine (S) (M428L/N434S, referred to as LS) changes within the C
-
terminus of the 
heavy chain constant region. The 
LS mutation was introduced by site
-
directed mutagenesis to 
increase the binding affinity for the neonatal Fc
-
receptor (FcRn), resulting in increased recirculation 
of functional IgG, thus increasing plasma half
-
life.
 
The bulk lot of the drug substance was m
anufactured 
under cGMP
 
using a stably transfected 
CHO
 
DG44 cell line and purified. The drug product was filled into glass vials and labeled at the VRC 
Pilot Plant. Each 10 mL glass vial contains 6.25 ± 0.10 mL at a concentration of 100 mg/mL ± 10 
mg/mL of 
VRC07
-
523LS in formulation buffer consisting of 50 mM Histidine, 50 mM Sodium 
Chloride, 5% Sucrose, and 2.5% Sorbitol at pH 6.8.  
 
More details on VRC
-
HIVMAB075
-
00
-
AB composition and manufacturing are found in the IB. 
 
 
P
RE
C
LINICAL 
S
AFETY
 
S
TUD
IES
 
The 
in vit
ro
 
preclinical safety studies performed to assess potential off target binding
 
by VRC01LS
 
and VRC07
-
523LS 
are summarized in 
Table 
2
.
3
-
1
. 
T
here was no unexpected off target binding.  
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
19
 
of 73
 
Table 
2
.
3
-
1
: 
In Vitro
 
Preclinical Safety Studies with VRC01LS 
and VRC07
-
523LS
 
Study Purpose
 
Study Outcome
 
Assessment of anti
-
phospholipid reactivity
 
VRC01LS does not react to phospholipids
. 
 
VRC07
-
523LS has slight reactivity to phospholipids. 
 
Assessment of anti
-
nuclear 
antigen reactivity
 
VRC01LS does not react with nuclear antigens
. 
 
VRC07
-
523LS does react with a small subset of 
nuclear antigens. 
 
Assessment of binding to a human epithelial cell 
line (HEp
-
2) by Immunohistochemistry
 
VRC01LS does not bind to HEp
-
2 cells
. 
 
VRC07
-
523LS has minimal reactivity with Hep
-
2 
cells. 
 
Assessment of potential “off target” binding in a 
human Tissue Cross
-
Reactivity study with 
VRC01LS and 
VRC07
-
523LS
 
VRC01LS variably stained 
cytoplasm and 
cytoplasmic granules in epithelial and/or deci
dual 
cells in 
several human tissues. The findings 
were 
judged of no toxicologic relevance for 
MAb 
[
19
, 
20
]
.
 
VRC07
-
523LS staining that was observed in both 
human and Sprague
-
Dawley rat tissues included 
cytoplasm, cytoplasmic granules, perinuclear, and/or 
apical cytoplasm of 
endothelium, epithelial cells, 
spindle cells, mononuclear cells, granulosa lutein 
cells, and neural cell processes. VRC07
-
523LS 
staining that was observed in human tissues only 
includ
ed cytoplasmic elements of hematopoietic cells, 
cells/processes associated with peripheral nerve, glial 
cell processes, reticular cells, mesothelial cells, 
interstitial cells, and adipocytes, and extracellular 
proteinaceous material in connective tissue of
 
the 
sclera.  
 
More information on these and other preclinical studies with VRC01LS
 
and VRC07
-
523LS
 
can be 
found in the IB. 
 
 
N
ON
H
UMAN 
P
RIMATE 
(NHP)
 
S
TUDIES
 
 
Several non
-
GLP studies of VRC01
LS
 
and VRC07
-
523LS 
have been completed in NHP to assess 
for 
preclinical evidence of potential efficacy for prevent
ion of HIV infection. 
Table 2
.4
-
1
 
is a brief 
summary of the studies performed and supports the plan to evaluate up to 40 mg/kg dose 
administered IV as a dose range of potent
ial interest for a preventive
 
or therapeutic
 
indication. 
More 
information on these studies can be found in the IB
 
for both study products
.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
20
 
of 73
 
Table 
2
.4
-
1
: Pre
-
clinical 
P
roof
-
of
-
concept 
S
tudies 
P
erformed with VRC01LS and VRC07
-
523LS in NHP
 
Study Outcome
 
Study
 
Purpose
 
Determine if VRC07
-
523LS could protect male 
Rhesus Macaques against SHIV infection compared 
to VRC01LS after IV administration of low sub
-
optimal protective dose (0.3 mg/kg) of MAb
 
7/12 animals were protected after receiving 
VRC01LS at 0.3 mg/kg 
IV, 3/4 animals were 
protected after receiving VRC07
-
523LS at 0.2 
mg/kg IV and 0/4 were protected after receiving 
VRC07
-
523LS at 0.05 mg/kg IV. VRC07
-
523LS 
showed >5
-
fold increase in potency compared to 
VRC01LS, consistent with its ability to better 
neutra
lize viruses 
in vitro
 
Determine serum and rectal tissue concentrations in 
female rhesus macaques administered 10 mg/kg of 
VRC01 (WT) or VRC01LS IV
 
Introduction of the LS mutation increased the half
-
life of VRC01LS 2.5
-
fold and reduced clearance 3
-
fold compared to VRC01 (WT). VRC01LS 
remained detectable in rectal tissue for more than 70 
days and persisted at significantly higher levels, 
while the VRC0
1 (WT) could not be measured after 
28 days 
[
5
]
.   
 
Determine serum and mucosal sample 
concentrati
ons in male and female cynomolg
us 
macaques administered 10 mg/kg of VRC07
-
523LS 
IV or 10 mg/mL of VRC01LS IV
 
When administered 
IV at a single dose of 10 mg/mL 
in cynomolgus macaques, the half
-
life 
of VRC01LS 
was about 30 days, a 3
-
fold increase compared to 
VRC01 (WT). Increased levels of VRC01LS were 
noted in rectal tissue, rectal secretions
,
 
and vaginal 
tissue at 28 days post ant
ibody infusion compared to 
VRC01 
[
5
]
. When administered IV at a single dose 
of 10 mg/kg in cynomolgus macaques, the half
-
life 
of VRC07
-
523LS was about 12 days. In all 4 
animals, plasma concentrations of VRC07
-
523LS 
exceeded 1
0 µg/mL at day 14 and were greater than 
3 µg/mL at day 28. Detectable concentrations of 
VRC07
-
523LS were found in rectal and vaginal 
secretions and tissues for at least 28 days (last 
collection point).
 
Determine serum and mucosal secretion 
concentrations 
in male and female rhesus macaques 
administered 10 mg/kg of VRC07
-
523LS SC or 
VRC01LS SC
 
When administered SC at a single dose of 10 mg/kg 
to rhesus macaques, the half
-
life of VRC01LS was 
about 28 days and VRC01LS was found in rectal, 
vaginal
,
 
and nasal secretions up to day 49 post 
administration (last day of testing). 
When 
administered SC at a single dose of 10 mg/kg in 
rhesus macaques, the half
-
life of VRC07
-
523LS was 
about 14 days. In all 6 animals, detectable 
concentrations of VRC07
-
523LS w
ere found in 
rectal, vaginal and nasal secretions for at least 49 
days (last collection point).
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
21
 
of 73
 
 
STUDY OBJECTIVES
 
 
P
RIMARY 
O
BJECTIVE
S
 
•
 
To eval
uate the safety
 
and tolerability
 
of 
VRC01LS 
or VRC07
-
523LS 
administered at 
40 
mg/kg IV
 
to HIV
-
1 
infected 
viremic 
adu
lts.
 
 
S
ECONDARY 
O
BJECTIVES
 
•
 
To evaluate the pharmacokinetics of VRC01LS
 
or VRC07
-
523LS
 
at 40 mg/kg IV through 
the first 
48 
weeks
 
post administration
.
 
•
 
To evaluate the effect on CD4
+
 
count 
and viral load 
through study week 
48
.
 
•
 
To determine whether anti
-
drug antibody (ADA) to VRC01LS 
or VRC07
-
523LS 
c
an be 
detected post
-
administration. 
 
 
E
XPLORATORY 
O
BJECTIVES
 
•
 
To evaluate HIV
-
1 isolates throughout the study for a variety of 
genotypic and phenotypic 
parameters including sensitivity 
to VRC01LS
 
or VRC07
-
523LS
 
neutralization.
 
 
STUDY DESIGN
 
This is
 
a
n open
-
label,
 
single dose 
study to examine 
the 
safety
, 
tolerability, 
pharmacokinetics
,
 
and 
virologic effect 
of
 
the 
MAbs
, VRC01
LS
 
or VRC07
-
523LS
, in 
HIV
-
1 infected viremic 
adults
 
conducted at the VRC and 
sites within the ACTG network
.
 
The hypothesis is that 
both 
VRC01
LS
 
and VRC07
-
523LS 
will be safe for administration to 
HIV
-
1 infected 
adults by the IV 
route
. 
The
 
secondary
 
hypothesis
 
is
 
that
 
VRC01LS
 
and VRC07
-
523LS 
will
 
be
 
detectab
le
 
in
 
human
 
sera
 
with
 
a
 
definable
 
half
-
life.
 
 
The study 
schema is 
shown in 
Table 
4
-
1
.
 
Table 4
-
1. VRC 607
/A5378
 
Study Schema
 
Parts
 
Participants
 
Product
 
Administration
 
Schedule
 
Day 
0
 
Part A
 
(Enrollment Complete)
 
7
 
VRC01LS
 
40 
mg/kg IV
 
Part B
 
7
 
VRC07
-
523LS
 
40
 
mg/kg IV 
 
Total*
 
1
4
 
 
*The
 
expected
 
enrollment
 
is
 
1
4
 
participants
 
(i.e., a minim
um of 7 
participants
 
in each part
)
. 
However, up
 
to 20 
participants
 
(i
.e., 10 
participants
 
in each part
) 
may be enrolled in the event that there are 
participants
 
who do not 
complete the sampling schedule, if additional PK evaluations are needed, or if additional 
participants
 
are needed for 
safety evaluations
.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
22
 
of 73
 
Enrollment
 
in
to Part A (VRC01LS)
 
is complete
. Participants 
will be enrolled into Part B (VRC07
-
523LS)
. 
Bl
ood 
and urine 
samples for s
afety
 
laboratory
,
 
and
 
PK
 
evaluations
 
will be collected from 
all 
participants
 
at specified time points
 
per the Schedule of Evaluations
 
(
Appendix III
). 
Participants
 
will
 
keep
 
a
 
daily
 
diary
 
of
 
solicited
 
systemic
 
symptoms
 
for
 
3
 
days
 
after
 
product 
administration
.
 
Participants
 
will 
be 
strongly encouraged
 
to 
initiate 3
-
drug 
antiretroviral therapy (
ART
), that is 
prescribed by their primary HIV clinician
 
and 
not study
-
provided
, 
any
 
time 
after
 
completing
 
day 
14 
study
 
evaluations
.
 
PK
-
enhancing agents will not be counted as part of the 3
-
drug ART regimen.
 
 
S
TUDY 
P
OPULATION
 
All inclusion and exclusion criteria must be met for eligibility.
 
4.1.1
 
Inclusion Criteria
 
A 
participant
 
must meet all of the following criteria:
 
1.
 
Able 
and willing to complete the informed consent process.
 
2.
 
18
-
70 years old 
 
3.
 
Available for clinic visits for 48 weeks after
 
study product administration
. 
 
4.
 
HIV
-
1
 
infected and clinically stable.
 
[Note: 
Documented HIV
-
1 infection by HIV enzyme immunoassay (EIA) 
per
formed by a
 
CLIA certified
 
outside lab 
within 28 days of enrollment is acceptable.] 
 
5.
 
At
 
least one plasma viral load ≥500 copies/mL
 
within 28 days of enrollment.
 
A 
plas
ma viral 
load within 28 days and closest to the day of enrollment, that is detectable but not greater 
than 
100,000 copies/mL
. 
 
[Note: outside 
laboratory results will be acceptable
]
.
 
6.
 
A 
CD4
+
 
count ≥350 cells/mcL 
on 
2 
of 
3 
consecutive testing occasions (or on
 
2 
of 
2 
sequential test
s
)
 
within 
28
 
days
 
prior to 
enrollment
. 
 
[
Note:
 
outside laboratory results will be acceptable
]
.
 
7.
 
In general good health
 
as assessed by a study clinician
 
and 
under the care of a 
primary 
health care provider for medical management of HIV
 
infection while participating in the 
study.
 
Willing to g
ive consent to contact and send laboratory results to the 
participant’s
 
primary health provider. 
 
8.
 
Willing to have blood samples collected, stored indefinitely, and used for various research 
purposes.
 
 
9.
 
Able to provide proof of identity to the satisfaction of the study clinician completing the 
enrollment process.
 
10.
 
Screening laboratory values 
within 
28
 
days prior to enrollment must meet the following 
criteria:
 
•
 
Absolute neutrophil count ≥800/mcL
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
23
 
of 73
 
•
 
Platelets 
≥100,000/mcL
 
•
 
Hemoglobin ≥10.0 g
/dL
 
•
 
Creatinine ≤1.31 mg/dL
 
•
 
ALT ≤2.5 x ULN
 
•
 
Negative Hepatitis B Surface Antigen
 
(HBsAg)
 
•
 
Undetectable Hepatitis C Viral Load
 
(HCV RNA)
 
[Note: Documented negative HBsAg and HCV RNA 
performed by an outside 
CLIA 
certified 
lab 
with
in 28 days of enrollment 
are 
acceptable.]
 
Female
-
Specific Criteria:
 
11.
 
If a woman is
 
sexually active with a male partner and 
has 
no history of hysterectomy, tubal 
ligation, or menopause
, she must
 
agree to use 
either 
a prescription birth control method or 
a 
barrier birth control method from the time of study enrollment until the last study visit,
 
or 
have a monogamous partner who has had a vasectomy
.
 
12.
 
Negative β
-
HCG (human chorionic gonadotropin) pregnancy test (urine or serum) on day of 
enrollment for women pr
esumed to be of reproductive potential.
 
4.1.2
 
Exclusion Criteria
 
A 
participant
 
will be excluded if one or more of the following conditions apply
:
 
1.
 
Previous receipt of humanized or human monoclonal antibody whether licensed or 
investigational.
 
2.
 
Prior use of antiret
roviral therapy.
 
3.
 
Ongoing AIDS
-
related opportunistic infection (including oral thrush)
.
 
4.
 
Active
 
drug or alcohol use or dependence
 
in the opinion of the site investigator
 
that 
would 
interfere with adherence to study requirements.
 
5.
 
Any h
istory of a severe 
allergic reaction
,
 
including 
generalized urticaria, angioedema or 
anaphylaxis prior to enrollment
,
 
that has a reasonable risk of recurrence during the study.
 
6.
 
Physical finding on examination considered clinically significant
.
 
7.
 
Hypertension 
that is 
not
 
well controlle
d.
 
8.
 
Weight >115 kg (253 pounds).
 
9.
 
Breast
-
feeding.
 
10.
 
Receipt of 
any 
investigational study produc
t with
in 28 days prior to enrollment.
 
11.
 
Any other chronic or clinically significant medical condition that in the opinion of 
the 
investigator would jeop
ardize the safety or rights of the volunteer.  
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
24
 
of 73
 
 
C
LINICAL 
P
ROCEDURES AND 
L
ABORATORY 
A
SSAYS
 
Evaluati
on of safety 
for
 
this study
 
will include laboratory studies, medical history, 
and 
physical 
assessment by clinicians
. 
The 
study 
schedule is provided in 
Appendix III
. Total blood volume 
drawn from each 
participant
 
will 
comply with
 
the NIH Clinical Center Guidelines
, which is 
available on the NIH intranet at: 
http://cc
-
internal.cc.nih.gov/policies/PDF/M95
-
9.pdf
.
 
 
All 
participants
 
will 
be counseled to continue follow up with their primary HIV care provider 
throughout the duration of the study
 
and to follow the DHHS guidelines to initiate ARVs for all 
HIV
-
infected individuals, regardless of CD4
+
 
count.
 
The study team will ensure that all 
participants 
have a primary health provider for medical management of HIV infection while participating in the 
study. Participants will be informed about the risks of not starting on ARV.
 
•
 
In 
Part A
,
 
participants will be encouraged to start ARVs
 
in the foll
owing situations specifically 
(with documentation): prior to enrollment into the study; at the time of any increase in viral 
load; when the CD4
+
 
count drops by 30%; when the CD4
+
 
cell count drops below 200 
cells/mm
3
; 
and should a female participant become 
pregnant during the study.
 
•
 
In 
Part B
,
 
i
nitiation of 3
-
drug ART
 
(prescribed by primary HIV clinician; not study
-
provided
)
 
will be strongly 
encouraged
 
after 
participants complete
 
day 14 study
 
evaluations
. 
P
K
-
enhancing 
agents will not be counted as part of 
the 3
-
drug ART regimen.
 
Participants
 
who are viremic on ARVs will be encouraged to talk to their primary care provider 
about their ARV regimen, per DHHS guidelines 
[
21
]
. 
 
Participants
 
who
 
receive the 
study product will continue to be followed for safety purposes 
according to the study schedule of evaluations. 
P
articipants
 
will not be discontinued or replaced in 
the study for initiating or changing ARVs. 
They will continue to be followed for safety purp
oses 
according to the study schedule of evaluations. 
ARV regimen changes will be documented in the 
participant’s
 
record. 
Additionally, 
PK 
assay for ARVs will be performed
 
in Part B
, if needed,
 
to 
evaluate for the presence of ART and the period before and d
uring viral rebound in participants who 
initiate ART. 
Data will be analyzed according to the Statistical Analysis plan in 
Section 6.4
. 
 
In Part B, a
 
participant who does not complete 
all of the 
required 
visit through day 14 will be 
replaced
 
(up to a total of 10 participants enrolled)
.
 
4.2.1
 
Screening
 
Screening for Part A:
 
(This part of the study has completed enrollment.)
 
The screening
 
p
rotocol, VRC 500 (NIH 11
-
I
-
0164
)
,
 
will be use
d
 
at the 
sites 
to screen for potential 
p
articipants
. 
Participants
 
will be recruited through Institutional Review Board (IRB)
-
approved 
advertising.
 
The evaluations and sample collection 
that will be 
included
 
in 
screening 
are a medical 
history, physical exam, 
any laboratory tests needed to confirm eligibility
,
 
and 
pregnancy test (for 
females of reproductive potential)
.
 
Additional assessments of health
 
will be conducted at screening 
based on clinical judgment.
 
Samples of PBMCs
, plasma
 
and
 
serum will also be collected. 
Informed 
consent documents will be reviewed
.
 
Counseling related
 
to 
pregnancy prevention 
(including 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
25
 
of 73
 
potential risk of study produc
t) 
will be performed
 
at screening and subsequently as noted in the 
Schedule of Evaluation
s
 
in 
Appendix III
. 
S
creening records will be kept 
documenting
 
the reason 
why an individual was screened but not enrolled into the clinical trial.
 
Screening for Part B:
 
Screening evaluations to determine eligibility must be completed within 28 days prior to study 
enrollment unless otherwise specified. 
Screening evaluations
, as noted in the Schedule of 
Evaluations in 
Appendix III
,
 
must occur prior to the 
participant 
starting any 
study product
s, 
treatments, or interventions.
 
4.2.2
 
Enrollment
,
 
Study Day
s and Visit Numbers
 
 
In this study, 
enrollment is defined as the day of assignment of a study identification
 
number
 
in the 
clinical database. 
A 
clinician will discuss the timin
g of 
the 
study product
 
administration
 
and
 
blood
 
sample collection before completing an enrollment to help ensure tha
t the 
participant
 
can comply 
with the projected schedule. 
Positive prevention counseling will be performed at enrollment and 
subsequently as noted in the Schedule of Evaluation
s
. 
An Assessment of Understanding (AoU) will 
be completed in association with 
screening 
into VRC 607
/A5378
. 
The schedule will not require 
administration in an inpatient unit or an overnight stay but 
inpatient administration is
 
an option
 
to 
facilitate collection of timed research samples. 
 
Day 0 is defined as the day of 
study product
 
administration.
 
Day 0 may occur on the same day as 
enrollment
,
 
or up to
 
4 weeks
 
(28 days)
 
after enrollment
 
in Part A or up 
to 1
0 
days after
 
enrollment 
in Part B
. This period may be increased with approval
 
from the protocol team (contact the protocol 
team 
at 
actg.teama5378@fstrf.org
)
. 
 
For c
alculating elapsed days, each subsequent calendar date is labeled by the next sequential “Study 
Day” as shown in the Schedule of Evaluations 
in 
Appendix III
. Because there may be more than 
1 
research sampling timepoint of interest per study day, each sample collection timepo
int has its own 
“Visit Number.”
 
For this reason, there may be more than one visit number recorded on the same 
calendar date.
 
Medical history and 
Day 0
 
evaluations prior to 
the 
study product
 
administration
 
are the baseline for 
subsequent safety assessments. 
 
4.2.3
 
Administration of 
Study Product
 
All study produc
t administration
s
 
will be 
completed 
according to 
the study schema
. 
For women of 
childbearing potential, study 
product 
admi
nistration may not proceed unless a negative pregnancy 
test has been obtained 
on the day of enrollment
 
and on the day of study product administration (Day 
0)
. 
Prior to
 
administration, 
temperature, blood pressure
, 
heart rate (
pulse
)
,
 
and weight will be 
collected
 
and
 
a targeted physical examination (based on signs, reported symptoms
,
 
or interim 
medical history) may be conducted
.
  
 
The
 
IV access will be placed in an
 
arm in an
 
aseptic manner.
 
A different site 
will
 
be used for 
collection 
of PK blood samples
;
 
however, the same
 
site
 
may be used after flushing 
the line if
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
26
 
of 73
 
another site is not available
.
 
Study product
 
will be administered with 
approximately 
100 mL normal 
saline IV 
with a target of 
about 
30 minutes
.
 
Infusions lasting longer than
 
30 minute
s are allowed.
 
If 
there is evidence of intolerance by the 
participant
,
 
the infusion rate will be slowed
 
or stopped
.
 
All 
participants
 
will be observed for at least 30 minutes following product administration.
 
4.2.4
 
Solicited Adverse Events
 
and 
Clinical 
Follow
-
up  
 
Participants
 
will be given a “Diary Card” to use as a memory aid
 
for solicited adverse events
 
and 
on 
which to record temperature and systemic symptoms daily
 
for 3 days
 
after study product 
administration
. 
Participants
 
will be trained to use 
a
 
se
cure 
electronic 
database 
but may complete
 
the 
paper 
“
diary
”
,
 
if preferred
. When the 
3
-
day diary card parameters are recorded directly by the 
participant
 
through a password
-
protected secure database, the 
participant’s
 
electronic record 
will be 
available to 
clinicians in real time,
 
and 
will be the source for these data. 
If concerns arise based on 
the electronic diary card data, or if a 
participant
 
use
s
 
a paper diary card, clinicians may follow up 
with additional phone calls during 
the 
reactogenicity period
,
 
as needed. 
The written (paper) diary 
may be used as a source document. When neither a written nor electronic diary card is available 
from the 
participant
, the study clinician will note the source of reactogenicity information recorded 
in the study databas
e. 
 
After
 
re
ceipt of study produc
t 
solicited 
systemic parameters
 
occurring 
within
 
3
 
days 
include: 
fever, 
unusually tired/feeling unwell, muscle aches, headache, chills, nausea
,
 
and joint pain. 
Participants
 
will record highest measured temperature daily. 
Re
actogenicity data will be
 
reviewed for accuracy 
and completeness at follow
-
up visits 
and 
recorded without an attribution assessment
. 
Clinicians will 
follow 
up with 
participants
 
and
 
collect resolution information for any 
reactogenicity 
symptoms that 
are not
 
resolved
 
within
 
3 days
.
 
Local reactogenicity parameters will include pain/tenderness, swelling
, redness, bruising
,
 
and 
pruritus (itchiness)
 
at the 
product administration site. Clinician assessment of the IV administration 
site will b
e conducted on day of 
study produc
t administration and during the scheduled follow
-
up 
timepoints after product administration.
 
Events that 
may
 
require a clinic visit include rash, urticaria, fever of 38.
6
°
C (
Grade 
2) or higher
 
lasting greater than 24 hours
,
 
or significant impai
rment in the activities of daily living
 
(such as those 
consistent with 
Grade 
2 or higher impairment)
. 
O
ther clinical concerns may prompt a study visit 
based on the judgment of a study clinician. Clinical laboratory assays and clinical evaluations will 
asse
ss safety and tolerability at 
specified intervals
 
after each 
administration
.
 
 
4.2.5
 
Pharmacokinetics Procedures 
 
PK 
samples will be collected as close as reasonably pos
sible to the target timepoint. 
However, 
actual time of collection is critical for 
PK 
analysis 
and will be reco
rded for all samples. 
The 
PK 
timepoints are shown in 
Appendix III
.
  
 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
27
 
of 73
 
4.2.6
 
Schedule of Evaluations 
 
Refer to the table in 
Appendix III
 
for details on the Schedule of Evaluations and the windows 
permitted for completion of each visit
. After enrollment, deviations from the visit windows are 
discouraged and will be recorded as protocol deviations,
 
but will be permitted at the discretion of 
the PI (or designee). 
 
Additional visits and diagnostic tests may be scheduled during the study if needed to assess 
participant
 
safety or for sample collection for immunological testing.
 
Any evaluation for an adverse event or possible exacerbation of a pre
-
existing condition may be 
evaluated at study team discretion as a “protocol related” evaluation
 
(contact the 
protocol
 
team at 
actg.teama5378@fstrf.org
)
.
 
In the event that 
Grade 
2 or higher proteinuria is detected, a nephrology consultation will be 
arranged
,
 
as well as any other clinically necessary investigations
.
 
4.2.7
 
Monitoring HIV Infection Status
 
HIV infection status will be monitored at specified intervals by CD4
+
/CD8
+
 
T cell count and
 
HIV
-
1 
RNA PCR for viral load. 
CD4
+
 
counts are known to have diurnal variation; therefore, 
participants
 
will be encouraged to return for appointments that include CD4
+
 
count at approximately the same 
time (e.g., morning or afternoon), whenever possible.
 
I
f the CD4
+
 
count decreases to less t
han 200 cells/mcl, the 
participant
 
will be promptly informed 
and strongly urged to seek evaluation and advice from their
 
primary
 
HIV
 
care provider
. 
Documentation of ARV counseling session performed by study staff to review current DHHS 
guidelines for ARV t
herapy will be included in the research record.
 
4.2.8
 
Concomitant Medications
 
Only routine prescription medications will be entered in the database at the time of enrollment
. 
Subsequently,
 
c
oncomitant medications 
associated
 
with
 
an adverse event that requires ex
pedited 
reporting
 
or the development of a new chronic condition requiring ongoing medical management 
will be recorded
 
in the database
. 
Other
wise,
 
concomitant medications 
taken 
throughout the study 
will be recorded in the 
participant’s
 
chart as needed for g
eneral medical records,
 
but will not be 
recorded in the study database.
 
In Part B, p
articipants
 
will
 
be 
strongly encouraged
 
to
 
initiate 3
-
drug 
ART (prescribed by their primary HIV clinician; not study
-
provided) 
any time 
after
 
completing
 
day 
14 
study
 
evaluations
. 
PK
-
enhancing agents will not be counted as part of the 3
-
drug ART regimen. 
The ART therapy will be documented as concomitant medications
 
and any changes in the ARV 
regimen will be recorded in the database
. 
 
 
D
ISCONTINUATION
 
OF 
S
TUDY 
P
ARTICIPAT
ION 
F
OLLOWING
 
P
RODUCT 
A
DMINISTRATION
 
Under certain circumstances, a 
participant
 
may be terminated from participating in the study or may 
ch
oose to withdraw participation.
 
A participant may be terminat
ed
 
from participating in the study 
for any of the following reasons:
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
28
 
of 73
 
•
 
Repeatedly non
-
compliant (missing visits or not following study procedures)
 
•
 
Develops a serious illness requiring ongoing medical care
 
•
 
E
nrolls
 
in another research study while 
on this study
 
•
 
P
regnancy
 
•
 
Study is stopped or canceled
 
Participants
 
who receive
d
 
study product
 
will 
be asked to 
continue follow
-
up 
visits for safety 
monitoring purposes 
according to the protocol
 
(Schedule of Evaluation
s
, 
Appendix III
)
, 
but 
collectio
n of samples that are for research purposes only 
will be discontinued
. 
Wom
en
 
who become 
pregnant will be 
asked to continue follow
-
up 
for safety monitoring 
(in which case we do not 
continue research blood draws) 
and to report the outcome of the 
pregnancy
 
to the study team. 
The 
study team will notify the 
A
ntiretroviral 
P
regnancy 
R
egistry
 
(
http://www.apregistry.com
; 
Telephone: 800
-
258
-
4263; Fax: 800
-
800
-
1052
) of any pregnancies that occur after receiving 
study 
product
 
for any 
participant
 
still on 
the 
study.
 
 
 
P
ROTOCOL 
C
RITERIA FOR 
P
AUSING 
THE
 
S
TUDY
 
AND 
R
ESUMING 
THE 
S
TUDY
 
A
dministration of
 
the 
study 
products 
and
 
new enrollments will be paused by the 
protocol team 
according to the criteria 
noted below. In the event of a p
ause
, 
the
 
IND Sponsor Medical Officer 
(MO) 
and Independent Safety Monitor (ISM) 
will be promptly notified
.
 
Refer to 
Section 5.3.2
, 
for 
definitions of “related” 
and “not related” to study product
 
when using these study pause criteria
. 
Pause c
riteria
 
are as f
ollow
s
: 
 
One
 
(or more) 
participant
 
experiences a 
Serious Adverse E
vent
 
(SAE)
 
that is a
ssessed as related to 
study produc
t, or
 
Two
 
(or more) 
participants
 
experience
 
the same 
Grade 
3
 
or higher
 
adverse event
s
 
(AE)
 
a
ssessed as 
related to study 
produc
t
 
(other than 
self
-
limited
 
Grade 
3 solicited reactogenicity AEs
)
. 
 
 
P
LAN FOR 
R
EVIEW OF 
P
AUSES AND 
R
ESUMING 
R
ULES  
 
Administration of t
he study produc
t and enrollments would resume only if review of the adverse 
events that caused the pause resulted in 
a recommendation to permit further study 
product 
administrations
 
and study enrollments.
 
The reviews to make this decision will occur as follows:
 
Pauses for 
related 
SAEs
: The IND Sponsor
 
MO
, with participation by the 
protocol team
, 
will 
conduct the review a
nd 
consult with the FDA to 
make the decision to resume
, amend
,
 
or close the 
study
,
 
and no
tify the IRB
 
accordingly
.
 
Pauses for 
related 
Grade 3
 
Events
: The IND Sponsor MO, 
in consultation with the 
protocol team
,
 
will conduct the review and make the decision to resume
, amend
,
 
or close the study for the 
Grade 
3
 
that meet the criteria for pausing the study. As part of the pause review, the reviewers will also 
advise on whether the study needs to be paused 
again for 
any subsequent
 
event
s
 
of the same type. 
The FDA
 
and the IRB 
will be notified of 
g
rade 3
 
pause reviews and 
the 
IND sponsor decisions.
 
 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
29
 
of 73
 
 
SAFETY AND ADVERSE EVENT REPORTING
 
 
A
DVERSE 
E
VENTS
 
An adverse event 
(AE) 
is any 
untoward or unfavorable medical 
occurrence
 
in a human 
participant
, 
including any abnormal sign (e.g., abnormal physical exam or laboratory finding), symptom, or 
disease 
temporally 
associated with the use of study treatment, whether or not considered related to 
the study treatment. 
In the event of 
proteinuria 
Grade 
2 or higher, a nephrology consultation will be 
arranged, as well as other clinically necessary investigations. 
 
Severity of AEs will be assessed using the 
Version 2.0 of the
 
DAIDS Table for Grading the Severity 
of Adult and Pediatric Adve
rse Events
 
[November 2014]. 
The table is available from:
 
 
http:
//rsc.tech
-
res.com/docs/default
-
s
ource/safety/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8
 
Additional information can be found in 
Appendix IV
.  
 
Reporting of all AEs will occur during the period from 
first study produc
t administration
 
through 
56 
days
 
(or 8 weeks) 
after 
study produc
t administration
. 
 
 
 
S
ERIOUS 
A
DVERSE 
E
VENTS 
(SAE)
 
The term “Serious Adverse 
Event
”
 
(SAE)
 
is defined in 21 CFR 312.32 as 
follows: “
An adverse 
event or suspected adverse reaction is considered serious if, in the view of either the investigator or 
the sponsor, it
 
results in
 
any of the following outcomes:
 
Death, a life
-
threatening adverse 
event
, 
inpatient hospitalization or pro
longation of existing hospitalization, a persistent or significant 
incapacity
 
or substantial disruption of the ability to conduct normal life functions
, or a congenital 
anomaly/birth defect. Important medical events that may not result in death, be life
-
th
reatening, or 
require hospitalization may be considered serious when, based upon 
appropriate medical judgment, 
they may jeopardize the 
patient or 
subject 
and may
 
require medical or surgical intervention to 
prevent one of the outcomes listed in this definition. Examples of such medical events include 
allergic bronchospasm requiring intensive treatment
 
in an emergency room or at home
, blood 
dyscrasias or convulsions
 
that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse.”
 
“Life
-
threatening” refers to an adverse event that at occurrence represents an immediate risk of 
death to the 
participant
. An event that may cause death
 
if it occurs in a more severe form is not 
considered life
-
threatening. Similarly, a hospital admission for an elective procedure is not 
considered 
an SAE
.
 
In Section 5.3 the term “Expedited Adverse Event” (EAE) encompasses the 
events that would be conside
red an SAE by the 21 CFR 312.32 
definition
.
 
 
A
DVERSE 
E
VENT 
R
EPORTING TO THE 
IND
 
S
PONSOR
 
5.3.1
 
E
xpedited 
A
dverse 
E
vent (EAE)
 
Reporting Criteria
 
Requirements, definitions and methods for expedited reporting of AEs are outlined in Version 2.0 
(January 2010) of the 
Manual for Expedited Reporting of Adverse Events to
 
DAIDS 
(DAIDS EAE 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
30
 
of 73
 
Manual), which is available on the 
Regulatory Support Center (
RSC
)
 
website at 
http://rsc.tech
-
res.com/clinical
-
research
-
sites/safety
-
reporting
. 
The SAE Reporting Category will be used for
 
this 
study.
 
The internet
-
based DAIDS Adverse 
Experience 
Reporting System (DAERS) 
will
 
be used for 
expedited AE reporting to DAIDS. In the event of system outages or technical difficulties, 
expedited AE reports may be submitted via the DAIDS EAE Form. 
This form is available on the 
DAIDS RSC website at 
http://rsc.tech
-
res.com/clinical
-
research
-
sites/safety
-
reporting/daids/paper
-
eae
-
reporting
. 
For questions about DAERS, please contact 
NIAID CRMS 
Support at 
CRMSSupport@niaid.nih.gov
 
or from within the DAER
S application itself. For 
questions about expedited reporting, please contact the 
DAIDS 
RSC 
Safety Office at 
(
DAIDSRSCSafetyOffice@tech
-
res.com
).
 
The study product
s
 
for which expedited reporting is required is as follows
:
 
•
 
VRC
-
HIVM
AB
08
0
-
00
-
AB
 
(
VRC01
LS
 
MAb
)
 
•
 
VRC
-
HIVMAB
075
-
00
-
AB (VRC07
-
523LS MAb)
 
The NIAID/DAIDS will report all unexpected SAEs related to the study products observed in this 
clinical trial to the FDA in accordance with 21 CFR 312.32 (IND Safety Reports).
 
While the 
participant
 
is in the study repo
rting period, 
as defined in 
Section 5.1
, 
the SAE 
Reporting Category will be used.
 
T
he 
EAE 
Manual should be consulted for further detail
s
.
 
Also
,
 
ensure that any protocol
-
specific 
reporting requirements are met.
 
A
n EAE report form 
will be completed 
and report
ed
 
to DAIDS within 3 days 
of investigator 
awareness, 
regardle
ss of relationship to study produc
t
.
 
The SAE criteria
 
are as follows
:
 
•
 
Results in death
 
•
 
Is life
-
threatening
1
 
•
 
Requires 
(unplanned) 
inpatient hospitalization or 
prolongation of hospitalization
2
 
•
 
Results in persistent or significant disabilities/incapacity.
 
•
 
Is a congenital anomaly/birth defect
3
 
•
 
Is an important medical event (may jeopardize the patient or may require intervention to 
prevent one of the outcomes above
 
Footnotes:
 
1
 
“Life
-
threatening” refers to an event in which the patient was at 
immediate 
risk of death at the time of the event. It 
does NOT refer to an event that hypothetically might have caused death if it were more severe.
 
2
 
Per ICH SAE definition, hospitalization is NOT an adverse event (AE), but is an outcome of the event. DO NOT 
REPORT: 
Any admission unrelated to an AE (e.g., for labor/delivery, cosmetic surgery, administrative or social 
admission for temporary placement f
or lack of a place to sleep); protocol
-
specified admission (e.g., for a procedure 
required by protocol); admission for diagnosis or therapy of a condition that exis
ted before receipt of study produc
t(s) 
and has not increased in severity or frequency as jud
ged by the clinical investigator. (NOTE: A new AIDS
-
defining 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
31
 
of 73
 
event in a subject already known to be HIV
-
infected would be considered an increase in severity of a pre
-
existing 
condition [HIV infection] and would be reportable.)
 
3
 
Clinically insignificant physical findings at births including those regarded as normal variants do NOT meet reporting 
criteria. If a clinically significant anomaly is reported, all findings (including those of no individual significance) 
should b
e includ
ed in the same report. 
For example, do NOT report an isolated finding of polydactyly (extra fingers 
or toes) or Mongolian spot in an infant. But if either finding occurred with a major cardiac defect, report all findings 
in the SAE Report.
 
5.3.2
 
Attribution Cat
egories
 
Attribution categories used (i.e.
,
 
terms used for assessment of 
relationship of AE to study produc
t) 
for this study 
are
 
consistent with those described in the DAIDS EAE Manual, Version 2.0 (January 
2010), as follows:
 
•
 
Related
 
–
 
There is a reasonable
 
possibility that the AE 
may be related to the study 
produc
t(s).
 
•
 
Not Related
 
–
 
There is not a reasonable possibility that the
 
AE is related to the study 
produc
t(s).
 
If circumstances arise where other attribution categories are used in describing an adverse
 
event
, 
the 
attribution terms “Definitely”, “Probably” and “Possibly” related will be mapped to the “Related” 
category while the terms “Unlikely”
,
 
“Probably Not Related” and “Not Related” will be mapped to 
the “Not Related” category under EAE Manual, Version 2.0.
 
 
R
EPORTING TO THE 
I
NSTITUTIONAL 
R
EVIEW 
B
OARD
 
5.4.1
 
Unanticipated Problem 
(UP) 
Definition
 
A serious
 
“Unanticipated P
roblem (UP)
”
 
is 
defined as any
 
incident, experience, or outcome that 
meets all three of the following criteria:
 
•
 
U
nexpected in nature, severity, or frequency in relation to the research risks that are 
described in the protocol, informed consent, 
IB
,
 
other study documents
,
 
or 
in consider
ation 
of
 
the characteristics of the 
participant
 
population being studied; 
and
 
•
 
R
elated to participation in the research; 
and
 
•
 
S
uggests that the research 
places 
participants
 
or others at a greater risk of harm (including 
physical, psychological, economic, or 
social harm) than was previously known or 
recognized.
 
Non
-
serious UP: 
An UP
 
that is n
ot an Adverse Event (UPnonAE) is a
n unanticipated problem that 
does not fit the definition of an adverse event, but which may, in the opinion of the investigator, 
involve risk to the 
participant
, affect others in the research study, or significantly impact the 
integrity of research data. S
uch events would be considered a non
-
serious UP. For example, we will 
report occurrences of breaches of confidentiality, accidental destruction of study records
 
or samples
, 
or unaccounted
-
for study drug.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
32
 
of 73
 
5.4.2
 
Protocol 
Deviation 
Definition
 
A Protocol 
Deviation 
i
s defined as any change, divergence, or departure from 
the IRB
-
approved 
study procedures in a research protocol. Protocol deviations are designated as serious or non
-
serious 
and further characterized as
:
 
•
 
Those that occur because a member of the research te
am deviates from the protocol.
 
•
 
Those that are identified before they occur
 
but cannot be prevented.
 
•
 
Those that are discovered after they occur.
 
Serious Protocol Deviation: A deviation that meets the definition of 
an SAE
 
or compromises the 
safety,
 
integrity
 
of the data,
 
welfare
,
 
or rights of 
participants
 
or others.
 
5.4.3
 
 
Non
-
Compliance 
Definition
 
Non
-
compliance is the failure to comply with applicable NIH 
Human Research Protections Program 
(
HRPP
)
 
policies, IRB requirements, or regulatory requirements for the prot
ection of human 
participants
. Non
-
compliance is further characterized as
 
serious, continuing
,
 
or minor.
 
“
Serious non
-
compliance
”
 
is 
defined as 
non
-
compliance that
:
 
•
 
I
ncreases risks, or causes harm, to participants
 
•
 
D
ecreases potential benefits to 
participants
 
•
 
C
ompromises the integrity of the NIH
-
HRPP
 
•
 
I
nvalidates the study data
 
“
Continuing
 
non
-
compliance
”
 
is non
-
compliance 
that is recurring
.
 
“
Minor n
on
-
compliance
”
 
is non
-
compliance 
that
 
is neither serious nor continuing.
 
5.4.4
 
Expedited Reporting to the 
IRB
 
Sites
 
under the oversight of the NIAID IRB will report the
 
following 
to the IRB 
within 7 calendar 
days of investigator awareness:
 
•
 
S
erious and non
-
serious UP
 
•
 
D
eaths
 
•
 
S
erious protocol deviations
 
•
 
S
erious or continuing non
-
compliance 
 
•
 
SAEs that are possibly
, probably, or definitely related to the rese
arch regardless of 
expectedness
 
The following waiver applies to reporting anticipated protocol deviations and expected UPnonAEs:  
Anticipated deviations in the conduct of the protocol will not be reported to the
 
IRB unless they 
occur at a rate greater than anticipated by the study team. Expected adverse events will not be 
reported to the IRB unless they occur at a rate great
er than that known to occur in healthy adults
. If 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
33
 
of 73
 
the rate of these events exceeds the rat
e expected by the study team, the events will be classified and 
reported as though they are unanticipated problems.
 
For Part B, 
ACTG sites under the oversight of a local IRB will follow their local IRB guidelines for 
expedited reporting. 
 
5.4.5
 
Annual Reporting 
to the IRB
 
Sites under the oversight of the NIAID IRB will report the
 
following to the IRB
 
in
 
a
 
summary at the 
time of Continuing Review:
 
•
 
S
erious and non
-
serious 
UP
 
 
•
 
E
xpected SAE
s that are possibly, probably, or definitely related to the research
 
•
 
SAE
s that
 
are not related to the research
 
•
 
A
ll 
AEs
, except expected AEs granted a waiver of reportin
g
 
 
•
 
S
erious and 
n
on
-
s
erious 
p
rotocol 
d
eviations 
 
•
 
S
erious, continuing, and minor non
-
compliance
 
 
•
 
A
ny trends or events which in the opinion of the investigator should be
 
reported
 
For Part B, 
ACTG sites under the oversight of a local IRB will follow their local IRB guidelines for 
annual reporting.
 
 
STATISTICAL CONSIDERATIONS
 
 
O
VERVIEW
 
A phase 1, single dose study of the safety and virologic effect of 
HIV
-
1 specific broadly 
n
eutralizing human monoclonal antibodies
, VRC
-
HIVMAB080
-
00
-
AB (VRC01LS)
 
or 
VRC
-
HIVMAB075
-
00
-
AB (VRC07
-
523LS)
, administered intravenously to HIV
-
infected adults.
 
In Part 
B, as
 
participants
 
will be strongly encouraged and
 
some
 
may 
initiate 3
-
drug ART 
(prescribed by 
their primary HIV clinician; not study
-
provided
; PK
-
enhancing agents not counted in the ART 
regimen
) after
 
completing 
day 
14 
study
 
evaluations
,
 
all analysis will be done separating the two 
periods of time (off concomitant ART and on concomit
ant ART).
 
Results from 
Part A and Part B 
may be analyzed, published, and presented separately since they 
involve two different MAbs
.
 
 
O
BJECTIVES
 
The primary objective is to evaluate the safety and tolerability of 
either 
VRC01LS
 
or VRC07
-
523LS
 
administered at 40 mg/kg IV to HIV
-
1 infected viremic adults. Secondary objectives include 
evaluation of the pharmacokinetics and the effects on CD4
+
 
and viral load through the first 
48
 
weeks post administration
 
of the study 
products
, as well as the 
presence of anti
-
drug antibody 
response. Exploratory objectives include evaluating HIV
-
1 isolates throughout the study for a 
variety of genotypic and phenotypic parameters including sensitivity to VRC01LS
 
or VRC07
-
523LS
 
neutralization.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
34
 
of 73
 
 
S
IZE AND 
A
CCRUAL
 
Rec
ruitment will target about 
14
 
HIV
-
1 infected viremic adults of age 18
-
70
, 7 participants enrolled 
in each part (Part A and Part B). 
The permitted accrual is 20 
participants (
or 
up to 10 participants in 
each part)
 
to allow for additional enrollments in the 
event that some 
participants
 
do not complete 
the sampling schedule, if additional PK evaluations are needed, or if additional 
participants
 
are 
needed for safety evaluations.
 
 
A
 
participant 
in Part B 
who 
does not complete 
all 
of the required 
visits through 
day 14 
will be 
replaced up to a maximum of 10 participants enrolled.
 
6.3.1
 
Sample Size Considerations
 
This study is primarily descriptive. For safety analysis, the goal is to identify safety concerns 
associated with the product
s
.  
 
The ability of the study to id
entify SAEs will be expressed in terms of the probability of observing a 
certain number of serious adverse events. Useful values are the minimum true rate such that the 
probability of observing at least one event is at least 90%, and the maximum true rate 
such that the 
probability of not observ
ing any event is at least 90%. 
With n=7
 
participants
 
in an arm, t
here is over 
90% chance to observe at least 
one
 
SAE if
 
the true rate is at least 0.281
 
and 
over 90% chance to 
observe no SAE if the true rate is no more
 
than 0.01
4.
 
Probabilities of observing 
zero
 
or more than 
1 
serious adverse event are presented in Table 6
.3
-
1 for 
a range of possible true event rates. These calculations provide a more complete picture of the 
sensitivity of this study design to identify 
potential safety problems with the product. 
 
Table 6
.3
-
1
:  Probability of E
vent for 
D
ifferent
 
S
cenarios (n=
7
)
 
True event rate
 
Pr (observing zero 
events)
 
Pr (observing more 
than one event)
 
0.005
 
0.966
 
0.001
 
0.010
 
0.932
 
0.002
 
0.020
 
0.868
 
0.008
 
0.035
 
0.779
 
0.023
 
0.050
 
0.698
 
0.044
 
0.100
 
0.478
 
0.15
 
0.150
 
0.321
 
0.283
 
0.200
 
0.21
 
0.423
 
0.300
 
0.082
 
0.671
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
35
 
of 73
 
Table 6
.3
-
2 gives the upper and lower bounds for 95% exact binomial confidence intervals of the 
true SAE rate at a
ll possible numbers of events. 
If none of the 
7
 
participants
 
experience serious 
adverse events, the 95% exact 2
-
sided upper confidence bound for the SAE rate is 
0.41
. 
 
Table 6
.3
-
2:
 
95% Confidence Intervals f
or 
t
he True Rate 
a
t Possible Observed 
Number of Events
 
(n=7
)
 
# of observed event
s
 
95% Confidence Interval
 
Lower Bound
 
Upper Bound
 
0
 
0
 
0.410
 
1
 
0.004
 
0.579
 
2
 
0.037
 
0.710
 
3
 
0.099
 
0.816
 
4
 
0.184
 
0.901
 
5
 
0.290
 
0.963
 
Table
s
 
6
.3
-
1
 
and 6
.3
-
2 apply to the secondary binary endpoints as well.
 
 
S
TATISTICAL 
A
NALYSIS
 
6.4.1
 
Analysis Variables
 
The analysis variables consist of baseline variables, pharmacokinetics
,
 
and safety variables for 
primary and secondary objective analyses.
 
6.4.2
 
Baseline Demographics
 
Baseline characteristics including demographics and laboratory measurements 
will be summarized
.
 
6.4.3
 
Safety Analysis
 
Summaries of the number and percentage of 
participants
 
experiencing any AE or reactogenicity will 
be tallied by subgroup and presented along with exact 95% confidence intervals for the proportion.
 
Solicited Adverse Event
s:
 
Solicited AE data 
will be
 
collected after each 
study product administration
. The number and 
percentage of 
participants
 
experiencing each type of solicited sign or symptom 
will be tabulated by 
severity. 
For a given sign or symptom, each 
participant’s
 
sol
icited AEs will be counted once under 
the maximum severity for all assessments.
 
Unsolicited Adverse Events:
 
Unsolicited AEs are code
d into MedDRA preferred terms. 
The number and percentages of 
participants experiencing each specific AE will be tabulated by
 
severity and relationship to 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
36
 
of 73
 
treatme
nt. 
For the calculations in these tables, each participant’s adverse experience will be counted 
once under the maximum severity or strongest recorded causal relationship to treatment.
 
A complete listing of adverse exper
iences for each participant will provide details including 
severity, relationship to treatment type, onset, duration
,
 
and outcome.
 
Local Laboratory Values:
 
Boxplots of local laboratory values will be generated for baseline values and for values measured 
d
uring the course of the study. 
Each boxplot will show the 1st quartile, the
 
median, and the 3rd 
quartile. 
Outliers, or values outside the 
boxplot, will also be plotted. 
If appropriate, horizontal lines 
representing boundaries for abnormal values will be pl
otted.
 
6.4.4
 
Tolerability Evaluation
 
The tolerability of the medical product represents the degree to which overt adverse effects can be 
tolerated by the 
participant
 
[
17
]. 
VRC 607
/A5378
 
is the first trial of VRC01LS
 
or VRC07
-
523LS
 
in 
HIV
-
1 viremic adults. The tolerability evaluation will be mostly descriptive by nature and consist of 
solicited AEs that occur during
 
the 3 days following 
study product 
administration and reasons for 
any withdrawal or discontinuation based upon 
participant
 
discomfort. This early assessment of 
tolerability of VRC01LS
 
or VRC07
-
523LS
 
will inform which parameters should be solicited or 
rout
inely assessed to further characterize the tolerability profile in a larger number of 
participants
.
 
6.4.5
 
Analysis of effect on CD4
+
 
and HIV Viral load
 
The positive response rate and the magnitude of CD4
+
 
response will be evaluated through 
48 
weeks 
post product 
administration. The profile of HIV viral load will be evaluated both numerically and 
graphically.
 
 
In Part B, as
 
participants
 
will be strongly encouraged and some
 
may 
initiate 3
-
drug ART 
(prescribed by their primary HIV clinician; not study
-
provided
; 
PK
-
enhancing agents not counted in 
the ART regimen
) after 
completing 
day 
14 
study
 
evaluations
,
 
all analysis will be done separating 
the two periods of time (off concomitant ART and on concomitant ART).
 
6.4.6
 
Pharmacokinetics Analysis
 
Blood samples for PK evaluat
ions will be collected at time points defined in the Schedule of 
Evaluations (
Appendix III
). 
 
Individual 
Participant
 
Pharmacokinetic Analysis: A non
-
compartmental 
PK 
analysis will be 
performed using Phoenix (Centara) or a similar program on the VRC01LS 
or VRC07
-
523LS 
concentration data generated from each 
participant
.
 
Calculated 
PK 
parameters will include: area
-
under
-
the
-
curve (AUC), maximum concentration (C
max
), clear
ance (CL), volume of distribution 
(Vdz), terminal elimination rate constant (

z
)
,
 
and the terminal half
-
life (T
1/2
).
 
C
max
 
will be taken 
directly from the observed concentration
-
time data.
 
The terminal slope, 

z
, will be determined from 
the log
-
linear porti
on of the curve and the terminal T
1/2 
calculated as 0.693/

z
. AUC
0
-
Clast
 
will be 
determined using the linear trapezoidal method, where C
last
 
is the concentration at 
336 
days or the 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
37
 
of 73
 
earlier if earlier samples are below the quantitative limit or the 
participant
 
does not complete the 
final PK sample collections.
 
If the final sample, C
last
, 
has measurable VRC01LS 
or VRC07
-
523LS 
concentrations, the remaining AUC after the final concentration (AUC
Clast
-
inf
) will be estimated as 
C
last
/

z
.
 
Additional compar
tmental analysis will be performed as warranted by the data.
 
Population Pharmacokinetic Analyses: Population 
PK 
analyses will be performed on the VRC01LS 
and the VRC07523LS 
PK 
data following IV administration to determine compartmental PK 
parameters with t
he program NONMEM.
 
One, two
,
 
and three compartment 
PK 
models will be 
assessed. Based on prior 
PK 
studies of antibodies, including VRC01, it is anticipated that a two
-
compartment model will adequately characterize the data.
 
The population analysis will gene
rate 
estimates for initial and final volumes of distribution (Vd
1
 
and Vd
2
), inter
-
compartmental clearance 
(Q)
,
 
and
 
CL.
 
Given the small 
participant
 
numbers, the population PK analysis will not include an 
exploratory covariate analysis to assess clinical fac
tors as fixed effects associated with VRC01LS 
and VRC07
-
523LS 
PK parameters.
 
The terminal half
-
life, t
1/2
β
, 
will be determined from CL
,
 
Vd
1
, 
Vd
2
, 
and Q. Final model selection will be based on changes in the objective function and 
graphically by goodness of fit plots.
 
The final population model will be assessed using bootstrap 
analysis and visual posterior predictive check. VRC01LS 
and VRC07
-
523LS 
do
sing strategies and 
their ability to achieve and maintain target 
study product 
concentrations will be performed using the 
final population 
PK 
model and Monte Carlo simulations with at least 5000 replicates.
 
In Part B, as 
participants
 
will be strongly encou
raged and some
 
may 
initiate 3
-
drug ART 
(prescribed by their primary HIV clinician; not study
-
provided
; PK
-
enhancing agents not counted in 
the ART regimen
) after 
completing 
day 
14 
study
 
evaluations
,
 
all PK analysis will be done 
separating the two periods of
 
time (off concomitant ART and on concomitant ART).
 
Additionally, 
PK
 
analysis for ARVs will be performed
 
i
n
 
Part B
, if needed, to evaluate
 
for the presence of ART 
and 
the 
period before and during viral rebound in participants who initiate ART.
 
 
6.4.7
 
Interim Ana
lyses
 
Preliminary analyses of pharm
acokinetics may be done once 
participants
 
complete
 
V
isit
 
21 (week 
24). This preliminary information will be used for subsequent studies that may begin while VRC 
607
/A5378
 
is still in progress. 
 
 
PHARMACY PROCEDURES
 
Refer to the 
IB
 
for further information about the 
investigational 
study produc
t
s
.  
 
 
S
TUDY 
P
RODUCT
S
 
AND 
A
DMINISTRATION 
R
EGIMEN
 
VRCHIVMAB080
-
00
-
AB (
VRC01
LS
)
 
and VRC
-
HIVMAB075
-
00
-
AB (VRC07
-
523LS) are
 
supplied 
at a concentration of
 
100 (± 10) mg/mL
 
an isotonic
 
and
 
sterile solution
; two fill volumes 
are available, 2.25
 
±
 
0.1 mL in a 3mL glass vial and 6.25
 
± 
0.1 mL in a 10 mL glass vial
 
Vials 
contain a clear, 
colorless to yellow liquid
,
 
essentially free of visible 
particles
; some opaque or 
translucent particles 
may be present
.
 
The formulation buffer 
for VRC01LS 
is composed of 25 mM 
sodium citrate, 50 mM sodium chloride, and 150 mM L
-
arginine hydrochloride at pH 5.8. 
The 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
38
 
of 73
 
formulation buffer for VRC07
-
523LS is composed of 50 mM histidine, 50 mM sodium chloride, 
5% s
ucrose, and 2.5% sorbitol at pH 6.8. 
Vials are intended for single use only and thus do not 
contain a preservative. 
 
VRC01LS 
and VRC07
-
523LS are
 
highly concentrated protein solution
s
 
and may develop white, 
opaque to translucent particles after thawing. Whe
n particles are observed, they may disappear after 
a few hours at room temperature or storage at 2
°
C to 8
°
C. 
 
For Part A, VRC01LS will be administered as 40
 
mg/kg IV once on D0. 
 
For Part B, VRC07
-
523LS will be administered as 40
 
mg/kg IV once on D0.
 
In ca
lculating the dose to administer and number of vials to thaw, it should be assumed that the 
concentration is 100 mg/mL and that a volume of 
at least 
2
 
m
L
 
or 
6 
mL can be withdrawn from a 
vial
.
 
In this trial, dose is limited or established based on 
participant
 
weight.
 
 
Preparation of 
VRC01LS
 
or VRC07
-
523LS 
will require a 100 mL bag of 0.9% sodium chloride for 
injection, USP (normal saline). 
Note that the normal saline bags referred to as “100 mL bags” in the 
IV administration instructions will typica
lly have 103 mL volume before any 
VRC01LS
 
or VRC07
-
523LS
 
is added and this is acceptable in the context of the instructions below. 
 
 
V
IALED 
S
TUDY 
P
RODUCT
 
S
TORAGE
 
The 
study
 
product label designate
s
 
long
-
term storage temperature 
as 
-
35
°
C to 
-
15
°
C. Clinical 
site 
storage
 
in 
a qualified, continuously monitored, temperature
-
controlled freezer
 
with temperature 
excursions between 
-
45
°
C to 
-
10
°
C is acceptable.
 
 
Following thaw, vials of 
VRC01LS
 
may be stored for up to 24 hours at controlled room temperature 
(maximum
 
27
°
C) and/or up to 4 weeks at 2
°
C to 8
°
C. 
Following thaw, vials of VRC07
-
523LS may 
be stored for up to 24 hours at controlled room temperature (maximum 27°C) and or up to 2 weeks 
at 2°C to 8°C. 
Product
s
 
may not be stored in direct sunlight. If stored at 2
°
C to 8
°
C, vials must be 
equilibrated to controlled room temperature (maximum 27
°
C) for a minimum of 30 minutes and 
may be held at room temperature for up to 8 hours prior to product preparation. 
 
7.2.1
 
Temperature Excursions
 
The site pharmacist must promptly re
port any storage temperature excursions 
outside of the normal 
allowance 
to the IND sponsor (see 
Appendix II
). The 
a
ffected 
product must be quarantined in a 
separate area. The IND Sponsor will notify the site pharmacist if continued 
clinical use of the 
product is acceptable.
 
 
P
REPARATION OF 
S
TUDY 
P
RODUCT
S
 
FOR 
A
DMINISTRATION 
 
This section describes how the site pharmacist will prepare 
the 
study 
product
s
 
for administration
 
and how the clinician will administer the 
product
s
. Clinician instructions on how to select an 
administration site are in 
Section 4.2.3
.  
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
39
 
of 73
 
The following instructions apply to 
thawing
 
VRC01LS
 
and VRC07
-
523LS
:
 
1.
 
Thaw 
vials for a minimum of 1 hour at controlled room temperature (maximum
 
27
°
C) after 
removing from freezer
.
 
 
2.
 
Keep the material 
at 
controlled 
room temperature 
(maximum 27
°
C) 
during the 
preparation 
period, 
up to the maximum storage times described in 
Section 
7.2
.
 
 
3.
 
Prior to preparation for administration, vials should be swirled for 30 seconds with sufficient 
force to 
re
suspend any visible particles
 
yet avoiding foaming. DO NOT SHAKE THE 
VIALS
.
 
If particles are observed, return the vials to 2
°
C to 8
°
C storage. If par
ticles 
redissolve within the maximum storage times described in 
Section 7.2
, the vials may be used 
for product preparation. If particles continue to be observed, do not use the vialed product 
for IV administration. Refrigerated produ
ct must be equilibrated at controlled room 
temperature (maximum 27
°
C) for a minimum of 30 minutes before preparation and must be 
used within 8 hours of any subsequent 
return to room temperature.
 
4.
 
If the thawed material is not administered within 24 hours of
 
thaw, follow the storage 
information provided in 
Section 7.2
. 
 
Preparation is to be done 
using aseptic technique
 
in a laminar flow biosafety cabinet
.
 
Assure that 
only the required vials are present in the preparation unit during dil
ution, and medication labels are 
strictly segregated to avoid mix
-
ups.
 
More information on product preparation can be found in the IB.
 
7.3.1
 
VRC
-
HIVMAB0
8
0
-
00
-
AB
 
or 
VRC
-
HIVMAB075
-
00
-
AB
: Preparation for 
IV 
Administration 
 
For each IV infusion order, the 
participant’s
 
weight
, 
dosage
, 
and 
group 
will be i
ncluded in the 
pharmacy order. 
The weight 
measured
 
within 
10 
days prior to the scheduled study pro
duct 
administration 
(Day 0) 
can be used
. 
To prepare an IV infusion, the pharmacist will calculate the 
total m
illigrams needed, retrieve the minimum number of thawed, particle free vials needed to 
prepare the full dose and add the calculated total milligrams needed to a 100 mL bag of normal 
saline using good pharmacy practices to maintain sterility. Prior to prepa
ration for administration
,
 
the vials should be gently swirled for 30 seconds to avoid foaming. DO NOT SHAKE THE VIAL. 
Typically, 50 to 100 mL of additional volume may be added to 100 mL bag of normal saline. Each 
pharmacist should test the capacity of the brand of saline bags that w
ill be used at the site to confirm 
the capacity 
for
 
additional volume.
 
Refer to the Manual of Procedures for Part B for alternative 
preparation instructions if 100 mL bags of 
normal 
saline are not available.
 
After preparation in IV bags, the prepared 
produ
ct 
may be stored at 2
°
C to 8
°
C up to 24 hours or at 
room temp
erature (maximum
 
30
°
C) 
for a maximum of 8 hours total including the infusion time, out 
of direct sunlight
.
 
If stored at 2
°
C to 8
°
C, prepared product must be equilibrate
d to room 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
40
 
of 73
 
temperature (max
imum 
30
°
C) for a minimum of 30 minutes prior to product administration.
 
Prior to 
IV administration, t
he nurse responsible for administration and another clinician will each check the 
bag label and confirm that the identifier is correct and that the correct total mg to be administered is 
shown based on 
the 
participant’s
 
current
 
weight
.
 
An in
-
line filter in
fusion set must be used for IV administration. In
-
line filters must comply with the 
following specifications
: 
1.2 micron PES (polyether sulfone) filter membrane, DEHP
-
free, latex
-
free (equivalent to Braun # 473994 filter extension set).
 
When the in
-
line fi
lter is added to the 
tubing, the administration set
 
must then be primed
. 
T
he administration set 
must be flushed 
with 
about 30 mL or appropriate volume of normal saline at the end of product administration.
 
The study product solution will be administered IV
 
over 
about 
30
 
minutes
 
using a volumetric pump. 
The total time needed to administer the dose may be longer based on factors such as 
participant
 
tolerance.
 
The mL/hr infusion rate may vary based on the total volume needed to administer the full 
dose.  
 
 
L
ABE
LING
 
OF 
S
TUDY 
P
RODUC
TS
 
Study product
 
v
ials 
will be individually labeled with the name of the material, volume, lot number, 
concentration, storage instructions, Investigational Use Statement (“Limited by Federal Law to 
Investigational Use”), and 
manufacturer informat
ion.
 
The prepared IV product label shall contain: 
 
•
 
Participant identifier 
 
•
 
Participant weight (kg)
 
•
 
Dose of 
VRC01LS or 
VRC07
-
523LS (40
 
mg/kg) and total amount (mg) added to the NS 
bag
 
•
 
Final volume of the IV product
 
•
 
For IV administration
 
•
 
Lot number
 
•
 
Do not infuse after date and time:
 
o
 
24 hours, if stored at 2°C to 8°C
 
o
 
8 hours, if stored at controlled room temperature (not to exceed 27°C)
 
 
S
TUDY 
P
RODUC
T 
D
ISTRIBUTION
/
A
CCOUNTABILITY
 
The VRC will follow 
the NIH CC pharmacy SOP
 
for distribution a
nd accountability of the study 
product.  
 
For 
the 
ACTG sites
,
 
VRC07
-
523LS will be available through the NIAID Clinical Research 
Products Management Center (CRPMC). The site pharmacist should obtain the study product for 
this protocol by following the instr
uctions in the 
Pharmacy Guidelines and Instructions for DAIDS 
Clinical Trials Networks 
manual.
 
Due to the small sample size, study 
product
 
will be shipped to each site as participants are enrolled. 
The site staff should coordinate with their respective sit
e pharmacy to inform the pharmacist when a 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
41
 
of 73
 
participant is being enrolled so an order for study 
product
 
can be placed with the CRPMC.
 
Study 
product should be available on site one day prior to the scheduled infusion (D0). Refer to the MOP 
for detailed study product ordering instructions. 
 
The site pharmacist is required to maintain complete records of all study products received from th
e 
NIAID CRPMC and subsequently dispensed.
 
 
S
TUDY 
P
RODUC
T 
D
ISPOSITION
 
At VRC, t
he empty vials and unused portion
s
 
of a vial will be discarded 
as per NIH CC pharmacy 
SOP
. 
 
At ACTG sites, all 
unused study products 
at
 
US C
linical 
R
esearch 
S
ite
s must be returned
 
to the 
NIAID CRPMC (or as otherwise directed by the sponsor) after the stu
dy is completed or 
terminated. 
The procedures to be followed are in the 
Pharmacy Guidelines and Instructions for 
DAIDS Clinical Trials Networks
 
manual.
 
 
HUMAN SUBJECT PROTECTIONS AND
 
ETHICAL OBLIGATIONS
 
This research study will be conducted in compliance with the protocol, Good Clinical Practices 
(GCP), and all applicable regulatory requirements.
 
 
I
NFORMED 
C
ONSENT
 
The study informed consent
 
form (ICF)
 
is provided in 
Appendix I
. It describes the investigational 
product to be used and all aspects involved in protocol participation.
 
Before a
n individual’s 
participation in the study, it is the investigator’s responsibility to obtain 
written 
ICF
 
from 
the 
participant
, after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol
-
specific procedures
 
are 
conducted
 
or study 
produc
t
 
is
 
administered.
 
The Assessment of Understanding quiz will
 
be 
completed before the study consent is signed.
 
The acquisition of 
ICF
 
will be documented in the 
participant’s
 
medical record
s,
 
as required by 
21 
CFR 312.62
. 
T
he 
ICF
 
will be signed and personall
y dated by the 
participant
 
and 
the person who 
conducted the 
ICF
 
discussion. The original signed 
ICF
 
will be retained in the medical chart
 
and a 
copy 
will be provided to the 
participant
.
  
 
 
R
ISKS AND 
B
ENEFITS 
 
8.2.1
 
Risks
 
VRC
-
HIVMAB08
0
-
00
-
AB
 
or 
VRC
-
HIVMAB075
-
00
-
AB
:
 
The f
irst human
 
clinical trial
s of 
predecessor
 
VRC01 MAb
 
determined that VRC01
 
is safe for further evaluation 
in HIV
-
1 
infected 
and healthy adults
. The solicited local and systemic signs and symptoms following administration 
of VRC01 were generally none to mild.
 
Some mild transient changes included elevated crea
tinine, 
elevated transaminases, neutropenia
,
 
and proteinuria. 
The SC administrations were sometimes 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
42
 
of 73
 
associated with mild 
transient 
local reactions (
Section 1.
3
.1
).
 
In the ongoing clinical trial VRC 606, 
VRC01LS is administered to healthy adults who reported mostly mild solicited adverse events 
(
Section 1.
3
.2
). 
VRC07
-
523LS 
is currently being evaluated in healthy adults in a Phase I dose 
escala
tion study, VRC 605. There have been no SAEs and no study safety pauses for AEs. 
VRC 
607
/A5378
 
is the first study to evaluate IV 
administration
s
 
of VRC
-
HIVMAB080
-
00
-
AB 
(VRC01LS) 
and 
VRC
-
HIVMAB075
-
00
-
AB (
VRC07
-
523LS
)
 
in HIV
-
1 
infected adults.
 
Administration
 
of 
some 
MAb
s
 
may 
cause
 
immune reactions such as acute anaphylaxis, serum 
sickness
,
 
and the generation of antibodies
. H
owever, these reactions are 
rare
 
and more often 
associated with 
MAb
 
targeted to human proteins or with the use of murine 
MAbs
 
which would have 
a risk of human anti
-
mouse antibodies 
[
22
]
.
 
In this regard, 
as 
VRC01LS
 
and VRC07
-
523LS are
 
targeted to a viral antigen and 
are
 
human
 
MAbs, they are
 
expected to have 
a 
low risk of such side 
effects. 
 
Typically, 
the side eff
ects of 
MAb
s are 
mild but may include 
reactions at injection site (pain, 
redness, bruising, swelling), 
fever, chills, rigors, nausea, vomiting, pain, headache, d
izziness, 
shortness of breath, bronchospasm, hypotension, hypertension, 
pruritus
, rash, urticaria, angioedema, 
diarrhea, tachycardia
,
 
or chest pain
. Clinical use of
 
MAb
s
 
that are
 
targeted to 
cytokines or 
antigens 
associated with human cells 
may be 
associated with an increased risk of infections
 
[
22
]
; however, 
this is not expected to be a risk for 
MAbs
 
like VRC01LS
 
and VRC07
-
523LS
 
targeted t
o a viral 
antigen.
 
It is known from published experience with human MAbs directed against the cell surface targets on 
lymphocytes, that infusion o
f a MAb may be associated with 
cytokine release, causing a reaction 
known as “cytokine release syndrome” (CRS)
 
[
23
]
.
 
Most infusion
-
related events occur within the 
first 24 hours a
fter beginning administration. Severe 
reactions, such as ana
phylaxis, angioedema, 
bronchospasm, hypotension
,
 
and hypoxia, are infrequent and more often associated with MAbs 
targeted to human proteins or 
when
 
non
-
human MAbs, such as a murine MAb, is used 
[
22
]
. 
Specifically, with
 
regard to CRS reactions, these most commonly occur within the first few hours of 
beginning the infusion and are more common with th
e first MAb infusion received. 
This is because 
the cytokine release is associated with lysis of the cells targeted by the MA
b and the burden of 
target cells is greatest at the ti
me of the first MAb treatment. 
With licensed therapeutic MAbs, CRS 
is managed by temporarily stopping the infusion, administering histamine blockers
,
 
and restarting 
the infusion at a slower rate 
[
24
]
.
 
Delayed allergic reactions to 
other 
MAb
s
 
may include a serum sickness type of reaction
, which 
may 
include rash
, fever, lymph nod
e enlargement, and joint pains.
 
These symptoms may not appear until 
several days after the exposure to the 
MAb
 
and
 
is noted to be more common with chimeric types of 
MAb
s
 
rather than with human 
MAbs
 
such as VRC01LS
 
and VRC07
-
523LS
 
[
22
]
.
 
There are several FDA
-
licensed 
MAb
s
 
for which reactions related to the rate of 
IV 
infusion have 
been described.
 
Some symptoms may be treated by slowing or stopping the infusion. Supportive 
treatment may also be indicated for some signs and symptoms.  
 
Part
icipation in this study may limit 
a 
participant’s
 
eligibility for other future MAb studies.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
43
 
of 73
 
Risks of Blood Drawing:
 
Blood drawing may cause pain and
 
bruising
 
and
 
may
,
 
infrequently
,
 
cause 
a feeling of lightheadedness or fai
n
ting. R
arely,
 
it 
may cause
 
infect
ion at the site where the blood is 
taken.
 
In this study
, an IV
 
line that can be used for the collection of blood 
may be placed 
and left in 
place for several hours on the days 
when there are fr
equent 
PK 
blood draws.
 
Problems
 
from use of 
an IV for blood drawing 
are generally mild and
 
may include pain, bruising, minor 
swelling or 
bleeding 
at the 
IV
 
site 
and rarely, infection, 
vein irritation (called phlebitis),
 
or blood clot.
 
 
8.2.2
 
Benefits
 
There are no direct
 
benefit
s to study 
parti
cipants
 
from study participation
. Others may benefit from 
knowledge gained in this study that may aid in the development 
of 
HIV 
prevention
 
or therapeutic
 
methods
.
 
 
I
NSTITUTIONAL 
R
EVIEW 
B
OARD
 
A copy of the protocol, 
ICF
, other written 
participant
 
information
, and any
 
advertising material will 
be submitted to the IRB for written approval.
 
The investigator must submit and, where necessary, obtain approval from the IRB for all subsequent 
protocol amendments and changes to the 
ICF
. The investigator will notify th
e IRB of 
unanticipated 
problems, non
-
compliance, 
deviations from the protocol
,
 
and serious 
SAE
s
 
as described in 
Section 
5.4
.
 
The investigator will be responsible for obtaining IRB approval of the annual Continuing Review 
throughout 
the duration of the study.
 
 
P
ROTOCOL 
R
EGISTRATION
 
Prior to implementation of this protocol, and any subsequent full version amendments, each site 
must have the protocol and the protocol 
ICF
(s) 
approved, by the 
appropriate
 
IRB
/ethics committee 
(EC) and any 
other applicable regulatory entity (RE). Upon receiving final approval, sites will 
submit all required protocol registration documents to the DAIDS Protocol Registration Office 
(DAIDS PRO) at the R
egulatory Support Center (RSC).
 
The DAIDS PRO will review t
he submitted 
protocol registration packet to ensure that all of the required documents have been received.  
 
Site
-
specific 
ICF(s)
 
WILL
 
be reviewed and approved by the DAIDS PRO and sites will receive an 
Initial Registration Notification from the DAIDS PRO 
that indicates successful completion of the 
protocol registration process. A copy of the Initial Registration Notification should be retained in 
the site's regulatory files.
 
Upon receiving final IRB/EC and any other applicable RE approval(s) for an amendme
nt, sites 
should implem
ent the amendment immediately. 
Sites are required to submit an amendment 
registration pack
et to the DAIDS PRO at the RSC.
 
The DAIDS PRO will review the submitted 
protocol registration packet to ensure that all the required documents 
have been received. Site
-
specific ICF(s) 
WILL NOT
 
be reviewed and approved by the DAIDS PRO and sites will receive an 
Amendment Registration Notification when the DAIDS PRO receives a complete registration 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
44
 
of 73
 
packet. A copy of the Amendment Registration Notif
ication should be retained in the site's 
regulatory files.
 
For additional information on the protocol registration process and specific documents required for 
initial and amendment registrations, refer to the current version of the DAIDS Protocol Registrat
ion 
Manual.
 
 
P
ARTICIPANT
 
C
ONFIDENTIALITY
 
The investigator must ensure 
that no information identifying the 
participant
 
will be released to any 
unauthorized party
.
 
Individual identifying information
 
will not be
 
included 
in any reports
. 
Participants
 
wil
l be 
identified only by coded
 
numbers
.
 
All records will be kept confidential to the 
extent provided b
y federal, state
,
 
and local law.
 
Medical records are made available for review 
when required by the F
DA
 
or oth
er authorized users, such as 
the study produc
t
 
man
ufacturer, only 
under the guidelines 
set by the Federal Privacy Act.
 
Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important 
to the evaluation of the study.
 
The investigator is obligated to inform 
the 
participants
 
that the above
-
named representatives will 
review their study
-
related records without violating the confidentiality of the 
participants
.
 
 
8.5.1
 
Loss or Destruction of Samples, Specimens or Data
 
The NIH Intramural Protocol Deviation definition rel
ated to loss of or destruction of samples or 
data will be followed
.
 
Any loss or unanticipated destruction of samples (for example, due to freezer 
malfunction) or data (for example, misplacing a printout of data with identifiers) that compromises 
the scient
ific integrity of the study will be reported to the IRB in accordance with institutional 
policies.
 
The PI will also notify the IRB if the decision is made to destroy the remaining samples.
 
 
P
LAN FOR 
U
SE AND 
S
TORAGE OF 
B
IOLOGICAL 
S
AMPLES
 
The plan for use and
 
storage of biological
 
samples from this protocol 
is 
as 
outlined in the following 
sections.
 
8.6.1
 
U
se of 
S
amples
, S
pecimens
 
and D
ata
 
Samples, specimens
,
 
and data collected under this protocol may be used to conduct protocol
-
related 
safety and immun
e response
 
eva
luations, 
exploratory laboratory evaluations related to the type of 
infection the 
study produc
t
 
was designed to prevent, exploratory laboratory evaluations related to 
vaccine 
or infectious disease 
research in general
,
 
and for research assay validation.
 
Gen
etic testing 
may be performed in accordance with the genetic testing information that was included in the study 
ICF
.
 
8.6.2
 
Storage and Tracking of Blood S
amples
 
and
 
Other S
pecimens
 
All of the stored study research samples will be labeled by a code (such as a num
ber) that only the 
study site can link to the 
participant
. Samples will be stored in secure facilities with controlled 
access at the sites. The NIAID Vaccine Immune T
-
Cell and Antibody Laboratory (NVITAL) in 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
45
 
of 73
 
Gaithersburg, MD, under the direction of the VRC
, NIAID, NIH (Bethesda, MD) will serve as a 
central repository for stored samples. Samples collected for research may be transferred for testing 
to the VRC/NIAID/NIH, other approved collaborators
,
 
or contract laboratories.
 
Data will be kept 
secure. 
Only ap
proved investigators or their designees will have access to samples and data.  
 
In the future, other investigators (both at NIH and outside) may wish to study these samples and/or 
data. Regulatory approval through the proper human 
participants
’
 
protection 
agency will be sought 
prior to any sharing of samples that constitutes human 
participant
 
research. The research use of 
stored, unlinked
,
 
or unidentified samples may be exempt from the need for IRB review and 
approval. When appropriate, exemption may be obtained through the proper regulatory procedures.
 
 
P
ARTICIPANT
 
I
DENTIFICATION AND 
E
NROLLMENT OF 
S
TUDY 
P
ARTICIPANTS
 
All study activities wil
l be carried out at the 
study site
. 
In Part A, study 
participants
 
will be recruited 
through on
-
site and off
-
site advertising done for the screen
i
ng protocol, VRC 500
 
(NCT 01375530) 
(
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=VRC+500&rank=1
)
.
 
In P
art B, study 
participants will be recruited and screened following the screening evaluation
s
 
in this protocol. 
Effort will be made to include women and minorities in proportions similar to that of the 
community from which they are recruited
 
and
 
will be lim
ited to p
ersons at least 18 years of age
 
and 
no older than 70
 
years of age
 
at enrollment
.
 
8.7.1
 
Participation of Children
 
Children are not eligible to participate in this clinical trial because
 
the study produc
t has not been 
previously evaluated in adults
.
 
If the product is assessed as safe for further study other protocols 
specifically designed for children may be conducted.
 
8.7.2
 
Participation of 
Site
 
Employees
 
Clinic sites will follow institutional policy regarding participation of site employees in VRC 
607
/A5378
. Site
-
specific policies related to employee involvement in research protocols have been 
provided to the NIAID IRB.
 
NIH
-
 
Specific Employee Participation 
 
NIH employees and members of their immediate families may participate in this protocol. We will 
follow the Guidelines for the Inclusion of Employees in NIH Research Studies and will give each 
employee a copy of the “NIH Information Sheet on Employee Research Participation
” and a copy 
of the “Leave Policy for NIH Employees Participating in NIH Medical
 
Research studies.”
 
Neither 
participation nor refusal to participate will have an effect, either beneficial or adverse, on the 
participant’s employment or work situation. The NIH information sheet regarding NIH employee 
research participation will be distr
ibuted to all potential 
participants
 
who are NIH employees.
 
The 
employee 
participant’s
 
privacy and confidentiality will be preserved in accordance with NIH 
Clinical Center and NIAID policies
. 
For NIH employee 
participants
, consent will be obtained by an 
in
dividual who is independent of the employee’s team. 
If the individual obtaining consent is a co
-
worker to the 
participant
, independent monitoring of the consent process will be included through 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
46
 
of 73
 
the Bioethics Consultation Service. P
rotocol study staff will 
be trained on obtaining potentially 
sensitive and private information from co
-
workers or subordinates. 
 
 
C
OMPENSATION
 
Compensation for time and inconvenience of study participation will be provided to 
participants
 
in 
accordance with the
 
local site
-
specific guidelines as outlined in the 
IRB approved 
site
-
specific 
Informed Consent.
 
The total compensation for the 
participant
 
is based on the
 
number of study clinic 
visits, 
injections completed
,
 
and other protocol
-
related activities
. 
 
 
S
AFETY 
M
ONITORING
 
Close cooperation between the designated members of the Protocol Team will occur to evaluate and 
respond to individual 
AEs
 
in a timely manner. 
The VRC designated Safety Officer for the day 
conducts a daily safety review of clinical data per VRC S
tandard Operating Procedures. 
The 
Protocol Safety Review Team (
PSRT
)
, comprised of the 
Study Chair, 
P
I
(s)
, 
Associate Investigators, 
Study Coordinator, 
Protocol Specialist
s
,
 
other Study C
linicians
,
 
DAIDS M
O
,
 
and an ISM
,
 
will 
review the summary study safety 
data reports on a weekly basis through 4 weeks afte
r the last 
participant
 
receives the last
 
product administration
,
 
in order to be certain that the 
study produc
t
 
has 
an acceptable safety profile
,
 
and will continue to monitor the study safety data reports o
n a monthly 
basis throug
h completion of the last 
study
 
visit.
  
 
 
ADMINISTRATIVE AND LEGAL OBLIGATIONS
 
 
P
ROTOCOL 
A
MENDMENTS AND 
S
TUDY 
T
ERMINATION
 
Protocol Amendments must be made only with the prior approval of the 
DAIDS/
NIAID
,
 
V
RC
, and 
ACTG
. 
Agreement from the 
protocol team 
and DAIDS Medical Officer (MO)
 
must be obtained for 
all protocol amendments and amendments to the 
ICF
. All study amendments will be submitted to 
the IRB for approval.
 
T
he
 
DAIDS,
 
VRC
,
 
ACTG,
 
the NIAID
 
or local
 
IRB
 
(as applica
ble)
, the Office of Human Research 
Protections, 
the 
study 
P
I,
 
and 
FDA
 
reserve the right to terminate the study. The 
PI
 
will notify the 
IRB in writing of the study’s completion or early termination.
 
 
S
TUDY 
D
OCUMENTATION AND 
S
TORAGE
 
The 
PI
 
will maintain a lis
t of appropriately qualified persons to whom trial duties have been 
delegated.
 
Source documents are original documents, data, and records from which the 
participant’s
 
data are 
obtained. These include but are not limited to hospital records, clinical and 
office charts, laboratory
 
and pharmacy records, 
microfiches, radiographs, and correspondence. 
 
The 
PI
 
and staff are responsible for maintaining a comprehensive and centralized filing system of 
all study
-
related (essential) documentation, suitable for inspe
ction at any time by representatives 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
47
 
of 73
 
from the 
DAIDS/
NIAID
,
 
V
RC
,
 
ACTG,
 
IRB, FDA, and/or 
other local, US, and international 
regulatory entities
. Elements include:
 
•
 
Participant
 
files containing completed 
ICF
, and supporting copies of source documentation 
(if k
ept)
.
 
•
 
Study files containing the protocol with all amendments, 
IBs
, 
and 
copies of all 
correspondence with the IRB
,
 
the 
NIAID’s
 
Division of AIDS and Vaccine Research Center
, 
and ACTG.
 
In addition, all original source documentation must be maintained and be 
readily available.
 
All essential documentation should be retained by the institution for the same period of time 
required for medical records retention. The FDA requires study records to be retained for up to 
2 
years after marketing approval or refusal (21
 
CFR 312.62). No study document should be destroyed 
without prior written agreement between the 
NIAID’s
 
Division of AIDS
, 
VRC
,
 
ACTG, 
and the 
investigator. Should the investigator wish to assign the study records to another party or move them 
to another loc
ation, they must notify the 
DAIDS/
NIAID
,
 
V
RC
, and ACTG
 
in writing of the new 
responsible person and/or the new location.
 
 
S
TUDY 
M
ONITORING
,
 
D
ATA 
C
OLLECTION AND 
D
ATA 
S
H
ARING
 
9.3.1
 
Study Monitoring
 
The 
DAIDS/
NIAID
 
and VRC
/NIAID monitors and
 
regulatory authorit
ies
 
inspectors 
(if applicable) 
or their 
authorized
 
representatives are responsible for contacting and visiting the investigator for the 
purpose of inspecting the facilities and, upon request, inspecting the various records of the trial, 
provided that 
particip
ant
 
confidentiality is respected.
 
Site visits by study monitors will be made in accordance with the IND Sponsor (DAIDS) policy to 
monitor the following: study operations, the quality of data collected in the research records, the 
accuracy and timeliness of
 
data entered in the database, and to determine that all process and 
regulatory requirements are met.
 
Site investigators will allow the study monitors, the NIAID 
or local 
IRB
 
(as applicable)
, FDA
, and 
other local, US or international regulatory entities
 
to
 
inspect study documents (e.g., consent forms, 
drug distribution forms, case report forms) and pertinent hospital or clinic records for confirmation 
of the study data.
 
9.3.2
 
Data Collection
 
Clinical research data will be collected in a secure electronic data man
agement system through a 
contract research organization, EMMES (Rockville, MD). Extracted data without patient identifiers 
will be sent to the 
PSRT 
for safety review and to 
Protocol Statistician for statistical analysis.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
48
 
of 73
 
9.3.3
 
Data Sharing
 
Data generated in this
 
study will be shared as de
-
identified data in the government
-
funded public 
repository, 
www.ClinicalTrials.gov
. Data may be shared prior to publication at approved public 
presentations or for collaborative development and will be shared at the time of publ
ication or 
within 1 year of the study completion date. 
 
 
L
ANGUAGE
 
All written information and other material to be used by 
participants
 
and investigative staff must use 
vocabulary and language that are clearly understood. 
 
 
P
OLICY 
R
EGARDING 
R
ESEARCH
-
R
ELATED 
I
NJURIES
 
The 
study site
 
will provide short
-
term medical care for any injury resulting from
 
participation in this 
research. In general, the National Institutes of Health, the Clinical Center, or the 
U.S. 
Federal 
Government will provide no long
-
term medical 
care or financial compensation for research
-
related 
injuries.
 
 
M
ULTI
-
SITE 
M
ANAGEMENT
 
For Part A, 
t
he Vaccine Research Center, NIAID, NIH is the coordinating center as well as a site for 
this protocol.
 
For Part B, 
the ACTG Network Coordinating Center will fu
nction as the coordinating center
.
 
The protocol plan 
for previous versions of the protocol was
 
to establish a Reliance Agreement with 
each collaborating study site such that the NIAID IRB is the IRB of Record for the conduct of the 
VRC 
607
/A5378
 
protocol
 
(Part A)
. 
A reliance agreement was established for the University of 
Pennsylvania for the previous protocol versions and will continue to be effective for version 4 of the 
protocol. However
 
for Part B,
 
the participating ACTG sites are not expected to esta
blish a reliance 
agreement and will use their local IRB as the IRB of Record for the conduct of VRC 607/A5378 
Version 4.0 at their site.
 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
49
 
of 73
 
 
REFERENCES
 
1.
 
UNAIDS. 
Fact sheet: 2014 statistics
. 2014; Available from: 
http://www.unaids.org/sites/default/files/media_asset/20150714_FS_MDG6_Report_en.pdf
.
 
2.
 
Wu, X., et al., 
Rational design of envelope identifies broadly neutralizing human monoclonal 
antibodies to HIV
-
1.
 
Science, 2010. 329(5993): p. 856
-
61.
 
3.
 
Rudicell, R.S
., et al., 
Enhanced Potency of a Broadly Neutralizing HIV
-
1 Antibody In Vitro 
Improves Protection against Lentiviral Infection In Vivo.
 
J Virol, 2014. 88(21): p. 12669
-
82.
 
4.
 
Kwon, Y., et al., 
Structure
-
guided modification and optimization of antibody VRC0
7.
 
Retrovirology, 2012. 9(Suppl 2): p. O34.
 
5.
 
Ko, S.Y., et al., 
Enhanced neonatal Fc receptor function improves protection against primate 
SHIV infection.
 
Nature, 2014. 514(7524): p. 642
-
5.
 
6.
 
Wu, X., et al., 
Selection pressure on HIV
-
1 envelope by broadl
y neutralizing antibodies to the 
conserved CD4
-
binding site.
 
J Virol, 2012. 86(10): p. 5844
-
56.
 
7.
 
Zalevsky, J., et al., 
Enhanced antibody half
-
life improves in vivo activity.
 
Nat Biotechnol, 2010. 
28(2): p. 157
-
9.
 
8.
 
Montefeori, D.C., 
Measuring HIV Neutra
lization in a Luciferase Reporter Gene Assay
, in 
HIV 
Protocols, Second Edition, Vol. 485
, V.R. Prasad, and Kalpana, G.V., Editor. 2009, Humana 
Press: New York, NY. p. 395
-
405.
 
9
.
 
Ozaki, D.A., et al., 
International technology transfer of a GCLP
-
compliant HI
V
-
1 neutralizing 
antibody assay for human clinical trials.
 
PLoS One, 2012. 7(1): p. e30963.
 
10
.
 
Todd, C.A., et al., 
Development and implementation of an international proficiency testing 
program for a neutralizing antibody assay for HIV
-
1 in TZM
-
bl cells.
 
J Immunol Methods, 
2012. 375(1
-
2): p. 57
-
67.
 
11
.
 
Allen, J.C. and H.G. Kunkel, 
Antibodies to genetic types of gamma globulin after multiple 
transfusions.
 
Science, 1963. 139(3553): p. 418
-
9.
 
12
.
 
Jefferis, R. and M.P. Lefranc, 
Human immunoglobulin allotypes: 
possible implications for 
immunogenicity.
 
MAbs, 2009. 1(4): p. 332
-
8.
 
13
.
 
Kickler, T.S., et al., 
The expression of IgG allotypes on platelets and immunization to IgG 
allotypes in multitransfused thrombocytopenic patients.
 
Blood, 1990. 76(4): p. 849
-
52.
 
14
.
 
Ledgerwood, J.E., et al., 
Safety, pharmacokinetics and neutralization of the broadly 
neutralizing HIV
-
1 human monoclonal antibody VRC01 in healthy adults.
 
Clin Exp Immunol, 
2015.
 
15
.
 
Lynch, R.M., et al., 
Virologic effects of broadly neutralizing antibody 
VRC01 administration 
during chronic HIV
-
1 infection.
 
Sci Transl Med, 2015. 7(319): p. 319ra206.
 
1
6
.
 
Gaudinski, M.R., et al., 
Safety and pharmacokinetics of the Fc
-
modified HIV
-
1 human 
monoclonal antibody VRC01LS: A Phase 1 open
-
label clinical trial in heal
thy adults.
 
PLoS 
Med, 2018. 15(1): p. e1002493.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
50
 
of 73
 
1
7
.
 
Patel, S.V. and D.A. Khan, 
Adverse Reactions to Biologic Therapy.
 
Immunol Allergy Clin 
North Am, 2017. 37(2): p. 397
-
412.
 
1
8
.
 
DHHS. 
Panel On Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use 
of antiretroviral agents in HIV
-
1
-
infected adults and adolescents. Department of Health and 
Human Services. Available at 
http://aidsinfo.nih.gov/ContentFiles/AdultandAdol
escentGL.pdf
. 
Assessed December 15, 2014.
 
19
.
 
Hall, W.C., et al., 
Tissue Cross
-
Reactivity Studies for Monoclonal Antibodies: Predictive Value 
and Use for Selection of Relevant Animal Species for Toxicity Testing
, in 
Preclinical Safety 
Evaluation of 
Biopharmaceuticals: A Science
-
Based Approach to Facilitating Clinical Trials 
(ed J. A. Cavagnaro)
. 2008, John Wiley & Sons, Inc.: Hoboken, NJ, USA. p. 208
-
40.
 
2
0
.
 
Leach, M.W., et al., 
Use of tissue cross
-
reactivity studies in the development of antibody
-
ba
sed 
biopharmaceuticals: history, experience, methodology, and future directions.
 
Toxicol Pathol, 
2010. 38(7): p. 1138
-
66.
 
2
1
.
 
DHHS. 
Panel On Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use 
of antiretroviral agents in HIV
-
1
-
infe
cted adults and adolescents.
 
January 28, 2016; Available 
from:
 
https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
.
 
2
2
.
 
Hansel, T.T., et al., 
The safety and side effects of monoclonal antibodies.
 
Nature reviews. Drug 
discovery, 2010
. 9(4): p. 325
-
38.
 
23.
 
Bugelski, P.J., et al., 
Monoclonal antibody
-
induced cytokine
-
release syndrome.
 
Expert review 
of clinical immunology, 2009. 5(5): p. 499
-
521.
 
24.
 
Vogel, W.H., 
Infusion reactions: diagnosis, assessment, and management.
 
Clin J Oncol Nur
s, 
2010. 14(2): p. E10
-
21.
 
 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
51
 
of 73
 
APPENDIX I
 
 
STUDY INFORMED CONSENT TEMPLATE
 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
52
 
of 73
 
TITLE:  VRC 607/ACTG A5378: A Phase
 
1, Single Dose Study of the Safety and Virologic 
Effect of an HIV
-
1 Specific Broadly Neutralizing Human Monoclonal Antibody, VRC
-
HIVMAB080
-
00
-
AB (VRC01LS) or VRC
-
HIVMAB075
-
00
-
AB (VRC07
-
523LS), Administered 
Intravenously to HIV
-
Infected Adults.
 
INTRODUCTIO
N
 
We invite you
 
to take part in a research study at the [insert institution’s name]. 
This study is a 
collaboration between the Vaccine Research Center (VRC), NIAID, NIH and the AIDS 
Clinical Trials Group (ACTG).
 
First, we want you to know that:
 
•
 
Taking part
 
in 
this study
 
is entirely voluntary.
 
•
 
You may choose not to take part, or you may withdraw from the study at any time. In 
either case, you will not lose any benefits to which you are otherwise entitled. 
You will 
be treated the same no matter what. 
 
•
 
If you 
are at the NIH and would like to
 
receive care at the NIH, you must be taking part 
in a study or be under evaluation for study participation.
 
•
 
You may receive no benefit from taking part. The research may give us knowledge that 
may help people in the future.
 
•
 
We will tell you about new information from this study or other studies that may affect 
your health, welfare, or willingness to stay in this study. If you want the results of the 
study, let the study staff know.
 
Second, some people have personal, religiou
s or ethical beliefs that may limit the kinds of 
medical or research treatments they would want to receive (such as blood transfusions). If you 
have such beliefs, please discuss them with your NIH doctors or research team before you 
agree to the study.
 
Now we will describe this research study. Before you decide to take part, please take as much 
time as you need to ask any questions and discuss this study with anyone at NIH, or with family, 
friends
,
 
or your personal physician or other health 
professional.
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
53
 
of 73
 
PURPOSE AND PLAN OF THE STUDY
 
In this study, we are testing two experimental products or drugs called “VRC01LS” and “VRC07
-
523LS”. Experimental means that these products have not been approved by the U.S. Food and 
Drug Administration (FDA), 
but the FDA
 
has 
allowed us to test them in research studies. VRC01LS 
and VRC07
-
523LS are antibodies directed against HIV virus. The main purpose of this study is to 
see if these antibodies are safe and how your body will respond to them. 
(An antibody is a 
type of 
protein that helps protect the body against foreign matter, such as bacteria and viruses; it can be 
either produced by your body or made in a laboratory.)
 
There are two different parts in this study (Part A and Part B). In Part A, 7 people got VRC0
1LS. In 
Part B, 7 people (up to 10 people) will get VRC07
-
523LS. People were put in Part A first and now 
Part A of the study is done. People will now be put in Part B. If you agree to take part in this study
 
(Part B)
,
 
you will get VRC07
-
523LS only and
 
we will measure the amount of the drug in your body 
and how much stays in your body over time. We will check to see if your immune system makes 
antibodies against the product you get.
 
About 14 to 20 people (7 to 10 people in each part) will take part in t
his study at the NIH Clinical 
Center in Bethesda, Maryland and sites within the 
ACTG
 
Network. The study will include a total of 
23 clinic visits per person over a period of about 11 months. 
 
You will be able to 
start
 
3
-
drug antiretroviral therapy (prescrib
ed by your primary HIV clinician; 
not study
-
provided) after 
you have completed 
the 
day 14 study
 
procedures
.
 
We strongly advise that 
you start antiretroviral therapy after you have completed this stage of the study. 
 
STUDY PRODUCTS
 
VRC01LS and VRC07
-
523LS a
re study products that contain monoclonal antibodies. 
“Monoclonal” means that all antibodies in each product are exactly the same. These antibodies 
target the virus that causes HIV infection. 
As of May 10, 2018, approximately 60 people have 
received one of
 
these 
antibodies and have not had any serious side effects or safety concerns.
  
 
In other research studies, over 840 adults with or without HIV
-
infection got other monoclonal 
antibodies similar to VRC01LS and VRC07
-
523LS, without serious side effects. 
 
VR
C01LS and VRC07
-
523LS are based on an antibody that was first found in an HIV
-
infected 
person. Both of these study products were developed by the Vaccine Research Center (VRC), NIH 
and made in a drug manufacturing laboratory. There are currently research s
tudies of these products 
in adults without HIV infection. This is the first study to give VRC01LS or VRC07
-
523LS to 
people with HIV infection.
 
There is currently no cure for HIV. We do not expect the products in this study to 
cure or 
control
 
your
 
HIV.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
54
 
of 73
 
In 
laboratory and animal studies, VRC01LS and VRC07
-
523LS were shown to attach to and 
inactivate many types of HIV viruses. It is not known if the products will act the same way when 
given to humans.
 
It will take many studies to learn if the products are usef
ul for preventing or 
treating HIV. This study alone will not answer this question. 
 
SCREENING VISIT
 
If you decide to join this study, you will be asked to sign this consent form. After you have signed 
the form, you will be asked some questions and will und
ergo some tests at the screening visit to see 
if it is safe for you to join the study.
 
At the
 
screening visit 
you will 
have a physical exam. You will 
be asked about your medical history, 
including your HIV history, any medicines you have taken in the past 
and are currently taking, and 
if you have ever received antibodies directed against the HIV virus 
or
 
taken any anti
-
HIV 
medicines. 
W
e will draw about 6 tubes of blood
 
from you 
for routine
 
blood tests, 
tests for Hepatitis 
B virus or Hepatitis C virus infect
ion, tests for HIV antibodies and viral load
 
(the amount of HIV in 
your blood)
, and CD4
+
/CD8
+
 
T cell count
 
(cells in your blood that fight infection)
. 
You will be 
informed if any tests show a medical problem. You will be advised if results show that you 
should 
seek medical care.  Some medical conditions may make you not eligible for a clinical trial of an 
investigational product.
 
If you are female and able to become pregnant, you will have a pregnancy test done to see if you are 
pregnant.
 
You cannot parti
cipate in this study if you are pregnant.
 
If you are not pregnant
 
or you are 
having sex that could lead to pregnancy
, you will be asked
 
and must agree
 
to use birth control 
before you are able to participate in this study. We will discuss effective birth co
ntrol methods with 
you.
 
ELIGIBILITY
 
You are eligible to participate in this study 
if
 
you have completed the screening process and are:
 
•
 
18 to 70 years old
 
•
 
HIV infected, 
have never taken antiretroviral (ARV) medications,
 
but otherwise in good general 
health 
 
•
 
Under the care of a primary care provider for management of HIV 
 
•
 
Willing to let the study team give your lab test results to your primary care provider while you 
are in this study.
 
•
 
Willing to receive 
VRC07
-
523LS
 
•
 
Willing to donate blood samples for future 
research
 
•
 
Willing to use birth control for the whole study, if you are able to become pregnant 
 
STUDY PROCEDURES
 
Study product infusion: If you agree to enroll in this study, you will get one dose of VRC07
-
523LS. 
The exact dose you get will depend on how mu
ch you weigh. 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
55
 
of 73
 
Before you are given the study product, your temperature, blood pressure, heart rate, and weight 
will be taken. You may also have a brief physical exam. 
If you are female and able to become 
pregnant, you must use an effective form of birth c
ontrol for the entire study. A pregnancy test will 
be done to see if you are pregnant. If you are pregnant, we will not give you the study product.
 
VRC07
-
523LS will be given to you by intravenous (IV) infusion. This means we will place a thin 
tube or IV li
ne into a vein in your arm. The IV line will be attached to a bag that contains the study 
product mixed with a liquid called “normal saline” or salt water. It will flow into your vein for 
about 30 minutes. If you have side effects during the infusion, it w
ill be slowed or stopped as 
needed. 
You will be observed for at least 30 minutes 
immediately 
after receiving the study product.
 
If possible, we will also place an IV line in your other arm to collect blood samples. We will draw 
your blood before and right 
after the infusion, then at least 5 more times over the next 4 hours from 
this IV line. There are other blood draws at 8, 12
,
 
and 36 hours after infusion
,
 
which 
are optional.
 
At least one IV line will stay in your arm for several hours. You will not lose a
ny benefits if you 
choose not to give the optional blood samples. If you choose to get these blood draws, you may be 
admitted to the hospital for an overnight stay. The hospital stay is for convenience only and not to 
give you care or treatment. 
 
We will g
ive you a thermometer and ask you to check your temperature every day for 3 days after 
you get the study product. You will need to record your temperature and any symptoms you may 
have. Even if you do not feel sick, it is still very important that you reco
rd this information. You 
will get a password to a secure website to enter this information on an electronic form or “diary”. If 
you do not have a computer, you may use a paper diary instead. 
 
If you have any side effects after you get the study product, you should tell a study nurse or doctor 
as soon as possible. You can reach the clinic staff by phone 24 hours a day. If you have symptoms, 
you may be asked to come into the clinic for an examina
tion before your next scheduled visit. It is 
very important that you follow the instructions you get from the clinic staff. 
 
Follow
-
up visits: After you get the study product, you will need to come back to the clinic 11 times 
over a 4
-
week period. During t
he next 9 months, you will have 
10
 
more follow
-
up visits. 
 
At 
most visits
, we will check you for any health changes or problems. 
Your temperature, blood 
pressure, and pulse will be taken and you will have a physical exam. 
We will ask you how you are 
feeling and if you have taken any medications. 
We will also provide 
pregnancy prevention 
counseling (counseling to prevent pregnancy) and positive prevention counseling (counseling to 
prevent 
illness and promote good health in p
eople who know they are HIV
-
positive) while you are 
in the study.
 
We will draw about 1 to 11 tubes of blood from you at each visit, depending on the type of visit. 
We 
will also ask you to provide a urine sample for a urin
e test
 
at most visits. 
We will tell
 
you right 
away if any of your test results show a health problem. You might need to have extra clinic visits 
and laboratory tests if you have health changes that need to be checked. The total amount of blood 
we draw from you will meet NIH guidelines. 
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
56
 
of 73
 
We 
will use some blood samples to see how long the study product remains in your body and if 
your immune system makes antibodies against it. Results of these tests are not for checking on your 
health and we will not give you these results.
 
We may also
 
use som
e blood samples to check the 
level of ARV medications in your blood while you are in this study.
 
 
 
Research
 
studies 
follow a set schedule. This helps us answer the research questions. The visit 
schedule is a little flexible, but it is important that you wo
rk with the staff to follow the schedule as 
closely as possible. You should try not to miss any visits. You should contact the clinic staff as soon 
as possible if you need to change the date or time of any visit. 
 
For the entire duration that you are on st
udy, which will be 48 weeks or about 11 months, 
a 
maximum of about 
922 mL 
(or about 2 pints) 
of blood will be collected. 
 
HIV TESTING AND MANAGEMENT 
 
As you take part in this study, you will have frequent testing of your HIV viral load and CD4
+
 
T cell 
coun
t for research purposes. These test results will be given to you and sent to your primary care 
provider. You should discuss these results and any questions about management of your HIV 
infection with your primary care provider. 
 
This study does not include
 
standard medical care or management of your HIV infection. The U.S. 
Department of Health and Human Services and the clinical research team recommend that all HIV
-
infected individuals take (ARV) medication to reduce the chance of getting sick from HIV, inc
rease 
life expectancy with HIV infection
,
 
and prevent the spread of HIV to others.
 
We will not give you ARV medications as part of this research study. 
You must have a primary 
health care provider for HIV to take part in this study. If you 
do not
 
have one 
and need help finding 
one or getting ARV medications, please tell a study doctor or nurse. We will help you find a 
qualified HIV doctor and ARV medications. 
You and your primary health care provider will make 
all decisions about starting, stopping, or chan
ging ARV medications. 
However
,
 
we 
strongly advise
 
that you start ARV medications after you have compl
eted the day 14 study procedure
s. 
We expect 
you to tell us about changes in your ARV medications. We do not expect VRC07
-
523LS to control 
HIV by itself. 
You should not change or stop ARV treatment without talking about it with your 
primary care provider. Changes in ARV treatment will not affect your continued participation in the 
study.
 
MONITORING OF THE STUDY
 
A group of physicians and scientists at NIH wi
ll monitor this study. This group will review the 
information from the study and will pay close attention to possible harmful reactions. If serious side 
effects occur, study product infusions may be delayed or canceled.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
57
 
of 73
 
GENETIC TESTING
 
In the future, genet
ic research tests may be done on your stored samples to help understand how 
VRC07
-
523LS works and interacts with your body. In research studies, genetic tests are done to see 
if different types of immune response are related to genetic differences in peopl
e
,
 
this includes 
testing your antibody genes. Genetic tests done in a research lab from your stored samples will not 
be recorded in your medical record and will not have your name on the sample. The performance of 
these tests is not for health care purpose
s.
 
HLA type is a genetic test. People with certain HLA types might be more likely to develop certain 
diseases. Simply having those HLA types 
does not
 
mean the
y will develop those diseases.
 
HLA 
typing can reveal family relationships. It is our policy not to
 
discuss your HLA results unless they 
have direct medical or reproductive implications for you or your family. Genetic information about 
you will not be revealed to others, including your relatives, without your permission. We will not 
release any informat
ion about you or your family to any insurance company or employer unless you 
sign a document allowing release of information.
 
VRC clinic only: HLA typing may be ordered through the NIH Clinical Center medical laboratory. 
If performed at the NIH Clinical Ce
nter, your HLA results will be in your medical record. 
 
STORED SAMPLES
 
We will collect blood samples from you during the study. We will keep these samples for future 
research to learn more about monoclonal antibodies, vaccines, the immune system, and/or 
other 
medical conditions. Results from research done with your stored samples will not be in your 
medical record or reported to you.
 
Some of your blood samples that are left over after all required study testing are done may be stored 
and used for VRC
-
appr
oved and ACTG
-
approved HIV
-
related research.
 
 
Labeling of Stored Samples: We will label your stored samples by a code (like a number). Only the 
study team can link this code to you. Any identifying information about you will be kept 
confidential as much as
 
the law allows. Despite protections, there is a small chance that information 
identifying you will be given to someone who should not get it.
 
Risks from Stored Samples: There is a risk of unplanned release of information from your medical 
records. The cha
nce that this information will be given to an unauthorized person without your 
permission is very small. Possible problems with the unplanned release of information include 
discrimination when applying for insurance and employment. Similar problems may occ
ur if you 
give information about yourself or agree to have your medical records released.
 
Future studies: In the future, other investigators (at NIH or outside of NIH
; in the ACTG or outside 
of the ACTG
) may wish to study your stored samples. When your sto
red samples are shared, they 
will be marked with a code. Your samples will not have any identifying information on them. Some 
information about you, such as your gender, age, health history, or ethnicity may also be shared 
with other researchers.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
58
 
of 73
 
Any futur
e research studies using your samples will be conducted in a way that protects the rights 
and privacy of study participants.
 
Your stored samples will be used only for research and will not be sold. The research done with 
your materials may be used to devel
op new products in the future but you will not receive payment 
for such products.
 
Making your Choice: You can only take part in this study if you agree to let us collect, store, and 
use your blood samples in future unspecified research. If you decide not t
o take part in this study, 
you may still take part in other studies at the NIH
 
or at the research site
.    
 
POSSIBLE STUDY RISKS
 
Risks of Blood Drawing and IV insertion:
 
The 
risks of drawing blood from a vein and having an IV 
include
 
pain, bruising, bleedi
ng, lightheadedness and fainting. Rarely, infection or inflammation can 
occur in the skin or vein.
 
Blood clots are possible risks when using an IV for blood draw.
 
Risks of VRC07
-
523LS:
 
This study is the first time that VRC07
-
523LS is being given to people 
with HIV infection. 
As of 
January 2018
,
 
the 
people 
who 
have received at least one dose of VRC07
-
523LS
 
had
 
no concerning reactions to the product. VRC07
-
523LS may have other unknown risks or 
side effects. We do not know if getting VRC07
-
523LS will affect ho
w you respond to any similar 
monoclonal antibody against HIV. 
 
General risks of monoclonal antibodies:
 
Side effects to infusions of monoclonal antibodies may
 
include 
fever, chills, shaking, nausea, vomiting, pain, headache, dizziness, trouble breathing, hi
gh or 
low blood pressure, itchiness, rash, hives, lip or face swelling, diarrhea, racing heart or chest pain
. 
These 
reactions may be related to how fast the product is infused. If you have symptoms while you 
get VRC07
-
523LS, tell the nurse right away. Slow
ing or stopping the infusion may help improve 
these symptoms.
 
Side effects may also include reactions at the injection site, such as redness, 
bruising, and swelling.
 
 
Some antibody products have a risk of serious allergic reactions 
or cytokine release syndrome 
that 
can be life
 
threatening.  
 
•
 
Anaphylaxis is one type of allergic reaction that may happen soon after an antibody product 
is given. This reaction can include difficulty breathing, low blood pressure, hives or rash, 
swelling in the mouth and face.    
 
•
 
Serum sickness is a delayed type of
 
allergic reaction that may happen several days to three 
weeks after an antibody product is given. This reaction can include hives or rash, fever, 
enlarged lymph nodes, muscle pains, joint pains, chest discomfort
,
 
and shortness of breath.
 
•
 
Cytokine release 
syndrome can happen when an antibody targets a cell protein that triggers 
immune cells to release cytokine (proinflammatory molecules in your body).
  
 
All of these reactions are very unlikely because VRC07
-
523LS is a fully human antibody that 
attacks the H
IV virus, and not your cells.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
59
 
of 73
 
In addition to the possible risks that are listed above, the study products may have other side effects 
that we do not know about yet. Taking part in this study may affect your eligibility for future studies 
of other experimen
tal monoclonal antibodies, antibody mixtures or other similar products.
 
We will give you any new information about risks or other information that becomes available that 
may affect your decision to continue in the study.
 
Risks during Pregnancy:
 
We do not k
now what effects the study products may have on a fetus or 
nursing infant. Women must agree not to
 
get pregnant during the study. 
We will discuss effective 
birth control methods with you.
 
If you are able to become pregnant, you
 
and your partner must use 
re
liable birth control from the time you start the study until you complete the last study visit.
 
If you can become pregnant, you must have a pregnancy test before you enter this study. The test 
must show that you are not pregnant. 
You must tell the clinic s
taff right away if you become 
pregnant during this study or think that you might be pregnant. If you become pregnant after getting 
the study product, we will not collect any more blood for research. However, you will be asked to 
continue with study follow
-
up visits to check on your health and to report the outcome of the 
pregnancy to us, which will be reported to the 
A
ntiretroviral 
P
regnancy 
R
egistry 
(
http://www.apregistry.com
). 
This report will not use your name or other information that could be 
used to i
dentify you.
 
POSSIBLE BENEFITS
 
This study will not provide you with any direct health benefit. You and others may benefit in the 
future from the information that we learn from the study.
 
COSTS TO YOU FOR YOUR PARTICIPATION
 
There are no costs to you for tak
ing part in this study. You or your health insurance will have to pay 
for all medical costs for medical care that you get outside this study. It is possible that you may 
have some expenses that are not covered by the study compensation provided.
 
COMPENSATI
ON TO YOU FOR YOUR PARTICIPATION
 
You will be compensated [insert site IRB
-
approved amount] for your study participation as follows: 
[insert site plan]. This will be based on the number and type of study visits that you complete. 
 
REASONS FOR REMOVING YOU 
FROM THE STUDY WITHOUT YOUR CONSENT
 
You may be removed from the study for several different reasons, including:
 
•
 
You 
do not
 
keep appointments or follow study procedures.
 
•
 
You get a serious illness that needs ongoing medical care.
 
•
 
You enroll in another resear
ch study at the same time you are in this study.
 
•
 
You become pregnant.
 
•
 
The study is stopped or canceled.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
60
 
of 73
 
A study may be stopped or canceled by a study sponsor, a regulatory agency or by the study 
investigators. If this happens
,
 
you will be told the reason why.
 
You may choose to stop taking part in the study at any time.
 
If you
 
received the study product
 
before you 
discontinue the study early
, you will be asked to 
continue to be part of the study and return for the rest of the st
udy visits
. At the visits you will have 
some tests performed for safety monitoring, however samples for research purposes will not be 
collected.
 
 
ALTERNATIVES
 
This study is not designed to treat or prevent HIV infection or any disease. You may choose to no
t 
take part in this study. 
You may be eligible for other studies. 
Instead of being in this study you have 
the choice of:
 
•
 
T
reatment with prescription drug available to you
 
•
 
T
reatment with experimental drugs, if you qualify
 
•
 
N
o treatment
 
Please talk to your 
doctor about these and other choices that may be available to you. Your doctor 
will explain the risks and benefits of these choices.
 
 
CONFLICT OF INTEREST
 
The research staff are reviewed at least yearly for conflicts of interest. You may ask the research 
t
eam for additional information.
 
The National Institutes of Health, including some members of the Vaccine Research Center 
scientific staff, developed the experimental product in this research study. The results of this study 
could play a role in whether the
 
FDA will approve the experimental product for sale at some time in 
the future. If approved, the future sale of the vaccine could lead to payments to NIH and some NIH
 
scientists. By
 
U.S. law, government scientists are required to receive such payments for 
their 
inventions.
 
 
 
You will not get any money from the development or sale of the product.
 
This protocol may have investigators who are not NIH employees. Non
-
NIH investigators are 
expected to follow the principles of the Protocol Review Guide but are not
 
required to report their 
personal financial holdings to the NIH.
 
CLINICALTRIALS.GOV
 
A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov
. This web 
site will not include information that can identify you. At most, the web
site will include a 
summary of the results. You can search this website at any time.
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
61
 
of 73
 
OTHER PERTINENT INFORMATION
 
1.
 
Confidentiality.  
 
When results of an NIH research study are reported in medical journals or at scientific meetings, 
the people who take par
t are not named and identified. In most cases, the NIH will not release any 
information about your research involvement without your written permission. However, if you 
sign a release of information form, for example, for an insurance company, the NIH will
 
give the 
insurance company information from your medical record. This information might affect (either 
favorably or unfavorably) the willingness of the insurance company to sell you insurance.
 
The Federal Privacy Act protects the confidentiality of your N
IH medical records. However, you 
should know that the Act allows release of some information from your medical record without 
your permission, for example, if it is required by the Food and Drug Administration, members of 
Congress, law enforcement official
s, National Institute of Allergy and Infectious Diseases 
institutional review board, study monitors, or other authorized people.
 
ACTG Clinical Research Sites: We will do everything we can to protect your privacy. In addition 
to the efforts of the study sta
ff to help keep your personal information private, we have gotten a 
Certificate of Confidentiality from the U.S. Federal Government. This certificate means that 
researchers cannot be forced to tell people who are not connected with this study, such as the 
court system, about your participation. Also, any publication of this study will not use your name 
or identify you personally.
 
Your records may be reviewed by the U.S. Food and Drug Administration (FDA), the ACTG, the 
U.S. Office for Human Research Protect
ions (OHRP), or other local, US, and international 
regulatory entities as part of their duties (insert name of site) institutional review board (IRB) (a 
committee that protects the rights and safety of participants in research), National Institutes of 
Heal
th (NIH), study staff, study monitors, and their designees. Having a Certificate of 
Confidentiality does not prevent you from releasing information about yourself and your 
participation in the study.
 
Even with the Certificate of Confidentiality, if the stu
dy staff learns of possible child abuse and/or 
neglect or a risk of harm to yourself or others, we will be required to tell the proper authorities.
 
2.
 
Policy Regarding Research
-
Related Injuries.  
 
The [insert institution’s name] will provide short
-
term med
ical care for any injury resulting from 
your participation in research here. 
The cost of this treatment will be charged to you or your 
insurance company. 
In general, no long
-
term medical care or financial compensation for research
-
related injuries will be 
provided by the [insert institution’s name], National Institutes of Health, or 
the Federal Government. However, you have the right to pursue legal remedy if you believe that 
your injury justifies such action.
 
3.
 
Payments.
 
The amount of payment to research 
participants 
is guided by the National Institutes of Health policies
 
or as approved by the Institutional Review Board (IRB) of the clinical research site
.  
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
62
 
of 73
 
4.
 
Problems or Questions.
 
If you have any problems or questions about this study or about any 
research
-
related injury, contact 
the Principal Investigator, [insert site PI name], or the Study Coordinator
, 
[study coordinator name]
 
at [contact phone number].
 
If you have any questions about your rights as a research 
participant
, you may 
contact:
 
VRC Clinic only: The 
Clinical Center Patient Representative at 301
-
496
-
2626.
 
ACTG Clinical Research Sites:
 
•
 
N
ame or title of person on the Institutional Review Board (IRB) or other organization 
appropriate for the site
 
•
 
T
elephone number of above
 
5.
 
Consent D
ocument.  
 
Please keep a copy of this document in case you want to read it again.
 
COMPLETE APPROPRIATE ITEM(S) BELOW:
 
Adult Study Participant’s Consent
 
 
I have read the explanation about this study and have been given the opportunity to discuss it and to
 
ask questions.  I 
hereby consent to take part in this study.
 
 
 
 
                
 
 
Signature of Adult Participant/Legal Representative               
 
Date
 
 
 
Print Name
 
 
 
 
Time
 
THIS CONSENT DOCUMENT HAS BEEN APPROVED FOR USE 
 
FROM XXXXXX THROUGH XXXXXX.
 
 
 
 
 
 
 
 
Signature of Investigator/Person Obtaining
 
Consent
 
 
 
 
 
Date
 
 
 
 
 
Print Name
 
Signature of Witness
 
 
 
 
 
Date
 
 
 
 
 
Print Name
 
PRODUCT: 
VRC01LS
/
VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
 
Page 
63
 
of 73
 
APPENDIX II
 
 
CONTACT INFORMATION
 
PRODUCT: 
VRC01LS/VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
Page 
65
 
of 73
 
APPENDIX
 
III
 
 
SCHEDULE OF EVALUATI
ON
S
PRODUCT: 
VRC01LS/VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
Page 
66
 
of 73
 
“Visits” 02G, 02H and 03A are optional
 
Schedule of 
Evaluations
 
Part A
 
Visit Number
 
01R
 
02
 
02A
 
02
B
 
02
C
 
02
D
 
02E
 
02F
 
02G
 
02H
 
03
 
03A
 
04
 
05
 
06
 
07
 
Time After Day 0 Infusion
 
 
Pre
 
EOI
 
30
 
1hr
 
2hr
 
3h
 
4hr
 
8hr
 
12hr
 
24hr
 
36hr
 
48hr
 
72hr
 
Wk1
 
Wk1
 
Day of Study
 
-
28 to 0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D1
 
D1
 
D2
 
D3
 
D5
 
D7
 
Study
 
Procedures
 
Tube
 
Screen
 
Enroll
 
Outpatient (with optional inpatient admission)
 
 
 
 
 
VRC 500 Screening Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 607
/A5378
 
Assessment of 
Understanding; Consent
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 
Physical exam
 
 
X
 
X
 
X
 
X
 
 
 
 
 
 
 
 
X
 
 
X
 
 
 
X
 
2
 
Medical history
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
 
X
 
 
X
 
 
 
X
 
3
 
Concomitant Medications
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
 
X
 
 
X
 
 
 
X
 
4
 
ARV Medication Record
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Product Administration
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5
 
Diary “Card” Reactogenicity 
Review
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
X
 
 
 
Pregnancy 
prevention counseling
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive prevention counseling
 
 
X
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Labs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBC, platelets
 
EDTA
 
3
 
 
3
 
 
 
 
 
 
 
 
 
 
 
3
 
 
 
3
 
ALT, AST, ALP, creatinine
 
GLT
 
4
 
 
4
 
 
 
 
 
 
 
 
 
 
 
4
 
 
 
4
 
Hepatitis BsAg
 
SST
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hep C viral load
 
SST
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
 
Pregnancy test: urine or serum
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV EIA
 
SST
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV PCR
 
EDTA
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
CD4
+
/CD8
+
 
EDTA
 
3
 
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
 
Research Samples
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Timed PK samples
 
SST
 
 
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
 
 
4
 
 
4
 
 
 
4
 
PBMC and plasma
 
EDTA
 
 
20
 
 
 
 
 
 
 
 
 
 
 
 
10
 
 
 
20
 
Serum
 
SST
 
 
24
 
 
 
 
 
 
 
 
 
 
 
 
8
 
 
 
16
 
Daily Volume (mL)
 
 
28
 
50
 
20
 
10
 
10
 
10
 
10
 
10
 
10
 
6
 
6
 
10
 
6
 
35
 
6
 
6
 
56
 
Cumulative Volume (mL)
 
 
28
 
78
 
98
 
108
 
118
 
128
 
138
 
148
 
158
 
164
 
170
 
180
 
186
 
221
 
227
 
233
 
289
 
PRODUCT: 
VRC01LS/VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
Page 
67
 
of 73
 
SCHEDULE OF EVALUATIONS (continued):
 
1
 
Physical exam
: Screening includes 
complete physical exam with vital signs, height and weight. Day 0 
physical exam includes vital signs (blood pressure, temperature and pulse) and weight (
used for ordering 
the study produc
t which is based on a “mg/kg” dose). At other visits if medically ind
icated, a targeted 
exam is performed. Otherwise only blood pressure (BP), pulse and temperature are required.
 
2
 
Medical history
: Screening, 01R and Day 0 evaluations include a complete medical history to evaluate 
eligibility criteria as defined in 
Section 4.1
. At other visits, an interim medical history will be done. 
 
3
 
Concomitant medications
: Concomitant medications must be entered in the database at enrollment and 
updated as required in 
Section 4.2.8
. 
 
4
 
ARV
 
medication record
: ARVs will be reviewed with the 
participant
 
throughout the study, however 
the ARV medication record will be documented in the research chart and database as indicated and 
whenever changes are reported.
 
5
 
Diary card reactogenicity
 
review
:
 
Participants
 
will begin to record 3
-
day reactogenicity as noted in 
Section 4.2.4
. Clinicians will review with the 
participant
 
at a minimum on Day 3 and prior to Day 3 as 
needed. If any reported reactogenicity is unresolved by Day 3
, it will continue to be reviewed with the 
participant
 
at each visit until resolved. Data from the data will be recorded in the database as noted in 
Section 4.2.4
.
 
6 
Pregnancy test
: Negative pregnancy test results must be confirmed 
for women of reproductive p
otential 
prior to study produc
t administration.
 
Visit Windows:
 
Screening
: evaluations for eligi
bility must be completed 
within 
28
 
days of enrollment as noted in 
Section 4.1
.
 
Visit 01R and Day 0
: Visit 01R m
ay be done on the same day as Day 0. Day 0 = day of product 
administration. Day 0 is preferably scheduled within 14 days after enrollment at “Visit 01R”, but 
may be scheduled up to 
28
 
days after enrollment. Day 0 evaluations prior to VRC01LS
 
administration
 
are the baseline for assessing subsequent AEs.  
 
EOI
 
= End of Infusion Blood draw “visits,” defined by minutes or hours after an infusion are relative 
to the exact time of the end of infusion (EOI). The exact time of start (T0), EOI and each PK draw is 
re
corded to ensure accurate PK analysis.  
 
Visit 02A
: up to 10 minutes post EOI
 
Visit 02B
 
& 02C
: ± 10 min
utes
 
Visits 02D
 
–
 
02F
: 
±
 
15 minutes
 
Visit 02G
: ± 30 minutes
 
Note
: This visit is optional.
 
Visit 02H
, 03, 
03A
: ± 1 hour
 
Note
: Visits 02H and 03A are 
optional.
 
Visit 04
: ± 6 hours
 
Visit 05
: ± 12
 
hours
 
Visits 06 
–
 
07
: 

 
1 day
PRODUCT: 
VRC01LS/VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
Page 
68
 
of 73
 
1
 
Physical exam
: If medically indicated, a targeted exam is performed. Otherwise only blood pressure (BP), pulse and temperature are 
required.
 
2
 
HLA type blood sample
 
is collected once in the study at the VRC Clinic; however, if HLA type is already available in the medical record it
 
does not 
need to be repeated. 
HLA type may also be obtained from a frozen sample.
 
3 
PK samples
: PK 
samples will be optional at visits 22 and 23 if VRC01LS levels are undetectable at the PK draw at visit 21.
 
Visit windows
: 
Visits 08 
–
 
11
: 

 
1 day;
 
Visits 12 
–
 
17
: 

 
2 days; 
Visits 18 
–
 
20
: 

 
5 days; 
Visits 21 
-
23
: ± 7 days  
Schedule of Evaluations 
Part A 
(continued)
 
Visit Number
 
08
 
09
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
Week of Study
 
Wk2
 
Wk2
 
Wk2
 
Wk3
 
Wk3
 
Wk4
 
Wk5
 
Wk6
 
Wk7
 
Wk8
 
Wk12
 
Wk16
 
Wk20
 
Wk24
 
Wk36
 
Wk48
 
Day of Study
 
D9
 
D12
 
D14
 
D16
 
D21
 
D28
 
D35
 
D42
 
D49
 
D56
 
D84
 
D112
 
D140
 
D168
 
252
 
336
 
Study Procedures
 
Tube
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 
Physical exam
 
 
 
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Interim medical history
 
 
 
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Concomitant medications
 
 
 
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
ARV medication record
 
 
 
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Pregnancy prevention counseling
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X
 
 
 
Positive prevention counseling
 
 
 
 
 
 
 
X
 
 
 
 
 
 
 
 
X
 
X
 
X
 
Clinical Labs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBC, 
platelets
 
EDTA
 
 
 
3
 
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
ALT, AST, ALP, creatinine
 
GLT
 
 
 
4
 
 
 
4
 
 
 
 
 
4
 
 
 
4
 
4
 
4
 
Pregnancy test: urine or serum
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X
 
 
X
 
HIV PCR
 
EDTA
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
CD4
+
/CD8
+
 
EDTA
 
 
 
3
 
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
2
 
HLA typing 
(VRC Clinic only)
 
EDTA
 
 
 
 
 
 
 
 
 
 
 
 
 
20
 
 
 
 
Research Samples
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
 
PK samples
 
SST
 
 
 
4
 
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
PBMC and plasma
 
EDTA
 
 
 
 
 
 
20
 
20
 
 
 
20
 
20
 
 
 
20
 
20
 
20
 
Serum
 
SST
 
 
 
 
 
 
24
 
16
 
 
 
24
 
24
 
24
 
24
 
24
 
24
 
24
 
Daily Volume (mL)
 
 
6
 
6
 
20
 
6
 
16
 
64
 
52
 
16
 
16
 
60
 
64
 
40
 
60
 
64
 
64
 
64
 
Cumulative Volume (mL)
 
 
295
 
301
 
321
 
327
 
343
 
407
 
459
 
475
 
491
 
551
 
615
 
655
 
715
 
779
 
843
 
907
 
PRODUCT: 
VRC01LS/VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
Page 
69
 
of 73
 
“Visit
s” 02G, 02H
,
 
and 03A are optional
 
Sche
dule of Evaluations Part B
 
Visit Number
 
01R
 
02
 
02A
 
02B
 
02C
 
02
D
 
02E
 
02F
 
02G
 
02H
 
03
 
03A
 
04
 
05
 
06
 
07
 
Time After Day 0 Infusion
 
 
Pre
 
EOI
 
30
 
1hr
 
2hr
 
3h
 
4hr
 
8hr
 
12hr
 
24hr
 
36h
 
48h
 
72hr
 
Wk1
 
Wk1
 
Day of Study
 
-
10
 
to 0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D1
 
D1
 
D2
 
D3
 
D5
 
D7
 
Study Procedures
 
Tube
 
Screen
 
Enroll
 
Outpatient (with optional inpatient admission)
 
 
 
 
 
VRC 607
/A5378
 
Assessment of 
Understanding; Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 
Physical exam
 
 
X
 
X
 
X
 
X
 
 
 
 
 
 
 
 
X
 
 
X
 
 
 
X
 
2
 
Medical history
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
 
X
 
 
X
 
 
 
X
 
3
 
Concomitant Medications
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
 
X
 
 
X
 
 
 
X
 
4
 
ARV Medication Record
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5
 
Study Product Administration
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
 
Diary “Card” Reactogenicity Review
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
X
 
 
 
Pregnancy prevention counseling
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive prevention counseling
 
 
X
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Labs
 
 
(numbers indicate volume of blood 
and
 
urine 
sample to be collected)
 
CBC, platelets
 
EDTA
 
3
 
 
3
 
 
 
 
 
 
 
 
 
 
 
3
 
 
 
3
 
ALT, AST, ALP, creatinine
 
GLT
 
4
 
 
4
 
 
 
 
 
 
 
 
 
 
 
4
 
 
 
4
 
Hepatitis BsAg
 
SST
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hep C viral load
 
SST
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7
 
Pregnancy test: urine or serum
 
URN
 
5
 
5
 
5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SST
 
3
 
3
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV EIA
 
SST
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV PCR
 
EDTA
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
CD4
+
/CD8
+
 
EDTA
 
3
 
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
 
Urinalysis
 
 
 
5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Samples
 
 
(numbers indicate volume of blood sample to be collected)
 
Timed PK samples
 
SST
 
 
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
 
 
4
 
 
4
 
 
 
4
 
PBMC and plasma
 
EDTA
 
 
20
 
 
 
 
 
 
 
 
 
 
 
 
10
 
 
 
20
 
Serum
 
SST
 
 
24
 
 
 
 
 
 
 
 
 
 
 
 
8
 
 
 
16
 
Daily 
Blood 
Volume 
(mL)
 
 
28
-
31
 
50
-
53
 
20
-
23
 
10
 
10
 
10
 
10
 
10
 
10
 
6
 
6
 
10
 
6
 
35
 
6
 
6
 
56
 
Maximu
m 
Cumulative 
Blood 
Volume 
(mL)
 
 
31
 
8
4
 
10
7
 
117
 
127
 
137
 
147
 
157
 
167
 
173
 
179
 
189
 
195
 
230
 
236
 
242
 
298
 
PRODUCT: 
VRC01LS/VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
Page 
70
 
of 73
 
SCHEDULE OF EVALUATIONS (continued):
 
1
 
Physical exam
: Screening includes complete physical exam with vital signs, height and weight. Day 0 physical 
exam includes vital signs (blood pressure, temper
ature and pulse) and weight. At other visits if medically 
indicated, a targeted exam is performed. 
Weight must be measured at enrollment (Visit 01R), which will be 
used for ordering the study product based on a “mg/kg” dose. 
Otherwise only blood pressure 
(BP), pulse and 
temperature are required.
 
2
 
Medical history
: Screening, 01R and Day 0 evaluations include a complete medical history to evaluate 
eligibility criteria as defined in
 
Section 4.1
. At other visits, an interim medical hist
ory will be done. 
 
3
 
Concomitant medications
: Concomitant medications must be entered in the database at enrollment and 
updated as required in 
Section 4.2.8
. 
P
articipants will
 
be 
strongly encouraged 
to
 
initiate 3
-
drug ART (prescribe
d 
by their primary HIV clinician; not study
-
provided) 
after 
completing
 
day 
14 
study
 
evaluations
. Document them 
as concomitant medications
.
 
4
 
ARV medication record
: ARVs will be reviewed with the 
participant
 
throughout the study, however the ARV 
medication 
record will be documented in the research chart and database as indicated and whenever changes are 
reported.
 
5
 
Study Product Administration
:
 
Administration should occur within 10 days after enrollment per
 
Section 
4.2.2
 
and Day 0 visit window details below.
 
Study product should be available on site one day prior to the scheduled 
infusion (D0). Refer to the MOP for detailed study product ordering instructions.
 
6
 
Diary card reactogenicity
 
review
: 
Participants
 
will begin to record 3
-
day reactogenicity as noted in 
Section 
4.2.4
. Clinicians will review with the 
participant
 
at a minimum on Day 3 and prior to Day 3 as needed. If any 
reported reactogenicity is unresolved by Day 3, it will con
tinue to be reviewed with the 
participant
 
at each visit 
until resolved. Data from the data will be recorded in the database as noted in 
Section 4.2.4
.
 
7
 
Pregnancy test
: Negative pregnancy test results must be confirmed for women of 
reproducti
ve potential prior 
to study produc
t administration.
 
Visit Windows:
 
Screening
: evaluations for eligibility must be completed with
in
 
28 days of enrollment as noted in 
Section 
4.1
.
 
Visit 01R and Day 0
: Visit 01R may be 
done on the same day as Day 0. 
Day 0 = day of
 
product 
administration. 
Day 0 
should be
 
scheduled within 
10
 
days after enrollment at “Visit 01R”. Day 0 
evaluations prior to VRC07
-
523LS administration are the baseline for assessing subsequent AEs.  
 
EOI
 
= End
 
of Infusion Blood draw “visits,” defined by minutes or hours after an infusion are relative to the 
exact time of the en
d of infusion (EOI). 
The exact time of start (T0), EOI and each PK draw is recorded to 
ensure accurate PK analysis.  
 
Visit 02A
: up to 1
0 minutes post EOI
 
Visit 02B & 02C
: ± 10 minutes
 
Visits 02D 
–
 
02F
: ±
 
15 minutes
 
Visit 02G
: ± 30 minutes 
Note
: This visit is optional.
 
Visit 02H, 03, 
and 
03A
: ± 1 hour 
Note
: 
Visits 02H and 03A are optional.
 
Visit 04
: ± 6 hours
 
Visit 05
: ± 12 hours
 
Visits 06 
–
 
07
: 

 
1 day
 
Note
: 
These v
isits cannot occur on the same day.
 
Visit 07 cannot occur on the same 
day as Visit 08.
PRODUCT: 
VRC01LS/VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
Page 
71
 
of 73
 
1
 
Physical exam
: If medically indicated, a targeted exam is performed. Otherwise only blood pressure (BP), pulse and temperature are require
d.
 
2
 
HLA type blood sample
 
is collected once in the study at the VRC Clinic; however, if HLA typ
e is already available in the medical record it does not 
need to be repeated.  HLA type may also be obtained from a frozen sample.
 
3 
PK samples
: PK samples will be optional at visits 22 and 23 if VRC07
-
523LS levels are undetectable at the PK draw at visit 
21.
 
If needed, PK assay 
for ARVs 
will
 
be performed; however, no additional blood draw is required.
 
Visit windows
: 
Visits 08 
–
 
11
: 

 
1 day
 
(
Note
: Visit 08 cannot occur on the same day as Visit 07. Visits 09, 10, and 11 cannot occur on the same 
day.)
;
 
Visits
 
12 
–
 
17
: 

 
2 days; 
Visits 18 
–
 
20
: 

 
5 days; 
Visits 21 
-
23
: ± 7 days  
 
Schedule of Evaluations Part B 
(continued)
 
Visit Number
 
08
 
09
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
Week of Study
 
Wk2
 
Wk2
 
Wk2
 
Wk3
 
Wk3
 
Wk4
 
Wk5
 
Wk6
 
Wk7
 
Wk8
 
Wk1
2
 
Wk1
6
 
Wk2
0
 
Wk2
4
 
Wk3
6
 
Wk4
8
 
Day of Study
 
D9
 
D12
 
D14
 
D16
 
D21
 
D28
 
D35
 
D42
 
D49
 
D56
 
D84
 
D112
 
D140
 
D168
 
D
252
 
D
336
 
Study 
Procedures
 
Tube
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 
Physical exam
 
 
 
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Interim medical history
 
 
 
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Concomitant medications
 
 
 
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
ARV medication record
 
 
 
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Pregnancy prevention 
counseling
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X
 
 
 
Positive prevention counseling
 
 
 
 
 
 
 
X
 
 
 
 
 
 
 
 
X
 
X
 
X
 
Clinical Labs
 
 
(numbers indicate volume of blood 
and urine 
sample to be collected)
 
CBC, platelets
 
EDTA
 
 
 
3
 
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
ALT, AST, ALP, creatinine
 
GLT
 
 
 
4
 
 
 
4
 
 
 
 
 
4
 
 
 
4
 
4
 
4
 
Pregnancy test: urine or serum
 
URN
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5
 
 
5
 
SST
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
 
 
3
 
HIV PCR
 
EDTA
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
CD4
+
/CD8
+
 
EDTA
 
 
 
3
 
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
3
 
2
 
HLA typing (VRC Clinic only)
 
EDTA
 
 
 
 
 
 
 
 
 
 
 
 
 
20
 
 
 
 
Urinalysis
 
 
 
 
5
 
 
 
5
 
 
 
 
5
 
5
 
5
 
5
 
5
 
5
 
5
 
Research Samples
 
 
(numbers indicate volume of blood sample to be collected)
 
3
 
PK samples
 
SST
 
 
 
4
 
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
PBMC and plasma
 
EDTA
 
 
 
 
 
 
20
 
20
 
 
 
20
 
20
 
 
 
20
 
20
 
20
 
Serum
 
SST
 
 
 
 
 
 
24
 
16
 
 
 
24
 
24
 
24
 
24
 
24
 
24
 
24
 
Daily
 
Blood
 
Volume (mL)
 
 
6
 
6
 
20
 
6
 
16
 
64
 
52
 
16
 
16
 
60
 
64
 
40
 
60
 
64
-
67
 
64
 
64
-
67
 
Maximum 
Cumulative 
Blood 
Volume (mL)
 
 
304
 
310
 
330
 
336
 
352
 
416
 
468
 
484
 
500
 
560
 
624
 
664
 
724
 
791
 
855
 
922
 
PRODUCT: 
VRC01LS/VRC07
-
523LS
 
PROTOCOL: VRC 607/A
5378, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
Page 
72
 
of 73
 
APPENDIX
 
IV
 
 
 
TABLE FOR GRADING SEVERITY OF ADVERSE EVENTS
 
 
PRODUCT: 
VRC01LS/VRC07
-
523LS
 
PROTOCOL: VRC 607/A
537
8, VERSION 4.0 
 
DATE:  MAY 29, 2018
 
 
Page 
73
 
of 73
 
 
The 
U.S. Department of Health and Human Services, National Institutes of Health, National 
Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) 
Table for Grading the Severity of Adult and Pediatric Adverse Events, Versi
on 2.0. [November 
2014]
 
will be used in this study
. 
The 
table
 
is available at the following link
:
 
http://rsc.tech
-
res.com/docs/default
-
source/safety/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8
 
 
The grading table, the Manual for Expedited Reporting of Ad
verse Events to DAIDS, and 
supplementary tutorial and tools can be found on the Division of AIDS Regulatory Support 
Center (RSC) website: 
 
 
http://rsc.tech
-
res.com/clinical
-
research
-
sites/safety
-
reporting
 
 
The Table will be used as posted at the link above with the following exemption:
 
•
 
Weight loss will be recorded as an adverse event only if it is considered deleterious to the 
participant’s health.
 
 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY
MEDICAL RECORD
•  Adult Patient or     •  Parent, for Minor Patient
INSTITUTE: National Institute of Allergy and Infectious Diseases
STUDY NUMBER: 16-I-0147 PRINCIPAL INVESTIGATOR:  
STUDY TITLE: VRC 607/ACTG A5378: A Phase 1, Single Dose Study of the Safety and Virologic Effect of an HIV 
Specific Broadly Neutralizing Human Monoclonal
 Antibody, VRC-HIVMAB080-00-AB (VRC01LS) or 
VRC-HIVMAB075-00-AB (VRC07-523LS) Administered Intravenously to HIV-Infected Adults.
Continuing Review Approved by the IRB on 05/07/18
Amendment Approved by the IRB on 07/09/18 (D) Date Posted to Web: 08/22/18
Study Consent [Version 4.0]
PATIENT IDENTIFICATION CONSENT TO PARTICIPATE IN A CLINICAL
RESEARCH STUDY
•   Adult Patient or    •   Parent, for Minor Patient
NIH-2514-1 (07-09)
P.A.: 09-25-0099
File in Section 4:  Protocol Consent (1)
INTRODUCTION
We invite you to take part in a research study at the National Institutes of Health (NIH). This study is a collaboration 
between the Vaccine Research Center (VRC), NIAID, NIH and the AIDS Clinical Trials Group (ACTG).
First, we want you to know that:
 
Taking part in this study is entirely voluntary.
 
You may choose not to take part, or you may withdraw from the study at any time.  In either case, you 
will not lose any benefits to which you are otherwise entitled. You will be treated the same no matter 
what.
 
If you are at the NIH and would like to receive care at the NIH, you must be taking part in a study or be 
under evaluation for study participation. 
 
You may receive no benefit from taking part. The research may give us knowledge that may help people 
in the future.
 
We will tell you about new information from this study or other studies that may affect your health, 
welfare, or willingness to stay in this study. If you want the results of the study, let the study staff know. 
Second, some people have personal, religious or ethical beliefs that may limit the kinds of medical or research treatments 
they would want to receive (such as blood transfusions).  If you have such beliefs, please discuss them with your NIH 
doctors or research team before you agree to the study.
Now we will describe this research study.  Before you decide to take part, please take as much time as you need to ask 
any questions and discuss this study with anyone at NIH, or with family, friends or your personal physician or other 
health professional.
CONTINUATION SHEET for either:
MEDICAL RECORD
NIH 2514-1, Consent to Participate in A Clinical Research Study
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study
STUDY NUMBER: 16-I-0147 CONTINUATION:  page 2  of 10 pages
PATIENT IDENTIFICATION CONTINUATION SHEET for either:
NIH-2514-1 (10-84)
NIH-2514-2 (10-84)
P.A.: 09-25-0099
PURPOSE AND PLAN OF THE STUDY
In this study, we are testing two experimental products 
or drugs called “VRC01LS” and “VRC07-523LS”.  Experimental 
means that these products have not been approved by the U.S. Food and Drug Administration (FDA), but the FDA has
allowed us to test them in research studies.  VRC01LS and
 VRC07-523LS are antibodies directed against HIV virus. The 
main purpose of this study is to see if these antibodies ar
e safe and how your body will resp
ond to them. (An antibody is 
a type of protein that helps protect the body against foreign matter such as bacteria and viruses; it can be either 
produced by your body or made in a laboratory.)
There are two different parts in this study (Part A and Part B). In Part A, 7 people got VRC01LS. In Part B, 7 people (up 
to 10 people) will get VRC07-523LS. People were put in Part A first and now Part A of the study is done. People will now 
be put in Part B. If you agree to take part in this study (Part B), you will get VRC07-523LS only and we will measure the 
amount of the drug in your body and how much stays in your body over time. We will check to see if your immune 
system makes antibodies against the product you get. 
About 14 to 20 people (7 to 10 people in each part) will take part in this study at the NIH Clinical Center in Bethesda, 
Maryland and sites within in the ACTG Network. The study will include a total of 23 clinic visits per person over a period 
of about 11 months. 
After you complete the day 14 study procedures, we strongly ad
vise that you start the antiviral therapy prescribed by 
your primary HIV physician (not study-provided).
STUDY PRODUCTS
VRC01LS and VRC07-523LS are study products that contain m
onoclonal antibodies. “Monoclonal” means that all the 
antibodies in each product are the same. These antibodies target 
the virus that causes HIV infection. As of May 10, 2018, 
approximately 60 people have received one of these antibodi
es and have not had any serious side effects or safety 
concerns. 
VRC01LS and VRC07-523LS are based on an antibody that was first found in an HIV infected person. Both of these study 
products were developed by the Vaccine Research Center (VRC), NIH and made in a drug manufacturing laboratory.  
There are currently research studies of these products in adults without HIV infection. This is the first study to give 
VRC01LS or VRC07-523LS people with HIV infection.
There is currently no cure for HIV. We do not expect the products in this study to cure or control your HIV. 
In laboratory and animal studies, VRC01LS and VRC07-523LS we
re shown to attach to and inactivate many types of HIV 
viruses. It is not known if the products will act the same way when given to humans.  It will take many studies to learn if 
the products are useful for preventing or treating HIV.  This study alone will not answer this question.
CONTINUATION SHEET for either:
MEDICAL RECORD
NIH 2514-1, Consent to Participate in A Clinical Research Study
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study
STUDY NUMBER: 16-I-0147 CONTINUATION:  page 3  of 10 pages
PATIENT IDENTIFICATION CONTINUATION SHEET for either:
NIH-2514-1 (10-84)
NIH-2514-2 (10-84)
P.A.: 09-25-0099
SCREENING VISIT 
If you decide to join this study, you will be asked to sign this consent form. After you have signed the form, you will be 
asked some questions and will undergo some tests at the screening visit to see if it is safe for you to join the study.
At the screening visit you will have a physical exam. You will be asked about your medical history, including your HIV 
history, any medicines you have taken in the past and are currently taking, and if you have ever received antibodies 
directed against the HIV virus or taken any anti-HIV medicines. We will draw about 6 tubes of blood from you for routine 
blood tests, tests for Hepatitis B virus or Hepatitis C virus infection, tests for HIV antibodies and viral load (the amount of
 
HIV in your blood), and CD4
+
/CD8
+
T cell count (cells in your blood that fight infection). You will be informed if any tests 
show a medical problem. You will be advised if results show that you should seek medical care.  Some medical conditions 
may make you not eligible for a clinical trial of an investigational product.
If you are female and able to become pregnant, you will have a pregnancy test done to see if you are pregnant. You 
cannot participate in this study if you are pregnant. If you are not pregnant or you are having sex that could lead to 
pregnancy, you will be asked and must agree to use birth control before you are able to participate in this study. We will 
discuss effective birth control methods with you.
ELIGIBILITY
You are eligible to participate in this study because you have completed the screening process and are:
 
18 to 70 years old
 
HIV infected, have never taken antiretroviral (ARV) medications, but otherwise in good general health
 
Under the care of a primary care provider for management of HIV 
 
Willing to let the study team give your lab test results to your primary care provider while you are in this study.
 
Willing to rece
ive VRC07-523LS
 
Willing to donate blood samples for future research
 
Willing to use birth control for the whole s
tudy, if you are able to become pregnant 
STUDY PROCEDURES
Study product infusion: If you agree to enroll in this study, you will get one dose of VRC07-523LS. The exact dose you 
get will depend on much you weigh. 
Before you are given the study product, your temperature, blood pressure, heart rate, and weight will be taken. You may 
also have a brief physical exam. If you are female and able to become pregnant, you must use an effective form of birth 
control for the entire study. A pregnancy test will be done to see if you are pregnant. If you are pregnant, we will not 
give you the study product. 
CONTINUATION SHEET for either:
MEDICAL RECORD
NIH 2514-1, Consent to Participate in A Clinical Research Study
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study
STUDY NUMBER: 16-I-0147 CONTINUATION:  page 4  of 10 pages
PATIENT IDENTIFICATION CONTINUATION SHEET for either:
NIH-2514-1 (10-84)
NIH-2514-2 (10-84)
P.A.: 09-25-0099
VRC07-523LS will be given to you by intravenous (IV) infusion. This means we will place a thin tube or IV line into a vein
in your arm. The IV line will be attached to a bag that contains the study product mixed with a liquid called “normal 
saline” or salt water. It will flow into your vein for about 30 minutes.  If you have side effects during the infusion, it will 
be slowed or stopped as needed. You will be observed for at least 30 minutes immediately after receiving the study 
product.   
If possible, we will also place an IV line in your other arm to collect blood samples. We will draw your blood before and 
right after the infusion, then at least 5 more times over the next 4 hours from this IV line. There are other blood draws at 
8, 12 and 36 hours after infusion, which are optional. At least one IV line will stay in your arm for several hours. You will 
not lose any benefits if you choose not to give the optional blood samples. If you choose to get these blood draws, you 
may be admitted to the hospital for an overnight stay. The hospital stay is for convenience only and not to give you care 
or treatment. 
We will give you a thermometer and ask you to check your temperature every day for 3 days after you get the study 
product. You will need to record your temperature and any symptoms you may have. Even if you do not feel sick, it is 
still very important that you record this information. You will get a password to a secure website to enter this information 
on an electronic form or “diary”. If you do not have a computer, you may use a paper diary instead. 
If you have any side effects after you get the study product, 
you should tell a study nurse or doctor as soon as possible. 
You can reach the clinic staff by phone 24 hours a day. If you have symptoms, you may be asked to come into the clinic 
for an examination before your next scheduled visit. It is very important that you follow the instructions you get from the 
clinic staff. 
Follow-up visits: After you get the study product, you w
ill need to come back to the clinic 11 times over a 4-week period. 
During the next 9 months, you will have 10 more follow-up visits. 
At most visits, we will check you for any 
health changes or problems. Your temperature, blood pressure, and pulse w
ill be 
taken and you w
ill have a physical exam. We will ask you how you are feeling 
and if you have taken any medications. 
While you are in the study, we will also provide counseling about preventing pregnancy as well as positive-prevention 
counseling to help prevent illness and promote good health.
We will draw 
about 1 to 11 tubes of blood from you at each visit, depending on the type of visit. We w
ill also ask you to 
provide a urine sample for a urine test at most visits. We will tell you right away if any of your test results show a health
problem. You might need to have extra clinic visits and laboratory tests if you have health changes that need to be 
checked. The total amount of blood we draw from you w
ill meet NIH guidelines.
We will use some bl
ood samples to see how long the study product remains in your body and if your immune system 
makes antibodies against it. Results of these tests are not for checking on your health and we w
ill not give you these 
results. We may also use some blood samples to check the level of ARV medications in your blood while you are in this 
study.  
Research studies follow a set schedule. This helps us answer the research questions. The visit schedule is a little flexible, 
but it is important that you work with the staff to follow the schedule as closely as possible. You should try not to miss any
visits. You should contact the clinic staff as soon as possible if you need to change the date or time of any visit. 
For the entire duration that you are on study, which will be 48 weeks or about 11 months, a maximum of about 922 mL 
(or about 2 pints) of blood will be collected. 
CONTINUATION SHEET for either:
MEDICAL RECORD
NIH 2514-1, Consent to Participate in A Clinical Research Study
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study
STUDY NUMBER: 16-I-0147 CONTINUATION:  page 5  of 10 pages
PATIENT IDENTIFICATION CONTINUATION SHEET for either:
NIH-2514-1 (10-84)
NIH-2514-2 (10-84)
P.A.: 09-25-0099
HIV TESTING AND MANAGEMENT 
As you take part in this study, you will have frequent test
ing of your HIV viral load and CD4+ T cell count for research 
purposes.  These tests will be given to you and sent to your primary care provider. You should discuss these results and
any questions about management of your HIV infection with your primary care provider.  
This study does not include standard medical care or the management of your HIV infection. The U.S. Department of 
Human Services and the clinical research team recommend that all HIV-infected individuals take (ARV) medication to 
reduce the chance of getting sick from HIV, increase life expectancy with HIV infection and prevent the spread of HIV to 
others. 
We will not give you ARV medications as part of this research study.  You must have a primary health care provider for 
HIV to take part in this study.  If you do not have one and need help finding one or getting ARV medications, please tell 
a study doctor or nurse. We will help you find a qualified HIV doctor and ARV medications. You and your primary health 
care provider will make all decisions about starting, stopping or changing ARV medications. However, we strongly advise 
that you start ARV medications after you have completed th
e day 14 study procedures. We expect you to tell us about 
changes in your ARV medications. We do not expect VRC07-523LS to control HIV by itself. You should not change or stop 
ARV treatment without talking about it with your primary care provider. Changes in ARV treatment will not affect your 
continued participation in the study.
MONITORING OF THE STUDY
A group of physicians and scientists at NIH will monitor this study.  This group will review the information from the study 
and will pay close attention to possible harmful reactions. If serious side effects occur, study product infusions may be 
delayed or canceled.
GENETIC TESTING
In the future, genetic research tests may be done on your stored samples to help understand how VRC07-523LS works 
and interacts with your body. In research studies, genetic tests are done to see if different types of immune response are 
related to genetic differences in people; this includes testing your antibody genes. Genetic tests done in a research lab 
from your stored samples will not be recorded in your medical record and will not have your name on the sample. The 
performance of these tests is not for health care purposes.
HLA type is a genetic test. People with certain HLA types migh
t be more likely to develop certain diseases.  Simply having 
those HLA types does not mean they will develop those diseases. HLA typing can reveal family relationships. It is our 
policy not to discuss your HLA results unless they have direct medical or reproductive implications for you or your family.  
Genetic information about you will not be revealed to others, including your relatives, without your permission.  We will 
not release any information about you or your family to any insurance company or employer unless you sign a document 
allowing release of information.
HLA typing may be ordered through the NIH Clinical Center medical laboratory.  If performed at the NIH Clinical Center, 
your HLA type results will be in your medical record.
CONTINUATION SHEET for either:
MEDICAL RECORD
NIH 2514-1, Consent to Participate in A Clinical Research Study
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study
STUDY NUMBER: 16-I-0147 CONTINUATION:  page 6  of 10 pages
PATIENT IDENTIFICATION CONTINUATION SHEET for either:
NIH-2514-1 (10-84)
NIH-2514-2 (10-84)
P.A.: 09-25-0099
HLA typing may be ordered through the NIH Clinical Center medical laboratory. If performed at the NIH Clinical Center, 
your HLA results will be in your medical record. 
STORED SAMPLES
We will collect blood samples from you during the study.  We will keep these samples for future research to learn more 
about monoclonal antibodies, vaccines, the immune system, and/or other medical conditions.  Results from research 
done with your stored samples will not be in your medical record or reported to you.
Some of your blood samples that are left over after all required study testing are done may be stored and used for VRC-
approved and ACTG-approved HIV-related research.
Labeling of Stored Samples: 
We will label your stored samples by a code (like a number).  Only the study team can 
link this code to you.  Any identifying information about you will be kept confidential as much as the law allows.  Despite 
protections, there is a small chance that information identifying you will be given to someone who should not get it.
Risks from Stored Samples: 
There is a risk of unplanned release of information from your medical records. The 
chance that this information will be given to an unauthorized person without your permission is very small. Possible 
problems with the unplanned release of information include discrimination when applying for insurance and employment. 
Similar problems may occur if you give information about yourself or agree to have your medical records released.
Future studies: 
In the future, other investigators (at NIH or outside of NIH; in the ACTG or outside of the ACTG) may 
wish to study your stored samples. When your stored samples are shared, they will be marked with a code.  Your 
samples will not have any identifying information on them.  Some information about you, such as your gender, age, 
health history, or ethnicity may also be shared with other researchers.
Any future research studies using your samples will be conducted in a way that protects the rights and privacy of study 
participants.
Your stored samples will be used only for research and will not be sold.  The research done with your materials may be 
used to develop new products in the future but you will not receive payment for such products.
Making your Choice: 
You can only take part in this study if you agree to let us collect, store, and use your blood 
samples in future unspecified research.  If you decide not to take part in this study, you may still take part in other 
studies at NIH.    
POSSIBLE STUDY RISKS
Risks of Blood Drawing and IV insertion: The risks of drawing from a vein and having an IV include pain, bruising, 
bleeding, lightheadedness and fainting. Rarely, infection or inflammation can occur in the skin or vein. Blood clots are 
possible risks when using an IV for blood draw.
Risks of VRC07-523LS:  This study is the first time that VRC07-523LS is being given to people with HIV infection. As of 
January 2018, the people who have received at least one do
se of VRC07-523LS had no concerning reactions to the 
CONTINUATION SHEET for either:
MEDICAL RECORD
NIH 2514-1, Consent to Participate in A Clinical Research Study
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study
STUDY NUMBER: 16-I-0147 CONTINUATION:  page 7  of 10 pages
PATIENT IDENTIFICATION CONTINUATION SHEET for either:
NIH-2514-1 (10-84)
NIH-2514-2 (10-84)
P.A.: 09-25-0099
product. VRC07-523LS may have other unknown risks or side effects We do not know if getting VRC07-523LS will affect 
how you respond to any similar monoclonal antibody against HIV. 
General risks of monoclonal antibodies: Side effects to infusions of monoclonal antibodies may include fever, chills, 
shaking, nausea, vomiting, pain, headache, dizziness, trouble 
breathing, high or low blood pressure, itchiness, rash, 
hives, lip or face swelling, diarrhea, racing heart or chest pain
. These reactions may be related to how fast the product is 
infused. If you have symptoms while you get VRC07-523LS, tell the nurse right away. Slowing or stopping the infusion 
may help improve these symptoms. Side effects may also include reactions at the injection site, such as redness, 
bruising, and swelling. 
Some antibody products have a risk of serious allergic reactions or cytokine release syndrome that can be life-
threatening.  
 
Anaphylaxis is one type of allergic reaction that may happen soon after an antibody product is given.  This 
reaction can include difficulty breathing, low blood pressure, hives or rash, swelling in the mouth and face.   
 
Serum sickness is a delayed type of allergic reaction that may happen several days to three weeks after an 
antibody product is given.  This reaction can include hives or rash, fever, enlarged lymph nodes, muscle pains, 
joint pains, chest discomfort and shortness of breath. 
 
Cytokine release syndrome can happen when an antibody targets a cell protein that triggers immune cells to 
release cytokine (proinflammatory molecules in your body).
All of these reactions are very unlikely because VRC07-523LS 
is a fully human antibody that attacks the HIV virus, and 
not your cells. 
In addition to the possible risks that are listed above, the study products may have other side effects that we do not 
know about yet.  Taking part in this study may affect your eligibility for future studies of other investigational monoclonal 
antibodies, antibody mixtures
 and other similar products.
We will give you any new information about risks or other information that becomes available that may affect your 
decision to continue in the study.
Risks during Pregnancy: We do not know what effects the study products may have on a fetus or nursing infant.  
Women must agree not to get pregnant during the study. We will discuss effective birth control methods with you. If 
you are able to become pregnant, you 
and your partner must use reliable birth control from the time you start the 
study until you complete the last study visit. 
If you can become pregnant, you must have a pregnancy test before you enter this study. The test must show that you 
are not pregnant. You must tell the clinic staff right away if you become pregnant during this study or think that you 
might be pregnant. If you become pregnant after getting the study product, we will not collect any more blood for 
research.  However, you will be asked to continue with study follow-up visits to check on your health and to report the 
outcome of the pregnancy to us, which will be reported to the Antiretroviral Pregnancy Registry 
(
http://www.apregistry.com
). This report will not use your name or other information that could be used to identify 
you. 
CONTINUATION SHEET for either:
MEDICAL RECORD
NIH 2514-1, Consent to Participate in A Clinical Research Study
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study
STUDY NUMBER: 16-I-0147 CONTINUATION:  page 8  of 10 pages
PATIENT IDENTIFICATION CONTINUATION SHEET for either:
NIH-2514-1 (10-84)
NIH-2514-2 (10-84)
P.A.: 09-25-0099
POSSIBLE BENEFITS
This study will not provide you with any direct health benefit. You and others may benefit in the future from the 
information that we learn from the study.
COSTS TO YOU FOR YOUR PARTICIPATION
There are no costs to you for taking part in this study.  You or your health insurance will have to pay for all medical costs 
for medical care that you get outside this study.  It is possible that you may have some expenses that are not covered by 
the study compensation provided.
COMPENSATION TO YOU FOR YOUR PARTICIPATION
You will be compensated for your study participation as follows:  
The compensation is $175 for outpatient scheduled visits
 including blood drawing. Compensation for IV product 
administration visit and follow-up blood sample collections within the first 24 hours after administration will be 
compensated at a combined amount of $600.  Compensation for timely completion of all 3 days of an electronic diary will 
be $25 total. Compensation for visits that do not include blood drawing is $75.
Total compensation for completion of the study is estimate
d to range from $4275 to $4300.  Actual compensation is 
based on the number and type of study visits you complete.  Your compensation will be reported to the Internal Revenue 
Service as taxable income.
REASONS FOR REMOVING YOU FROM THE STUDY WITHOUT YOUR CONSENT
You may be removed from the study for several different reasons, including:
 
You don't keep appointments or follow study procedures.
 
You get a serious illness that needs ongoing medical care.
 
You enroll in another research study at the same time you are in this study.
 
You become pregnant.
 
The study is stopped or canceled.
A study may be stopped or canceled by a study sponsor, a regulatory agency or by the study investigators. If this 
happens you will be told the reason why.
You may choose to stop taking part in the study at any time.  
If you received the study product before you discontinue the study early, you will be asked to continue to be part of the 
study and return for the rest of the study visits At the visits you will have some tests performed for safety monitoring, 
however samples for research purposes will not be collected.
CONTINUATION SHEET for either:
MEDICAL RECORD
NIH 2514-1, Consent to Participate in A Clinical Research Study
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study
STUDY NUMBER: 16-I-0147 CONTINUATION:  page 9  of 10 pages
PATIENT IDENTIFICATION CONTINUATION SHEET for either:
NIH-2514-1 (10-84)
NIH-2514-2 (10-84)
P.A.: 09-25-0099
ALTERNATIVES
This study is not designed to treat or prevent HIV infection or any disease.  You may choose to not take part in this 
study. You may be eligible for other studies. Instead of being in this study you have the choice of:
 
Treatment with prescription drug available to you
 
Treatment with experimental drugs, if you qualify
 
No Treatment
CONFLICT OF INTEREST
The research staff are reviewed at least yearly for conflicts of interest.  You may ask the research team for additional 
information.
The National Institutes of Health, including some members of the Vaccine Research Center scientific staff, developed the 
experimental product in this research study. The results of this study could play a role in whether the FDA will approve 
the experimental product for sale at some time in the future.  If approved, the future sale of the vaccine could lead to 
payments to NIH and some NIH scientists. By U.S. law, government scientists are required to receive such payments for 
their inventions.
You will not get any money from the development or sale of the product.
This protocol may have investigators who are not NIH employees.  Non-NIH investigators are expected to follow the 
principles of the Protocol Review Guide but are not required to report their personal financial holdings to the NIH.
CLINICALTRIALS.GOV
A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov
. This web site will not include 
information that can identify you. At most, the website will include a summary of the results. You can search this 
website at any time  
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY
MEDICAL RECORD
•
Adult Patient or    
•
Parent, for Minor Patient
STUDY NUMBER: 16-I-0147 CONTINUATION:  page 10   of  10 pages
PATIENT IDENTIFICATION CONSENT TO PARTICIPATE IN A CLINICAL
RESEARCH STUDY (Continuation Sheet)
•  Adult Patient or   • 
 Parent, for Minor Patient
NIH-2514-1 (07-09)
P.A.: 09-25-0099
File in Section 4:  Protocol Consent
OTHER PERTINENT INFORMATION
1. Confidentiality.  
When results of an NIH research study are reported in medical journals or at scientific meetings, 
the people who take part are not named and identified.  In most cases, the NIH will not release any information about 
your research involvement without your written permission.  However, if you sign a release of information form, for 
example, for an insurance company, the NIH will give the insurance company information from your medical record.  This 
information might affect (either favorably or unfavorably) the willingness of the insurance company to sell you insurance.
The Federal Privacy Act protects the confidentiality of your NI
H medical records.  However, you should know that the Act 
allows release of some information from your medical record without your permission, for example, if it is required by the 
Food and Drug Administration (FDA), members of Congress, law enforcement officials, National Institute of Allergy and 
Infectious Diseases institutional review board, study monitors or other authorized people.
2. Policy Regarding Research-Related Injuries.  
The Clinical Center will provide short-term medical care for any 
injury resulting from your participation in research here.  In general, no long-term medical care or financial compensation 
for research-related injuries will be provided by the National Institutes of Health, the Clinical Center, or the Federal 
Government.  However, you have the right to pursue legal remedy if you believe that your injury justifies such action.
3. Payments.  
The amount of payment to research volunteers is guided by the National Institutes of Health policies.  
4.  Problems or Questions.  
If you have any problems or questions about this study or about any research-related 
injury, contact the Principal Investigator, 
, or the Study Coordinator, 
 at 301-
451-8715.
If you have any questions about your rights as a research subject, you may call the Clinical Center Patient Representative 
at 
.
5. Consent Document.  
Please keep a copy of this document in case you want to read it again.
COMPLETE APPROPRIATE ITEM(S) BELOW:
A. Adult Patient’s Consent B. Parent’s Permission for Minor Patient.
I have read the explanation about this study and have been given the 
opportunity to discuss it and to ask questions.  I hereby consent to take 
part in this study.
I have read the explanation about this study and have been given the 
opportunity to discuss it and to ask questions.  I hereby give permission 
for my child to take part in this study.  
(Attach NIH 2514-2, Minor’s Assent, if applicable.)
Signature of Adult Patient/Legal Representative Date
Print Name
Signature of Parent(s)/Guardian Date
Print Name
THIS CONSENT DOCUMENT HAS BEEN APPROVED FOR USE 
FROM MAY 07, 2018 THROUGH MAY 06, 2019.
Signature of Investigator Date
Print Name
Signature of Witness Date
Print Name